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Abstract 
Multidrug resistance in bacteria is a phenomenon of due scientific concern. Extended-spectrum 
P-iactamases (ESBLs) are the enzymes produced by resistant bacteria which impart resistance 
against advanced-generation cephalosporins. CTX-M enzymes have become the most prevalent 
ESBLs. The work presented in this thesis has explored the prevalence of ESBL-producers among 
bacterial isolates of clinical origin and their molecular mechanism of resistance. The mode of 
spread of resistance and the risk factors for acquisition of these organisms have also been 
discussed. Furthermore, this study describes interaction of different CTX-M variants as well as 
selected carbapenemases with their corresponding target drugs and inhibitors. 
The first study was made to find the prevalence of ESBL-producing Escherichea coli and 
Klebsiella pneumoniae in neonatal intensive care unit (NICU) and to identify the risk factors 
associated with the acquisition of these organisms. Risk factors associated with ESBL-producing 
E. coli and/or K. pneumoniae acquisition status of neonates were assessed. Of 253 neonates 
admitted, 238 entered the active surveillance system. ESBL-producing K. pneumoniae was 
responsible for 7 infections and 51 colonizations while ESBL-producing E. coli was responsible 
for 9 infections and 88 colonizations. Concurrent isolation of both the organisms occurred in 30 
neonates. The logistic regression model identified 'length of stay in the NICU' as the single 
independent risk factor. Imipenem, cefepime and amikacin were suggested as the drugs of 
choice in this study. 
The second study aimed at (i) characterizing the mode of transmission of b/ocnc-w and 
blavEM among ESBL-producing f. coli strains of NICU, and (ii) identifying risk factors for "sex-
associated ESBL-producing E. coli acquisition status" of the neonates. The 97 ESBL-producing £ 
coli strains which were obtained from neonates were screened for blOcn-M, WortM, anJiA, rmtA, 
rmtB and integrons using both genomic and plasmidic DNA. Five WOCTX-M.I5, 2 rmtB. 2 6/onM-i and 
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13 Classl integrons were detected. All the b/Ocrx-M-is positive isolates, except one were found to 
be donaily related by Enterobacterial Repititive Intergenic Consensus (ERIC)-PCR. Plasmid-
mediated-conjugal transfer might be the mechanism of spread of resistance in the described 
setting. Moreover, the study reported modelling of CTX-M-15 enzyme which is one of the most 
common ESBLs in India. 'Length of stay in NiCU' was found as the single independent risk factor 
among the 32 risk factors studied. Hence, male neonates who are colonized or infected by ESBL-
producing E. coli might have a longer stay in NICU compared to their female counterparts. 
The third study was conducted to assess potential risk factors for diabetic foot ulcers 
infected with multidrug-resistant-organisms (MDROs) and to investigate antibiotic susceptibility 
patterns and ESBL-production in bacteria isolated from these ulcers. MRSA, VRSA, ESBL-
producing Gram negative bacteria, and all the Gram-negative bacteria that were resistant to at 
least four of the antibiotics tested were considered as MDROs in this study. Seventy-seven 
diabetic foot ulcer-patients were studied. Gram-negative bacteria! isolates were tested for ESBL 
production by double-disc-diffusion method. An alarming number of patients were MDRO-
positive (72.7%). ESBL-positive strains constituted 19.8% of total isolates. Staphylococcal isolates 
identified as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
Staphylococcus aureus (VRSA), were 3.7% (n=8) and 0.5% (n=l) respectively. Twenty-two study 
factors were found to be significantly associated with MDRO infection status of ulcers in the 
univariate analysis. Multiple logistic regressions proved that MDRO status was the only 
significant, independent predictor of glycemic control (Odds Ratio = 4.22, P = <0.01). The study 
concluded that MDRO infected patients have poor glycemic control. 
The fourth study aimed at (i) characterizing the mode of transmission of blocn^ and 
WOTTM among ESBL-producing f. coli strains isolated from infected diabetic foot ulcers, and (ii) 
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identifying tiie risk factors for "sex-associated multidrug resistant Gram-negative bacterial 
(MDRGNBHnfection status" of the ulcers. For this study, bacteria resistant to at least 4 of the 
test antibiotics were designated as MDRGNB. Also, ail ESBL-producers were considered as 
MDRGNB. A search for blOcn-M, bla^M, armA, rmtA, rmtB genes and integrons was made among 
the ESBL-producing E. coll strains using both genomic and plasmidic DNA. The ESBL-producing f. 
coll (14/51; 27.5%), K. pneumoniae (9/38; 23.7%) and Pseudomonas aeruginosa (20/61; 32.8%) 
strains identified in the previous study were subjected to molecular typing by ERIC-PCR. PCR 
amplified btaoTL^ genes were cloned and sequenced. Risk factors for "sex-associated MDRGNB-
infection status" of ulcers were assessed. Modelling was performed using Swiss-Model-Server 
and verified by Procheck and verify3D programmes. Discovery Studio2.0 (Accelrys) was used to 
prepare Ramachandran plots. Z-scores were calculated using 'WHAT IF'-package. Only 7 Classl 
integrons, 2 blocn-M-is, and 1 WOTEM-I were detected. Ceftazidime and cefotaxime resistance 
markers were present on the plasmidic DNA of both the b/ocrx-M-is positive strains and were 
transmissible through conjugation. Multivariate analysis proved 'Glycemic control at discharge' 
as the single independent risk factor. It was concluded that male diabetic patients with 
MDRGNB-infected foot ulcers had poor glycemic control and hence they might have higher 
mortality rates compared to their female counterparts. Plasmid-mediated conjugal transfer, 
albeit at a low frequency might be the possible mechanism of transfer of b/oox-M-is resistance 
marker in the described setting. 
The fifth study dealt with six Aclnetobacter bauntannll strains which were isolated from 
urinary tract infection patients attending outpatient clinics at Aligarh hospital, India. Four strains 
were identified as ESBL-producers. A search for WOCTX-M, blchm, armA, rmtA, rmtB and integrons 
was performed among the ESBL-producers using both genomic and plasmidic DNA. Molecular 
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typing was performed by ERIC-PCR. The PCR amplified blOax-M genes were cloned and 
sequenced. Two 6/OCTX-M-I5 and IbkhuA-iso genes and 3 Classl integrons were amplified. The 
ceftazidime and cefotaxime resistance markers were located on the plasmid DNA of the clonally 
related b/acTx.M-15-positive strains and were transmissible through conjugation. Ramachandran Z-
score for modelied-enzyme was found to be 0.044. Amikacin and ampiciilin/sulbactam proved to 
be the drugs of choice. 
In the sixth study, the database maintained exclusively for p-lactamase enzymes 
(http://www.lahev.org/studies: last accessed on 17/10/2009) was searched for CTX-M enzyme 
sequences submitted in 2009 from across the globe. The five ESBL-types explored in the study 
included CTX-M-15, CTX-M-53, CTX-M-71, CTX-M-82 and CTX-M-89. The corresponding gene 
sequences for these enzymes appear in GenBank with accession nos. as [GenBank: GQ3391021. 
[GenBank: gOZfiSZS^. [GenBank: £JS1S13S], [GenBank: £Q2SfifiSi] and [GenBank: £J3Z1S331, 
respectively. The amino acid residues through which these CTX-M-variants interact with drugs 
and inhibitors were not reported till the time of writing of thesis. Hence, the study was aimed at 
reporting the same. GenBank sequence with accession number [GenBank: GQ3391021 was used 
as a reference sequence for detecting mutations. Homolc^ models for Crx-M-15, CTX-M-53, 
CTX-M-71, CT^-M-82 and CTK-M-89 were prepared using Swiss Model Server. Ramachandran Z-
scores for the enzyme structures modelled from these sequences were found to be -0.083, 
0.006, -0.103, -0.007 and 0.092, respectively. Each of these models were docked with target 
drugs (cefotaxime and ceftazidime) and inhibitors (clavulanate, sulbactam and tazobactam) 
using the targeted docking mode of 'Molecular Docking Server'. 
(httD://www.dockingserver.com). This server uses the MMFF94 force field for energy 
minimization of ligand molecules and is based on the well-known AutoDock program. Discovery 
Studio analysis of the docked structures involving ceftazidime revealed that irrespective of the 
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crx-M-type, ceftazidime interacted invariably with the residues A226, G227, L228, P229, 
A/r230, S231, W232, R285, T288, D289, G290 and iyY291. All the CTX-M-types excluding CTX-M-
71 interacted with davulanic acid through the residues A226, G227, [228, P229. T288 and D289. 
Ours was the first study to report modelling of CTX-M-15/53/71/82/89 enzymes and their 
docking with target drugs and inhibitors to the best of our knowledge. In short, the study 
identified amino acid residues crucial to 'CTX-M-drug' and 'CTX-M-inhibitor' interactions. 
Researchers are expected to duly utilize these informations for designing new drugs resistant to 
hydrolysis by CTX-M enzymes as well as more potent and versatile CTX-M-inhibitors. Sulbactam 
was found to bind most efficiently into the active sites of the studied CTX-M-variants on the 
basis of interaction energies. More experimental studies are awaited to validate these findings. 
Scope is still left to determine the 3D structures of the rapidly emerging variants of CTX-M by X-
ray crystallography. 
The seventh study aimed at describing the mode of interaction of carbapenemases with 
target drugs and inhibitors. SMEl, KPC2, IMll and SFCl were the carbapenem hydrolyzing 
enzymes explored in the study. The target drugs included imipenem, meropenem, ertapenem 
and doripenem. Both traditional inhibitors (davulanic acid, sulbactam and tazobactam) as well 
as novel inhibitors (LN1-255 and NXL-104) were considered in the study. The study was based on 
interaction energies. Ramachandran Z-scores for modelled IMll and SFCl enzymes were found 
to be 0.741 and -0.837, respectively. Each of the study enzymes was docked with target drugs 
and inhibitors using the targeted docking mode of 'Molecular Docking Server*, as mentioned 
above. The binding of NXL-104 (a novel inhibitor) to KPC2 carbapenemase was found to be very 
similar to the binding of clavulanate (a traditional inhibitor) to the same. On the basis of 
interaction energies, it was concluded that sulbactam was overall superior inhibitor compared 
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to davuianate, tazobactam, LNl-255 and NXL-104. NXL-104 was found next to sulbactam in 
efficacy. LNl-255 might only be effective against IMIl-producing bacteria. 
The nucleotide sequences obtained in the thesis worl< appear in GenBank as [GenBank: 
SQlSSnSi. [GenBank: GQ1452171. [GenBank: 6Q1452181. [GenBank: g$U<S521S], [GenBank: 
GQ14S2201. [GenBank: GQ1452211. [GenBank: 6Q1452221. [GenBank: GQ1745031. [GenBank: 
GQ1745041. [GenBank: GQ1745051. [GenBank: GQ1745061. [GenBank: GQ1745071. [GenBank: 
FJ9978641. [GenBank: FJ9978651. [GenBank: FJ9978661. and [GenBank: FJ9978671. 
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Multidrug resistance in bacteria is a phenomenon of due scientific concern. Extended-spectrum 
P-lactamases (ESBLs) are the enzymes produced by resistant bacteria which impart resistance 
against advanced-generation cephalosporins. CTX-M enzymes have become the most prevalent 
ESBLs. The work presented in this thesis has explored the prevalence of ESBL-producers among 
bacterial isolates of clinical origin and their molecular mechanism of resistance. The mode of 
spread of resistance and the risk factors for acquisition of these organisms have also been 
discussed. Furthermore, this study describes interaction of different OTX-M variants as well as 
selected carbapenemases with their corresponding target drugs and inhibitors. 
The first study was made to find the prevalence of ESBL-producing Escherichea coll and 
Klebsiella pneumoniae in neonatal intensive care unit (NICU) and to identify the risk factors 
associated with the acquisition of these organisms. Risk factors associated with ESBL-producing 
E. coll and/or K. pneumoniae acquisition status of neonates were assessed. Of 253 neonates 
admitted, 238 entered the active surveillance system. ESBL-producing K. pneumoniae was 
responsible for 7 infections and 51 colonizations while ESBL-producing E. coll was responsible 
for 9 infections and 88 colonizations. Concurrent isolation of both the organisms occurred in 30 
neonates. The logistic regression model identified 'length of stay in the NICU' as the single 
independent risk factor. Imipenem, cefepime and amikacin were suggested as the drugs of 
choice in this study. 
The second study aimed at (i) characterizing the mode of transmission of blOcn-M and 
WOTEM among ESBL-producing £ coll strains of NICU, and (ii) identifying risk factors for "sex-
associated ESBL-producing E. coti acquisition status" of the neonates. The 97 ESBL-producing E. 
coll strains which were obtained from neonates were screened for bhcn-M, bloju*, armA, rmtA, 
rmtB and integrons using both genomic and plasmidic DNA. Five b/oox-M-is, 2 rmtB, 2 b/OrtMi and 
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13 Classl integrons were detected. All the blacn4A-is positive isolates, except one were found to 
be clonally related by Enterobacterial Repititive Intergenic Consensus (ERIC)-PCR. Plasmid-
mediated-conjugal transfer might be the mechanism of spread of resistance in the described 
setting. Moreover, the study reported modelling of CTX-M-15 enzyme which is one of the most 
common ESBLs in India. 'Length of stay in NICU' was found as the single independent risk factor 
among the 32 risk factors studied. Hence, male neonates who are colonized or infected by ESBL-
producing E. coli might have a longer stay in NICU compared to their female counterparts. 
The third study was conducted to assess potential risk factors for diabetic foot ulcers 
infected with multidrug-resistant-organisms (MDROs) and to investigate antibiotic susceptibility 
patterns and ESBL-production in bacteria isolated from these ulcers. MRSA, VRSA, ESBL-
producing Gram negative bacteria, and all the Gram-negative bacteria that were resistant to at 
least four of the antibiotics tested were considered as MDROs in this study. Seventy-seven 
diabetic foot ulcer-patients were studied. Gram-negative bacterial isolates were tested for ESBL 
production by double-disc-diffusion method. An alarming number of patients were MDRO-
positive (72.7%). ESBL-positive strains constituted 19.8% of total isolates. Staphylococcal isolates 
identified as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
Staphylococcus aureus (VRSA), were 3.7% (n=8) and 0.5% (n=l) respectively. Twenty-two study 
factors were found to be significantly associated with MDRO infection status of ulcers in the 
univariate analysis. Multiple logistic regressions proved that MDRO status was the only 
significant, independent predictor of giycemic control (Odds Ratio = 4.22, P = <0,01). The study 
concluded that MDRO infected patients have poor giycemic control. 
The fourth study aimed at (i) characterizing the mode of transmission of WOOK-M and 
blorm among ESBL-producing £ coli strains isolated from infected diabetic foot ulcers, and (ii) 
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identifying the risk factors for "sex-associated multidrug resistant Gram-negative bacterial 
(MDRGNB)-infection status" of the ulcers. For this study, bacteria resistant to at least 4 of the 
test antibiotics were designated as MDRGNB. Also, all ESBL-producers were considered as 
MDRGNB. A search for WOOX-M, WOTEM, armA, rmtA, rmtB genes and integrons was made among 
the ESBL-producing E. coli strains using both genomic and plasmidic DNA. The ESBL-producing E. 
coli (14/51; 27.5%), K. pneumoniae (9/38; 23.7%) and Pseudomonas aeruginosa (20/61; 32.8%) 
strains identified in the previous study were subjected to molecular typing by ERIC-PCR. PCR 
amplified 6/OCTX.M genes were doned and sequenced. Risk factors for "sex-associated MDRGNB-
infection status" of ulcers were assessed. Modelling was performed using Swiss-Model-Server 
and verified by Procheck and verify3D programmes. Discovery Studio2.0 (Accelrys) was used to 
prepare Ramachandran plots. Z-scores were calculated using 'WHAT IF'-package. Only 7 Classl 
integrons, 2 blocn-M-is, and 1 bla-nM-i were detected. Ceftazidime and cefotaxime resistance 
markers were present on the plasmidic DNA of both the b/oox-M-is positive strains and were 
transmissible through conjugation. Multivariate analysis proved 'Glycemic control at discharge' 
as the single independent risk factor. It was concluded that male diabetic patients with 
MDRGNB-infected foot ulcers had poor glycemic control and hence they might have higher 
mortality rates compared to their female counterparts. Plasmid-mediated conjugal transfer, 
albeit at a low frequency might be the possible mechanism of transfer of b/ocnc-w is resistance 
marker in the described setting. 
The fifth study dealt with six Acinetobacter baumannii strains which were isolated from 
urinary tract infection patients attending outpatient clinics at Aligarh hospital, India. Four strains 
were identified as ESBLiiroducers. A search for b/Ocnc-M, WOTEM, armA, rmtA, rmtB and integrons 
was performed among the ESBL-producers using both genomic and plasmidic DNA. Molecular 
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typing was performed by ERIC-PCR. The PCR amplified WOOX-M genes were cloned and 
sequenced. Two b/onx-M-is and ZWOTEM-ISO genes and 3 Classl integrons were amplified. The 
ceftazidime and cefotaxime resistance markers were located on the plasmid DNA of the clonaily 
related b/oax-M-is-positive strains and were transmissible through conjugation. Ramachandran Z-
score for modelled-enzyme was found to be 0.044. Amikacin and ampicillin/sulbactam proved to 
be the drugs of choice. 
In the sixth study, the database maintained exclusively for ^-lactamase enzymes 
(http://www.lahev.org/studies: last accessed on 17/10/2009) was searched for CTX-M enzyme 
sequences submitted in 2009 from across the globe. The five ESBL-types explored in the study 
included CTX-M-15, CrX-M-53, CTX-M-71, CTX-M-82 and CTX-M-89. The corresponding gene 
sequences for these enzymes appear in GenBank with accession nos. as [GenBank: GQ3391021. 
[GenBank: P<MW7Ml [GenBank: FJ8154361. [GenBank: J2fi2Sfim] and [GenBank: FJ9718991. 
respectively. The amino acid residues through which these CTX-M-variants interact with drugs 
and inhibitors were not reported till the time of writing of thesis. Hence, the study was aimed at 
reporting the same. GenBank sequence with accession number [GenBank: GQ3391021 was used 
as a reference sequence for detecting mutations. Homology models for CTX-M-15, CTX-M-53, 
CTX-M-71, CTX-M-82 and CTX-M-89 were prepared using Swiss Model Server. Ramachandran Z-
scores for the enzyme structures modelled from these sequences were found to be -0.083, 
0.006, -O.103, -0.007 and 0.092, respectively. Each of these models were docked with target 
drugs (cefotaxime and ceftazidime) and inhibitors (clavulanate, sulbactam and tazobactam) 
using the targeted docking mode of 'Molecular Docking Server'. 
(http://www.dockingserver.comV This server uses the MMFF94 force field for energy 
minimization of ligand molecules and is based on the well-known AutoDock program. Discovery 
Studio analysis of the docked structures involving ceftazidime revealed that irrespective of the 
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CrX-M-type, ceftazidime interacted invariably with the residues A226, G227, L228, P229, 
A/r230, S231, W232, R285, T288, D289, G290 and IA291. All the CTX-M-types excluding CTX-M-
71 interacted with clavulanic acid through the residues A226, G227, L228, P229, T288 and D289. 
Ours was the first study to report modelling of CTX-M-15/53/71/82/89 enzymes and their 
docking with target drugs and inhibitors to the best of our Itnowledge. in short, the study 
identified amino acid residues crucial to 'CTX-M-drug' and 'CTX-M-inhibitor' interactions. 
Researchers are expected to duly utilize these informations for designing new drugs resistant to 
hydrolysis by CTX-M enzymes as well as more potent and versatile CTX-M-inhibitors. Sulbactam 
was found to bind most efficiently into the active sites of the studied CTX-M-variants on the 
basis of interaction energies. More experimental studies are awaited to validate these findings. 
Scope is still left to determine the 3D structures of the rapidly emerging variants of CTX-M by X-
ray crystallography. 
The seventh study aimed at describing the mode of interaction of carbapenemases with 
target drugs and inhibitors. SMEl, KPC2, IMIl and SFCl were the carbapenem hydrolyzing 
enzymes explored in the study. The target drugs included imipenem, meropenem, ertapenem 
and doripenem. Both traditional inhibitors (clavulanic acid, sulbactam and tazobactam) as well 
as novel inhibitors (LNl-255 and NXL-104) were considered in the study. The study was based on 
interaction energies. Ramachandran Z-scores for modelled IMIl and SFCl enzymes were found 
to be 0.741 and -0.837, respectively. Each of the study enzymes was docked with target drugs 
and inhibitors using the targeted docking mode of 'Molecular Docking Server*, as mentioned 
above. The binding of NXL-104 (a novel inhibitor) to KPC2 carbapenemase was found to be very 
similar to the binding of clavulanate (a traditional inhibitor) to the same. On the basis of 
interaction energies, it was concluded that sulbactam was overall superior inhibitor compared 
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to clavulanate, tazobactam, LN1-255 and NXL-104. NXL-104 was found next to sulbactam in 
efficacy. LNl-255 might only be effective against IMIl-producing bacteria. 
The nucleotide sequences obtained in the thesis work appear in GenBank as [GenBank: 
QQX^nW. [GenBank: qq%^m7l [GenBank: SQiSSmi, [GenBank: GQ1452191. [GenBank: 
GQ1452201. [GenBank: GQ1452211. [GenBank: GQ1452221. [GenBank: GQ1745031. [GenBank: 
GQ1745041. [GenBank: GQ1745051. [GenBank: GQ1745061. [GenBank: GQ1745071. [GenBank: 
FJ9978641. [GenBank: FJ9978651. [GenBank: FJ9978661. and (GenBank: FJ9978671. 
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1.1 Antibiotics, modes of action and the basic concept of antibiotic resistance 
An antibiotic is a drug used to treat infections caused by bacteria and other 
microorganisms. Originally, antibiotic was defined as a substance produced by one 
microorganism that selectively inhibited the growth of another. Synthetic antibiotics, 
usually chemically related to natural antibiotics, have since been produced that 
accomplish comparable tasks. There are several major classes of antibiotics that can be 
categorized based on their mode of antibacterial action. In general, antibiotics can be 
cat^orized as those that inhibit cell wall synthesis, protein synthesis, and nucleic acid 
synthesis (Table 1.1). 
'Selective pressure' refers to the environmental conditions that allow organisms 
with novel mutations or newly acquired characteristics to survive and proliferate. 
Mutations that increase an organism's resistance to antimicrobial agents occur naturally 
in bacteria. Exposure to a stimulus that inhibits or kills the susceptible majority of a 
bacterial population allows a resistant subset of strains to grow at the expense of 
susceptible organisms. A minority of strains present in a given setting may be resistant 
to the antibiotic being used. The selective factor is the antibiotic (usually) to which the 
sub-population is resistant. Hence, the phenomenon of antibiotic resistance is based on 
selection for organisms that have enhanced ability to survive doses of antibiotics that 
would have previously been lethal. 
1.1.1 Multidrug resistance (MDR) in bacteria 
We have come a long way using antibiotics after the landmark discovery of 'Penicillin' in 
1928. Bacteria have also got them selected with hardier resistance mechanisms. 
Infections due to the bacteria belonging to Enterobacteriaceae are increasingly being 
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Table 1.1 Major antibiotic classes and resistance strategies employed by bacteria against thenn 
Class of antibiotics 
Beta lactanris: penicillins, 
cephalosporins 
Aminoglycosides: 
gentamydn 
Quinolones 
Tetracyclines 
Glycopeptides: vancomycin 
Maaoiides 
Trimethoprim 
Sulfonamides 
Glycylcydine (Tigecycline) 
Mtods of action 
Block cell wall formation 
Block protein synthesis 
Inhibit DNA replication 
Block protein synthesis 
Block cell wall formation 
Block protein synthesis 
Block formation of nucleic 
adds and f-met 
Blocks protein synthesis 
Rasistancs stratagy used by 
bacteria 
Inactivation, mutation 
Inactivation, mutation 
Mutation of binding molecules 
Inactivation, drug efflux 
Mutation of binding molecules 
Ribosome protection 
Mutation of binding molecules 
Over expression of efflux pumps 
such as MexXY and AcrAB 
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reported (Chiu et al., 2009; Huang et al., 2009]. A phenomenon of great concern in the 
nnedical community is the rise in multi-drug resistant organisms, defined as bacteria 
with simultaneous resistance to more than one class of antibiotics [Guyot et al., 1999]. 
Patients infected with such organisms experience significantly higher degrees of 
treatment failure, prolonged antibiotic usage and morbidity associated with infection 
[Gupta & Stamm, 2002; Sobel & Kaye, 2004]. 
1.2 Mechanisms of antibiotic resistance 
The definition of bacteria as resistant or susceptible is critical for clinicians. It is also very 
important to note the difference between intrinsic and acquired resistance to an 
antibiotic. Intrinsic resistance can best be described as resistance of an entire species to 
an antibiotic, based on inherent characteristics requiring no genetic alteration. This is 
usually due to the absence of a target for the action of a given antibiotic or the inability 
of a specific drug to reach its target. For example, mycoplasmas are always resistant to 
p-lactam antibiotics since they lack peptidoglycan (which the ^-lactams act upon). 
Similarly, the outer membrane of gram negative cells can prevent an antibiotic from 
reaching its target. For example, Pseudomonas aeruginosa exhibits high intrinsic 
resistance to many antibiotics due to its drug efflux pumps and restricted outer 
membrane permeability. Acquired resistance can arise either through mutation or 
horizontal gene transfer. Presence of the antibiotic in question leads to selection for 
resistant organisms, thereby shifting the population towards resistance. 
Mechanisms of antibiotic resistance and the over coming methods are thus an 
intense area of research. Several mechanisms of antimicrobial resistance are readily 
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spread to a variety of bacterial genera. First, the organism may acquire genes encoding 
enzymes, such as ^-lactamases, that destroy the antibacterial agent before it can have 
an effect. Second, bacteria may acquire efflux pumps that extrude the antibacterial 
agent from the cell before it can reach its target site and exert its effect. Third, bacteria 
may acquire several genes for a metabolic pathw/ay wfhich ultimately produces altered 
bacterial cell walls that no longer contain the binding site of the antimicrobial agent. 
Fourth, bacteria may acquire mutations that limit access of antimicrobial agents to the 
intracellular target site via down regulation of porin genes [Tenover, 2006]. Thus, 
normally susceptible populations of bacteria may become resistant to antimicrobial 
agents through mutation and selection, or by acquiring from other bacteria the genetic 
information that encodes resistance. Acquired resistance that develops due to 
chromosomal mutation and selection is termed as vertical evolution. 
1.2.1 Inhibition of cell wall synthesis 
There are two major groups of cell wall synthesis inhibitors, the 3-lactams and the 
glycopeptides. As bacterial cell walls are wholly unlike the membranes of eukaryotes, 
they are an obvious target for selectively toxic antibiotics. The p-lactams include the 
penicillins, cephalosporins, and the carbapenems. These agents bind to the penicillin 
binding proteins (PBPs) that cross-link strands of peptidoglycan in the cell wall. In gram 
negative cells, this leads to the formation of fragile spheroplasts that are easily 
ruptured. In gram positive cells, autolysis is triggered by the release of lipoteichoic acid 
[Greenwood, 2000]. 
1.2.1.1 The mechanism of 3-lactam resistance 
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Beta-lactamases play a major role in the development of p-lactam resistance. These 
enzymes catalyze hydrolysis of the p-lactam ring and, thereby, inactivate these 
antibiotics. Many bacteria contain chromosomally encoded p-lactamases necessary for 
cell wfall production and it is only the over-production of these enzymes that causes 
resistance [Greenwood, 2000]. Beta-lactamases encoded on plasmids or other 
transmissible elements can also lead to resistance [Normark & Normark, 2002]. There 
are also some bacteria that possess altered PBP's that result in reduced penicillin 
binding [6reenv»»ood, 2000]. Since 1970s, several compounds, such as clavulanic acid, 
have been discovered that have the ability to bind irreversibly to p-lactamases and, 
thereby, inhibit their action. Combinations of these compounds with p-lactam drugs 
have been very successful in treatment of disease [Bryan, 1984]. The glycopeptides are a 
group of antibiotics that include vancomycin, avoparcin, and others that bind to acyl-D-
alanyl-D-alanine. Binding of this compound prevents the addition of new subunits to the 
growing peptidoglycan cell wall, thus limiting their action to gram positive organisms. 
1.2.1.2 Glycopeptide resistance 
Glycopeptide resistance in enterococci has developed through enzymes that use D-
alanyl-D-lactate in place of acyl-D-alanyl-D-alanine, allowing cell wall synthesis to 
continue. Other mechanisms of resistance involve the over-production of peptidoglycan 
precursors which overwhelm the drug [Greenwood, 2000]. 
1.2.2 Inhibition of protein synthesis 
There are many types of antibiotics that inhibit bacterial protein synthesis. These drugs 
take advantage of structural differences between bacterial ribosomes and eukaryotic 
ribosomes. The aminoglycoside antibiotics are a group whose mechanisms of action are 
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still being investigated. The mennbers of this group contain sugar and consist of 
streptomycin, neomycin, kanamycin, gentamycin, tobramycin and amikacin. These drugs 
enter bacterial cells by an active transport that involves quinones that are absent in 
anaerobes and streptococci, thus excluding these organisms from the spectrum of 
action. Aminoglycosides irreversibly bind to 16S rRNA and block the initiation complex. 
By binding to 16S rRNA the aminoglycosides increase the affinity of the A site for tRNA 
regardless of the anticodon specificity. Aminoglycoside resistance mechanisms include: 
(a) the deactivation of aminoglycosides by N-acetylation, adenylytation or 0-
phosphorylation, (b) the reduction of the intracellular concentration of aminoglycosides 
by changes in outer membrane permeability, decreased inner membrane transport, 
active efflux, and drug trapping, (c) the alteration of the 30S ribosomal subunit target by 
mutation, and (d) methylation of the aminoglycoside binding site [Shakil et al., 2008]. 
Chloramphenicol is a broad-spectrum antibiotic produced by Streptomyces 
venezuelae. Chloramphenicol inhibits peptide bond formation on 70S ribosomes [Bryan, 
1984]. This drug is especially useful as it can penetrate eukaryotic cells and 
cerebrospinal fluid, making it a drug of choice for treatment of meningitis and 
intracellular bacterial infections such as those caused by chlamydia. It is not in 
widespread use, however, because of potentially fatal side-effects, namely, aplastic 
anemia [Greenwood, 2000], Resistance to chloramphenicol is conferred by the enzyme 
chloramphenicol acetyl-transferase. A number of these enzymes have been discovered, 
each altering the chloramphenicol molecule to prevent binding to the bacterial 
ribosome. Chloramphenicol resistance in gram negative cells can also arise from 
alteration in outer membrane permeability that prevents the drug from entering the ceil 
[Bryan, 1984]. 
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The tetracyclines are another group of broad-spectrum antibiotics that inhibit 
bacterial protein synthesis. They are absorbed into the cell by active transport and, once 
there, bind to the 30S subunit to prevent binding of aminoacyl tRNA [Roberts, 1996]. 
Resistance to the tetracyclines occurs via three mechanisms. First, production of a 
membrane efflux pump removes the drug as rapidly as it enters and there are several 
genes encoding these pumps. Second, several ribosome protection proteins act to 
prevent tetracycline from binding to the ribosome, thereby conferring resistance. Third, 
a protein found only in Bacteroides spp. enzymatically inactivates tetracycline [Roberts 
et al., 1996]. Interestingly, efflux pump inhibitors have recently been discovered that 
may allow combinations of these inhibitors and tetracyclines to be used against 
previously resistant strains [Chopra, 2002]. The macrolides are a group of antibiotics 
commonly used to treat gram positive and intracellular bacterial pathogens. 
Erythromycin was the first of these, and several other important macrolides have been 
discovered since, including clarithromycin and azithromycin. Azithromycin has a longer 
plasma half-life which allows treatment with a single dose for some pathogens or a once 
daily dose for others. Clarithromycin has enhanced absorption and causes less 
gastrointestinal discomfort [Gaynor & Mankin, 2003]. It was originally believed that 
erythromycin inhibited protein synthesis by competing with amino acids for ribosomal 
binding sites, but further research showed that several mechanisms were involved. The 
macrolides are now believed to promote dissociation of tRNA from the ribosome, inhibit 
peptide bond formation, inhibit ribosome assembly, and prevent amino acid chain 
elongation [Gaynor & Mankin, 2003]. There are two major mechanisms of macrolide 
resistance. First, an efflux pump has been found that removes the drug from the cell. 
Second, modification of the ribosome can confer resistance. Mutations at several sites 
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of the ribosome can allosterically prevent macrolide binding and a common alteration is 
dimethylation of one nucleotide on the 23S rRNA. This dimethylation not only prevents 
macrolide binding, but also confers resistance to lincosamide and streptogramin 
antibiotics [Gaynor & Mankin, 2003]. The streptogramins are another class of antibiotics 
that inhibits bacterial protein synthesis, mostly in gram positive organisms (due to 
decreased permeability of the gram negative outer membrane). These antibiotics are 
actually combinations of structurally different drugs, types A and B that act 
synergistically. These compounds bind to separate sites on the SOS subunit. Type A 
drugs block attachment of substrates at two sites on the SOS subunit, whereas type B 
drugs cause release of incomplete protein chains. The synergistic effect arises from a 
conformational change induced by the binding of a type A drug which significantly 
increases affinity of type B drugs [Johnston et al., 2002]. Streptogramins currently in use 
include virginiamycin, pristinamycin, and quinupristin/dalfopristin. Resistance to 
streptogramin antibiotics can be found in several forms. Efflux pumps for both type A 
and B streptogramins have been identified. Type A streptogramins can be inactivated by 
one of the virginiamycin acetyl-transferases, and several enzymes have been identified 
that can inactivate type B streptogramins. Alteration of bacterial ribosomal proteins or 
RNA can also confer resistance. A common mutation is the dimethylation of one 
nucleotide on the 23S rRNA, mentioned previously, that gives rise to resistance to type B 
drugs, as well as macrolides and lincosamides [Johnston et al., 2002]. 
1.2.3 Inhibitors of nucleic acid synthesis 
The sulfonamides and the diaminopyrimidines should be discussed together, as both the 
drugs indirectly inhibit nucleic acid synthesis by inhibiting folate synthesis. Folate is a 
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coenzyme necessary for the synthesis of purines and pyrimidines. Although both types 
of drugs are useful on their own, they exhibit a synergistic effect when combined. 
Sulfonamides are currently not used commonly in medicine, but the combination drug 
trimethoprim-sulfamethoxazole (TMP/SMX) is sometimes used in the treatment of 
urinary tract Infections. Sulfonamides serve as an analog of p-aminobenzoic acid. 
Therefore, they competitively inhibit an early step in folate synthesis. 
Diaminopyrimidines, of which trimethoprim is the most common, inhibit dihydrofolate 
reductase, the enzyme that catalyzes the final step In folate synthesis [Greenwood, 
2000]. Sulfonamides are rendered ineffective by over-production of p-aminobenzoic 
acid or production of an altered dihydropteroate synthetase. The substrate for 
dihydropteroate synthetase is p-aminobenzoic acid, and the altered form has a much 
lower affinity for sulfonamides than for p-aminobenzoic acid [Then, 1982]. 
Trimethoprim resistance can also result due to over-production of dihydrofolate 
reductase or production of an altered, drug-resistant form can lead to resistance [Bryan, 
1984]. In addition, both drugs can be enzymatically inactivated, resulting in resistance 
[Then, 1982]. 
The quinolones are a chemically varied class of broad-spectrum antibiotics 
widely used to treat many diseases, including gonorrhea and anthrax. Drugs in this class 
include nalidixic acid, norfloxacin, and ciprofloxacin. Quinolones inhibit bacterial growth 
by acting on DNA gyrase and topoisomerase IV, which are necessary for correct 
functioning of supercoiled DNA [Greenwood, 2000]. Although quinolones target both 
enzymes, in gram negative organisms the primary target is DNA gyrase and, in gram 
positive organisms, the primary target is topoisomerase IV [Ruiz, 2003]. There are three 
main mechanisms of resistance to quinolones. Resistance to some quinolones occurs 
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with decreased expression of membrane porins. Cross-resistance to other drugs 
requiring these porins for activity also results from these changes. A second mechanism 
of resistance is expression of efflux pumps in both gram negative and gram positive 
bacteria [Novak et al., 1999] and the third mechanism is alteration of the target 
enzymes. Several mutations have been described in both quinolone target proteins that 
result in reduced binding affinities [Ruiz et al., 2003]. It is believed that high-level 
quinolone resistance is due to a series of successive mutations in the target genes, 
rather than a single mutation [Novak et al., 1999]. 
1.2.4 Genetic mechanisms of resistance 
Bacteria also develop resistance through the acquisition of new genetic material from 
other resistant organisms. This is termed horizontal evolution, and may occur between 
strains of the same species or between different bacterial species or genera. 
Mechanisms of genetic exchange include conjugation, transduction, and transformation 
[McManus, 1997]. 
1.2.4.1 Transformation involves the passage of DNA to a recipient cell through a specific 
medium. 
1.2.4.2 Transduction is a process whereby DNA is transferred from a donor to a recipient by 
way of a host, a phage. It is still unknown whether this process causes clinically observed 
resistance to antibiotics. Because this process is highly dependent on specific phages, it 
may occur only within certain bacterial species. Only a limited amount of DNA that can 
be packed into the head of a phage can normally be transferred. 
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1.2.4.3 Conjugation is the process when DNA transfers from a donor to a recipient by simple, 
direct cell-to-cell contact. The process allows for the passage of more than one 
functional gene at a time, so that multiple resistance could occur within a single step. 
Furthermore, many different organisms can act as recipients, allowing DNA (resistant 
genes) to be donated freely from different sources. Resistance can be passed from 
commensals in the gut to a pathogen existing in the same environment. Conjugation is 
thus an important and highly efficient process for transferring genes, and the acquisition 
of resistance by most pathogens is probably a result of this process. Other mobile 
genetic elements include transposons and integrons. 
1.2.4.4 Transposons are sequences of DNA that are capable of transposing or moving from one 
location to another within the genomic DNA or between plasmids and genomic DNA. 
Transposons may contain one or more genes, including those necessary for 
translocation, and often contain either resistance genes or genes necessary for 
degradative enzymes [Scott, 2002]. These genes are flanked by insertion sequences that 
allow insertion of the DNA into the piasmid or genomic DNA. 
1.2.4.5 Integrons are mobile elements that consist of conserved sequences of DNA bordering 
"cassettes" of genes. The conserved sequences contain the genes necessary for 
integration, promotion, and capture of cassettes. Gene cassettes are promoter-less 
units that contain the genes for antibiotic resistance or for virulence factors [Roe & 
Pillai, 2003]. Integrons are capable of carrying several gene cassettes and are associated 
with multiple antibiotic resistance and pathogenicity islands. 
1.2.4.6 Plasmids are double stranded, circular or linear DNA molecules capable of autonomous 
replication. They are mostly a phenomenon of the prokaryotic world, although they 
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exist in some groups of primitive eukaryotes as yeast, fungi and cellular slime moulds 
[Rush & Misra, 1985]. They belong to a special biological category of extra-
chromosomal, accessory DNA elements [Campbell, 1981]. Natural plasmids have 
systems guarantying their autonomous replication, controlling the copy-number and 
ensuring stable inheritance during cell division. Many plasmids can promote their 
horizontal transfer among bacteria of different genera and kingdoms, through the 
conjugation process. However, the presence of plasmids must have some biological cost 
for the bacterial host. It is therefore plausible that a selfish element that does not 
benefit its host can be eliminated from the bacterial population. The plasmid-encoded 
functions have been extensively investigated and there is ample evidence that natural 
plasmids have evolved as an integral part of the bacterial genome, providing additional 
functions to their host [Thomas & Nielsen, 2005]. Resistance genes located on plasmids 
offer immediate advantage to their host under antimicrobial pressure. Bacterial plasmid 
genome sequence comparisons provided the historical events through which plasmids 
are assembled. Their evolution seems to proceed by the assemblage of modular 
components by transposition, homologous recombination, and illegitimate 
recombinational events [Bennett, 2004]. This is particularly evident when the 
phenomenon of antimicrobial resistance is analyzed. Antimicrobial resistance arises 
from a complex multi-factorial process supported by mobile genetic elements that 
contain and transfer resistance determinants. Resistance genes located on plasmids 
move from one bacterium to another, conferring phenotypic characteristics. Several 
resistance plasmids have been described to carry virulence factors, such as bacteriocins, 
siderophores, cytotoxins, or adhesion factors [Martinez & Baquero, 2002] and virulence 
plasmids have been described to carry resistance genes [Herrero et al., 2006]. For 
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plasmids carrying virulence and resistance linked determinants, an infective population 
vtfill be selected for antimicrobial resistance, and antimicrobial resistance pressure will 
select the virulence traits. However, once those determinants have been selected in the 
bacterial host, they can evolve further and eventually be transferred to other bacterial 
population. The acquisition of antimicrobial resistance genes on virulence plasmids 
could represent a novel tool in bacterial evolution, implementing adaptive strategies to 
explore and colonize novel hosts and environments [Martinez & Baquero, 2002]. 
Plasm id-mediated resistance to p-lactam antibiotics in E. coli is of major concern 
in hospitals. Studies show that for both nosocomial and community acquired infections 
the mortality and morbidity in prolonged hospitalization, are twice as high in patients 
infected with antibiotic-resistant strains than with susceptible strains [Lautenbach et al., 
2001]. Bacteria can possess plasmids that can code for more than one ^-lactamase in 
addition to their expression of chromosomal enzyme. Due to carriage of plasmids and 
promiscuous exchange of such material between bacteria, these resistance genes have 
spread widely and are also subject to mutation [Lee et al., 2001]. Plasmid mediated p-
lactamases were first recognized in Gram-negative bacteria in the early 1960s, shortly 
after the introduction of ampicillin [Livermore, 1993]. 
1.3 P-Lactam resistance 
Figure 1.1 shows structures of some of the P-lactam antibiotics and the carbapenems as 
well. There are three major ways by which bacteria avoid the bactericidal effect of p-
lactams: 
(a) Production of P-lactamases: p-lactamases are bacterial enzymes that hydrolyze 
the P-lactam ring and render the antibiotic inactive before it reaches the PBP 
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(a) Cefoxitin (b) Ceftazidime 
O^K i -^ vc 
(c) Cefotaxime (d) Ceftriaxone 
")!^ ^ Vv ^ 
Fig 1.1(a) Structures of some of the p-lactams. Ail structures were retrieved from 
Drugbank (http://www.druebank.ca/search/chemauerv: accessed on 
17/10/09). 
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(e) Doripenem (f) Imipenem 
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HH 
d' 
y / 
~**'f 
H 
N 
V' 
- S H 
.. ^° 
H ^ 
OH 
(g) Meropenem (h) Ertapenem 
H0»»" 
Fig 1.1(b) Structures of the carbapenems. All structures were retrieved from 
Drugbank (http://www.clrugbank.ca/search/chemquerv) except the 
structure of 'Doripenem' which was taken from Pubchem 
(http://www.pubchem.ncbi.nlm.nih.gov/search): both websites were 
accessed on 17/10/09. 
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target. The underlying structural kinship that p-lactamases share with PBPs 
allows these enzymes to bind, acylate, and use a strategically located water 
molecule to hydrolyze and thereby inactivate the p-lactam [Massova & 
Mobashery, 1998]. 
(b) Altered PBPs that exhibit low affinity for P-iactam antibiotics: Examples are PBP 
2x of Streptococcus pneumoniae and PBP 2' (PBP 2a) of Staphylococcus aureus 
[Chambers , 1997]. These PBPs are relatively resistant to inactivatlon by 
penicillins and are able to assume the functions of other PBPs when the latter 
are inactivated. 
(c) Lack or diminished expression of outer membrane proteins (OMPs) in granv 
negative bacteria: The loss of OMPs restricts the entry of certain P-lactams into 
the peripiasmic space of gram-negative bacteria and hence access to PBPs on the 
inner membrane. Imipenem resistance in Pseudomonas aeruginosa and 
Klebsiella pneumoniae can arise from the loss of OmpD2 and of OmpK36, 
respectively [Livermore, 2001; Gootz, 2004; Jacoby et al., 2004]. The destruction 
of p-lactams by P-lactamases is the most important resistance mechanism in 
gram-negative bacteria. 
1.4 Extended-spectrum-^-lactamases (ESBLs) 
ESBLs are globular proteins composed of alpha-helices and beta-pleated sheets [Knox, 
1995]. These are p-lactamases that hydrolyze extended-spectrum cephalosporins with 
an oxyimino side chain. ESBLs are usually capable of hydrolyzing penicillins (e.g, 
ampicillin and piperacillin), cephalosporins of the first-, second-, third- and fourth-
generations, and the monobactam aztreonam (but not the cephamycins or 
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carbapenems) [Ambler et al., 1991]. The distinctive property of ESBLs (e.g. members of 
TEM and SHV families) of being inhibited by beta lactamase inhibitors such as clavulanic 
acid, tazobactam, or sulbactam, is duly exploited in the double-disk synergy test meant 
for ESBL-detection. 
The Ambler scheme and the Bush-Medeiros-Jacoby system [Ambler et al., 1991; 
Bush et al., 1995] are the two systems commonly used for the classification of beta 
lactamases (Table 1.2). Typically, the ESBLs derive from genes for TEM-1, TEM-2, or SHV-
1 by mutations that result in a change in the amino acid configuration around the active 
site of these enzymes. ESBLs are classified in group 2be in the Bush-Medeiros-Jacoby 
system and class A in the Ambler system. Authors have long back observed that point 
mutations in the SHV and TEM p-lactamases which cause single amino acid substitutions 
(Aspl04->Lys, Argl64^Ser, Argl64->His, Aspl79^Asn, Gly238-^Ser, and Glu240^Lys) 
are responsible for this resistance [Philippon & Jacoby, 1989; Jacoby & Medeiros, 1991]. 
Hence these enzymes are a potent weapon of bacteria and a significant research 
problem for scientists. 
1.4.1 Epidemiology 
Although these enzymes were first detected in Germany in 1983 among Klebsiella spp 
[Knothe et al., 1983], it was not long before that ESBLs were detected in the United 
States and Asia. The estimated prevalence of ESBL-producing strains of E. coli and K. 
pneumoniae in the United States is relatively low [Pfaller & Segreti, 2006]. In contrast, 
the prevalence of ESBL-producing K. pneumoniae is high in the Asian Pacific region and 
in Latin America [Pfaller & Segreti, 2006]. The SENTRY surveillance program reported the 
frequency of ESBL-producing K. pneumoniae to be approximately 37% in Latin America 
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Table 1.2 Classification schemes for beta lactamases 
BiiA-Jacoby-Medeiros 
system 
Groupl 
cephalosporinases 
Group 2 penicillinases 
(clavulanic acid 
suscqitible) 
Group 3 metallo-beta 
lactamase 
(metalloenzymes) 
Group 4 
Major 
subgroups 
-
2a 
2b 
2be 
2br 
2c 
2e 
2f 
2d 
3a 
3b 
3c 
Ambler System 
C (cq>baloqx)rinases) 
A (sefine ^4actainases) 
A 
A 
A 
A 
A 
A 
D(oxacillin-
bydrolyzing) 
B (metalloenzyines) 
B 
B 
Not classified 
Main attributes 
Usually chromosomal; Resistance to all ^ 
lactams except carbapenems; Not inhibited 
Sti^ rfQriococcd pemcillinases 
Broad-spectrum - TEM-1, TEM-2, SHV-1 
ExtaKied-q)ectnmi-TEM-3-160, SHV-2-101 
Inhibitor resistant TEM (IRT) 
Carbraicillin-hydrolyzing 
Cephalosporinases inhibited by ciavulanate 
Carb^wnemases inhibited by ciavulanate 
Cloxacillin-faydrolyzing (OXA) 
Zinc-dependent caibapenemases 
Miscellaneous enzymes, most not yet sequenced 
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vs. 7% in the United States [Sader et al., 1998]. A study [IVlinarini et al., 2007] found tine 
prevalence of ESBL-producers among Klebsiella spp to be as high as 25.8% in Brazil. 
Prevalences of ESBL-producing Klebsiella spp has been reported to be 5%, 21.7%, 31% 
and 38% in Japan, Taiwan, Philippines and Malaysia/Singapore, respectively. In addition, 
the prevalence of ESBL-producing £ coli varies from 6% to 23% within one region 
[Parasakthi & Ariffin, 2001]. Several studies from India have also reported a high 
prevalence of ESBL producing pathogens (Babypadmini & Appaiaraju, 2004, Shal<il et al., 
2009]. Currently, the CTX-M type enzymes have started dominating the globe [Canton & 
Coque, 2006; Livermore et al., 2007]. PER- and OXA type enzymes are more common in 
P. aeruginosa and Acinetobacter spp., but there have been sporadic reports of PER type 
ESBLs in Enterobacteriaceae as well [Luzzaro et al., 2006]. Plasmid-borne KPC enzymes 
have been reported among K. pneumoniae and other enterobacteria from the United 
States and other countries [Gootz et al., 2009]. These are of due concern because of 
their ability to inactivate carbapenems. 
1.4.2 CTX-M: the leading therapeutic challenge 
These are now considered the most prevalent ESBLs worldwide [Livermore et al., 2007]. 
These enzymes show potent hydrolytic activity against cefotaxime and hence they are 
called as 'CTX-Ms'. Organisms producing CTX-M-type P-lactamases typically have 
cefotaxime minimum inhibitory concentrations (MICs) in the resistant range (16 to 256 
Mg/ml), while ceftazidime MICs are usually in the apparently susceptible range (2 to 8 
Mg/ml). However, some CTX-M-type ESBLs may actually hydrolyze ceftazidime and 
confer resistance to this cephalosporin (MICs as high as 256 kig/ml) [Poirel et al., 2002]. 
Aztreonam MICs are variable. CTX-M-type p-lactamases hydrolyze cefepime with high 
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efficiency [Tzouvelekis et al., 2000], and cefepime MiCs are higher than observed in 
bacteria producing other ESBL types pTu et al., 2002]. CTX-M-type p-lactamases have 
40% or less identity with TEIVI and SHV-type ESBLs. CTX-M beta-lactamases are 
commonly found in K. pneumoniae, E. coli, typhoidal and non typhoidal Salmonella, 
Shigella, Citrobacter freundii, Enterobacter, spp., and Serratia marcescens [Walther-
Rasmussen & Hoiby, 2004]. Different genetic elements may be involved in the 
mobilization of genes coding for CTX-M enzymes, designated as 'blocn-M- Insertion 
Sequences (e.g., \SEcpl or ISfcpl-like insertion sequences) have been repeatedly 
observed upstream of open reading frames (ORFs) encoding the CTX-M-1, CTXM-2, CTX-
M-3, CTX-M-9, CTX-M-13, CTX-M-14, CTX-M-15, CTX-M-17, CTX-M-19, CTX-M-20, and 
CTX-M-21 p-lactamases [Khalaf et al., 2009; Park et al., 2009; Rodriguez et al., 2009]. 
1.4.3 Structure-function relationships 
The study of the atomic structures of class A ESBLs has revealed that the active site is 
selectively "remodelled and expanded" to accommodate the bulky Rl side chain of 
extended spectrum cephalosporins [Knox, 1995]. 
1.4.3.1 The key players behind the substrate specificity of CTX-IMs 
Amino acid residues Asnl04, Asnl32, Ser237, and Asp240 have been identified as the 
key players behind the substrate specificity of the CTX-M beta-lactamases by several 
studies that used comparative sequence analyses, modelling, and mutagenesis 
techniques [Bauernfeind et al., 1996]. Ser237, has been observed to be involved in the 
extension of the substrate specificities of TEM and SHV ESBLs to cefotaxime [Knox, 
1995]. The Ser237Ala substitution in the CTX-M-4 enzyme induces a decrease both in 
relative hydrolytic activity against cefotaxime and in susceptibility to inhibition by 
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clavulanate [Gazouli et al., 1998]. The acyl intermediate structure of Toho-1 in complex 
with cefotaxime shows a rotation of the Ser237 side chain, which prevents steric clashes 
with the methoxyimino group of cefotaxime and which allows the formation of a 
hydrogen bond with the carboxylate group of cefotaxime [Shimamura et al., 2002]. It 
has been suggested that this interaction assists in bringing the carbonyl group of the ^-
lactam ring of cephalosporins to the optimal position in the oxyanion hole for acylation 
[Shimamura et al., 2002]. The relatively low penicillinase activities of CTX-M enzymes 
may be caused by Van der Waals contact between residue Ser237 and the methyl group 
of the thiazolidine ring. Asnl04, Asnl32, Ser237, and Asp240 residues establish 
hydrogen bonds with the amide and aminothiazole groups of the acyl-amide-cefotaxime 
chain. This unusual acyl intermediate of CTX-M enzymes in complex with cefotaxime 
may therefore be involved in the activities of the oxyimino-cephalosporinases by fixing 
cefotaxime tightly in the binding site [Shimamura et al., 2002]. 
1.4.3.2 The omega loop 
The structure of Toho-1 revealed that the omega loop (amino acid positions 161-179) 
has fewer hydrogen bond interactions with the ^3 strand in the vicinities of Asnl70 and 
Asp240 than the restricted-spectrum p-iactamase of Bacillus licheniformis, the enzyme 
most doseiy related to Toho-1 at the structural level. No hydrogen bond has been 
observed between the Phel60 residue and ThrlSl and Aspl57 residues, which both 
connect the N and C termini of the omega loop in restricted-spectrum p-lactamases 
[Ibuka et al., 1999]. These structural features may increase the flexibility of the omega 
loop. The structures of acyl intermediates of the Toho-1 enzyme show a shift of the 
omega loop to helix H5 [Shimamura et al., 2002] as a result of a complex structural 
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rearrangement in the hydrophobic core in the vicinity of the omega loop (the residues 
involved in the rearrangement are Cys69, Ser72, Metl35, Phel60, and Thrl65). This 
shift narrows the binding site, but the steric contacts of the Prol67 and Asnl70 residues 
with the aminothiazoie ring of cefotaxime are avoided. 
1.4.3.3 The steps of CTX-M evolutionary ladder: residues at positions 167 and 240 
Mutants with point mutations in common CTX-M enzymes exhibiting improved catalytic 
efficiencies against ceftazidime have been observed [Knox, 1995], The change in 
activities of CIK-Ms leading to the evolution of more variants may be due to point 
mutations present either inside or outside of the active site omega loop (amino acid 
positions 161 to 179) [Sturenburg et al., 2004]. For example the P167T mutation 
differentiates CTX-M-23 from CTX-M-l, CTX-IVI-3 and CTX-M-15. However the CTX-Ms, 
having identical residues present in the omega loop may still have some difference in 
their enzymatic activities due to mutations present outside the omega loop. The CTX-M-
15, CTX-M-16, and CTX'M-27 enzymes harbor the Asp240Gly substitution. The presence 
of Lys and Arg residues at position 240 are known to increase the enzymatic activities of 
the TEM and SHV ESBLs against ceftazidime [Knox, 1995]. The Lys and Arg residues are 
positively charged and can form an electrostatic bond with the carboxylic acid group on 
oxyimino substituents of ceftazidime [Huletsky et al., 1993; Cantu et al., 1996]. Neutral 
residue Gly240 is not able to form electrostatic interactions with ^-lactams but could 
favor the accommodation of the oxyimino-ceftazidime side chain [Bonnet et al., 2001; 
Bonnet etal., 2003]. 
1.5 Neonatal infections 
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Neonates are at much higher risk for developing infections [Fanos et al., 2007] because 
of their immature immune system, particularly the preterm ones. One reason for the 
increased risk is that antibodies, which help protect mothers from infections, do not 
cross through the placenta to the fetus until approximately 30 weeks of gestation. The 
antibodies present at birth take time to reach optimum levels, which also affects the 
protection provided to the neonate. Causes of infections in newborns can be divided 
into three main groups: intrauterine, intrapartum, and postnatal infections. All three 
groups include factors that increase the infant's risk of coming in contact with an 
organism that can cause an infection (Table 1.3). 
Intrauterine or factors that increase the risk before birth include the following: 
poor prenatal care, poor nutrition, recurrent abortions, and substance abuse. 
Intrauterine infections occur when pathogenic organisms cross the placenta into the 
fetal circulatory system. The organisms, such as cytomegalovirus (CMV), can reside in 
the amniotic fluid. Other organisms ascend from the vaginal track, infecting the 
membranes and causing them to rupture. This rupture of membranes can lead to 
infections of the respiratory and gastrointestinal tract of a newborn. 
Intrapartum or factors that increase the infants chance of becoming infected 
during the birthing process include: prolonged rupture of membranes {>12 to 18 hours), 
urinary tract infections, preterm labor, prolonged or difficult labor, maternal fever and 
maternal infections. Most infections during the birthing process are related to the infant 
coming into unavoidable contact with an infected birth canal. The birth canal can host 
bacteria that an infant's immune system cannot defend against. 
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Table 1.3 Causes of infections in newborns 
Infections 
Intrauterine 
Intrapartum 
Postnatal 
Risk Factors 
Poor nutrition. Poor prenatal care, Substance abuse 
PrenDature rupture of membranes. Maternal fever, Prolonged labor. Maternal 
UTl 
Male sex. Birth asphyxia. Low birth weight 
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Postnatal infections may be contracted after delivery, as in tlie case with 
infections contracted during resuscitation, or as a result of a nosocomial infection due to 
improper hand washing. Infections in the postnatal period are more common in those 
infants who require foreign objects to be introduced into their systems. Items like 
endotracheal tubes or indwelling catheters increase the risk of an infant becoming 
septic. 
The single most important risk factor for infection in the neonate is prematurity 
[Seo et al., 1992]. Neonatal factors that increase the infant's chance of becoming sick 
include: low birth weight, prematurity, birth asphyxia, meconium staining, and 
resuscitation. There is a significant correlation between gestational age and risk for 
neonatal infection [Elster et al., 2009]. Infants born at less then 32 weeks gestation are 
generally supposed to have higher risk of developing infection. Reasons for this include 
immature immune system, thinner skin, and the frequent need for insertion of foreign 
objects. Positive cerebrospinal fluid (CSF), urine, and bacterial blood cultures are lab 
results that confirm infection in a neonate. Other abnormal results which should be 
checked in an infent suspected of sepsis are hypoglycemia, hyperglycemia, metabolic 
acidosis, thrombocytopenia, or hyperbilirubinemia. The blood culture and complete 
blood count (CBC) are the most helpful tests to identify an infection and the causative 
organism. 
CBC findings that indicate an infection is present include: an elevated or 
decreased white blood count (WBC), a low platelet count, and a high l:T ratio [Aulia et 
al., 2003]. The l:T ratio is a calculation which is done to show the percentage of 
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immature to total white blood cells. When the l:T ratio is greater than 0.2, this indicates 
that there is a "left shift." This left shift means that there are more immature 
neutrophils than mature neutrophils circulating around in the bloodstream. A neutrophil 
is a type of white blood cell that defends the body against organisms that cause 
infection. When infection is present the neutrophils migrate out of the capillaries and 
into the infected site, where they ingest and destroy the pathogens causing the 
infection. When the demand for the neutrophils exceeds the supply in circulation, 
immature neutrophils are released into the blood to help fight off the infection. This is 
labeled a "left shift". As the infection diminishes and neutrophils are replenished, a 
"shift to the right" occurs, indicating that everything is back to normal. 
1.5.1 E. coli in neonatal infections 
E. coli is among the most common causes of gram negative neonatal infections 
worldwide. This bacterium is found in the mother's genital tract with a high incidence of 
colonization in the neonate. The pathogen can cause severe infections that may lead to 
respiratory distress, cardiovascular collapse, meningitis, multi-organ failure, and even 
death. E. coli is usually treated with gentamicin or amikacin. 
1.6 Diabetic foot infections 
The Indian diabetic population is expected to increase to 57 million by 2025 [Abdul et 
al., 1999]. Individuals with diabetes have at least a 10-fold greater risk of being 
hospitalized for soft tissue and bone infections of the foot than the individuals without 
diabetes [Boyko & Lipsky, 1995]. Figure 1.2 shows foot ulcer of a diabetic patient. 
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Fig 1.2 The diabetic foot ulcer [Source: Frykberg, 2002]. 
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1.6.1 Definition of 'Diabetic foof 
Diabetic foot refers to a variety of pathologic conditions which affect the feet of people 
suffering from diabetes. According to World Health Organization diabetic foot is defined 
as 'the foot of a diabetic patient that has the potential rislc of pathologic consequences, 
including infection, ulceration, and destruction of deep tissues associated with 
neurologic abnormalities, various degrees of peripheral arterial disease, and metabolic 
complications of diabetes in the lower limb' [Frykberg et al., 2006]. 
1.6.2 Definition of 'Diabetic foot infection' 
A diabetic foot infection is most simply defined as any inframalleolar infection in a 
person with diabetes mellitus [Lipsky et al., 2004]. Spectrum of infection includes 
paronychia, cellulitis, myositis, abscesses, necrotizing fasciitis, septic arthritis, tendonitis, 
and osteomyelitis. The most common and classical lesion, however, is the infected 
diabetic "mal perforans" foot ulcer. This wound results from a complex amalgam of risk 
factors [Lipsky et al., 2004]. Once the protective layer of skin is breached, underlying 
tissues are exposed to bacterial colonization. This wound may progress to become 
actively infected, and, by contiguous extension, the infection can involve deeper tissues. 
This sequence of events can be rapid (occurring over days or even hours), especially in 
an ischemic limb. Various immunologic disturbances, especially those that involve 
polymorphonuclear leukocytes, may affect some diabetic patients, and these likely 
increase the risk and severity of foot infections [Schubert & Heesemann, 1995]. It is 
estimated that 15% of diabetic patients would develop a foot ulcer during the course of 
their disease [Boulton AJM et al., 2004], Foot ulceration is the most common single 
28 
Chapter 1 
precursor to amputation and has been identified as a component in 85% of lower-
extremity amputations [Margolis et ai., 2005]. 
1.6.3 Wagner Classification System 
Diabetic patients may develop many types of foot wounds which are due to 
combination of neuropathy, ischemia and infection. For evaluation and determination of 
the severity of diabetic foot, various classification systems are in use. rt seems that poor 
clinical outcomes are generally associated with infection, peripheral vascular disease, 
and increasing wound depth; it also appears that the progressive cumulative effect of 
these comorbidities contributes to a greater likelihood of a diabetic foot ulcer leading to 
a lower-limb amputation. Most common and widely used classification system is the 
Wagner System [Wagner, 1981]. This system is basically anatomical with gradations of 
superficial ulcer, deep ulcer, abscess osteitis, gangrene of the fore foot, and gangrene of 
the entire foot. Only grade 3 addresses the problem of infection. In this system, foot 
lesions are divided into different grades starting from grade 0 to grade 5. Grade 0 
includes high risk foot but no active lesion and grade 5 includes gangrene of entire foot. 
But this system does not mention about ischemia or neuropathy which is the drawback 
of this system. Otherwise it is a sound predictor of risk of amputation. It is shown in 
table 1.4. 
1.6.4 Risk factors for diabetic foot ulceration and infection 
The major risk factors for foot ulceration are: nerve damage (neuropathy) and impaired 
blood supply in combination with deformities of the feet and the resulting increased 
pressures on areas of the sole. Other contributing factors include: a history of previous 
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Table 1.4 Wagner Classification System 
Grade 
0 
1 
2 
3 
4 
5 
Lesion 
No open Lesion 
Superficial ulcer 
Deep ulcer to tendon or joint capsule 
Deep ulcer with abscess, osteomyelitis, or joint sepsis 
Local gangrene- fore foot or heel 
Gangrene of entire foot 
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foot ulcers and amputation, inadequate footwear, a lack of (or low-quality) podiatry 
care, poor diabetes management, long duration of diabetes, chronic renal disease, poor 
visual acuity, psychological factors and behavioral factors, smoking, old age, low social 
status. Studies have reported 'male sex" as a significant risk factor for non-healing foot 
ulcers [Prompers et al., 2008]. 
1.6.5 Role of Infection 
Infection is an important complicating factor in ulceration. Diabetic patients are more 
prone to infection, as they have an altered response to infectious process owing to 
defects in their immune system [Delamaire et al., 1997]. Wound healing is delayed in 
diabetic patients as a result of abnormal cellular and inflammatory pathways involving 
fibroblasts, neutrophils, and advanced glycation end products [Yan et al., 2003]. The 
rate of infection parallels the level of blood glucose control and it may progress rapidly 
with devastating consequences. Furthermore, the neuropathic and ischemic deficiencies 
in diabetic patients predispose them to infection and then compound the problem by 
potentiating infection once a pathogen has been introduced. Many patients develop 
abscess formation, osteomyelitis and gangrene. Sepsis can track along the planes of the 
plantar fascia and flexor tendon sheaths. In the infected foot, edema may be 
responsible for the thrombosis of digital vessels and gangrene of the toes. Classical 
signs of infection may not always be present in the infected diabetic foot because of the 
consequences of neuropathy, alterations in the foot microcirculation, and leukocyte 
abnormalities. Fever, chills, and leukocytosis may be absent in up to two thirds of 
patients with diabetes with extensive foot infections, and hyperglycemia is often the 
sole presenting sign. 
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1.6.6 Microbes associated witti foot ulcers 
The microflora of leg and foot ulcers is usually polymicrobial [Citron et al., 2007] and 
several studies that used molecular techniques have emphasized the complex ecology of 
these wounds [Davies, 2003]. 
Knovi^ ledge of the etiologic agent(s) that caused the wound infection is helpful in 
selecting definitive antibiotic therapy. Staphylococci have been the predominant 
organisms isolated from both prospective, purpose-collected samples and retrospective 
analysis of clinical investigations. Staphylococci have been reported in varying 
frequencies from diabetic foot ulcers. Yates et al have recently observed a prevalence of 
43% for Staphylococci among the organisms isolated from infected foot ulcers [Yates et 
al., 2009]. Xu et al., observed a prevalence of 41% and 47% for S. aureus and S. 
epidermidis among the cases of diabetic foot ulcers, respectively [Xu et al., 2007]. 
Pseudomonas aeruginosa is another frequently identified organism and has been found 
in 12% of ulcers in a recent study [Martinez-Gomez et al., 2009]. A number of other 
aerobic species have also been reported, including £ coli [Varaiya et al., 2008], 
Enterobacter species [Percival et al., 2008], Klebsiella species [Goldstein et al., 2008], 
Enterococcus species [Martinez-Gomez et al., 2009], and Proteus species [Raja, 2007] 
etc. 
1.6.7 Treatment and management of diabetic foot infections 
One has to make careful choices among the various topical, oral, and parenteral 
antibiotic agents. Virtually ail severe and some moderate infections require parenteral 
therapy, at least initially. Highly bioavailable oral antibiotics can be used in most mild 
and in many moderate infections, including some cases of osteomyelitis. Topical therapy 
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may be used for some mild superficial infections. Sharp debridement and management 
of underlying infection and ischemia are also critical in the care of foot ulcers. Prompt 
and aggressive treatment of diabetic foot ulcers can often prevent exacerbation of the 
problem and eliminate the potential for amputation. Optimal management of diabetic 
foot infections can potentially reduce the incidence of infection-related morbidities, the 
need for and duration of hospitalization, and the incidence of major limb amputation. 
Despite a panoply of studies, the optimal management of diabetic foot infections 
remains poorly understood. Antibiotics, surgery, rehabilitation and/or off-loading, and 
glycemic control remain the cornerstones of treatment; alternative therapies remain 
largely unproven [Miller & Henry, 2009]. 
Some argue that many apparently uninfected diabetic foot ulcers are actually 
subclinically infected—that is, they contain a high "bioburden" of bacteria that results in 
"critical colonization" levels and impairs wound healing [Edmonds & Foster, 2004]. 
Available published evidence does not support the use of antibiotics for the 
management of clinically uninfected ulcerations, either to enhance wound healing or as 
prophylaxis against infection because antibiotic use encourages antimicrobial resistance, 
incurs financial cost, and may cause drug-related adverse effects. In some 
circumstances, it is difficult to decide whether a chronic wound is infected, such as 
when the foot is ischemic, has abnormal coloration or a fetid odor, has friable 
granulation tissue, is associated with unexpected pain or tenderness, or when an 
otherwise properly treated ulcer fails to show healing progress [Schultz et al., 2003]. 
1.6.8 Antibiotic regimens 
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Selection of the antibiotic regimen initially involves decisions about the route of 
therapy, the spectrum of microorganisms to be covered, and the specific drugs to 
administer and later involves choosing the definitive regimen and the duration of 
treatment. Initial therapy is usually empirical and is based on the severity of the 
infection and on any available microbiological data, such as recent culture results or 
current Gram-stained smear findings. For severe infections and for more-extensive, 
chronic moderate infections, it is safest to commence therapy with broad-spectrum 
agents. These should have activity against gram-positive cocci (including MRSA in 
locations where this pathogen is common), as well as gram-negative and obligate 
anaerobic organisms. Clinical trials suggest that fluoroquinolones, cephalosporins, beta-
iactam inhibitor penicillins, and carbapenems are effective. These suggested agents are 
derived from available published clinical trials and are not meant to be inclusive of all 
potentially reasonable regimens. Similar agents could be used, depending on various 
clinical, microbiological, epidemiological, and financial considerations. A study found 
imipenem to be equally potent agains Gram-positive and negative diabetic foot isolates 
while vancomycin was overall the most effective drug against Gram-positive isolates 
[Raja, 2007]. Importantly the author concluded that no antimicrobial agent can cover all 
of the organisms isolated from diabetic foot ulcers [Raja, 2007]. 
1.7 Urinary tract infections (UTIs) 
Urinary tract infections (UTIs) are among the most frequently reported infections among 
intensive care unit (ICU)-patients [Hassanzadeh et al., 2009]. UTIs are clinically defined 
as the bacterial colonization of any tissue along the urinary tract, from the urethral 
opening to the kidneys. The term urinary tract infection encompasses a broad range of 
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clinical entities that are associated with a common finding of a significant amount of 
bacteria in urine and a positive urine culture [Duse & Klugman, 1993]. The infection may 
be community acquired or nosocomial, often as a consequence of urethral 
catheterization. Urinary tract infections are very common in women [Perez-Lopez et al., 
2009]. 
1.7.1 Etiology 
Enterobacteriaceae are endogenous to the gastrointestinal tract and are often 
implicated in UTIs. E. coli causes about 80% of all the community acquired UTIs [Stamm, 
2006] followed by Klebsiella spp., Pseudomonas aeruginosa, and Proteus mirabilis [Gales 
et al., 2002]. S. saprophyticus [Widerstrom et al., 2007] and group D Streptococci 
(Enterococci) are the Gram positive enteric bacteria that commonly cause UTIs [Rebuck 
et al., 2000]. Infrequent causative agents of UTIs may include bacteria such as 5. aureus, 
Gardnerella vaginalis, Corynebacterium and Lactobacilli, yeasts such as Candida (in 
diabetic patients or patients with indwelling urinary catheters) and viruses such as 
Adenovirus type 2 (associated with acute haemorraghic cystitis in children) [Duse & 
Klugman, 1993]. Non-specific urethritis is frequently caused by sepsis of Chlamydia, 
Ureaplasma and Mycoplasma, mainly introduced by sexual contact. Gonococci may also 
invade the urinary tract as well as the reproductive system, by entering the bladder via 
the urethra with an interim phase or periurethral and distal urethral colonization 
[Hooton, 2000]. 
Acinetobacter baumannii, a gram-negative coccobacillus, is currently 
recognized by the Infectious Diseases Society of America as one of the most important 
pathogens threatening our health care delivery system [Talbot et al., 2006]. It is an 
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important opportunistic pathogen implicated in urinary tract infections [Bergogne-
Berezin & Towner, 1996]. The emergence of carbapenem-resistant A. baumannii was 
reported in the United States in 1991 [Go et al., 1994]. Since then, many hospital-wide 
outbreaks have been reported worldwide [Kohlenberg et al., 2009]. Indeed, the 
Antimicrobial Availability Task Force of the Infectious Diseases Society of America 
recently identified A. baumannii, among "particulariy problematic pathogens" for 
which there Is a desperate need for new drug development [Talbot et a!., 2006]. 
1.7.2 Antibiotic regimens 
When choosing an appropriate agent to combat these infections, there are several 
factors for clinicians to consider. First, the drug of choice should have good in vitro and 
in vivo activity against many of the organisms known to cause UTIs. Additionally, the 
agent should be able to achieve high and prolonged concentrations in the urine and 
surrounding urinary tract tissues without loss of activity [Bergan, 1997; Jancei & Dudas, 
2002]. In terms of the patient's well being, drugs should have the fewest and mildest 
side effects possible, with minimal effects on normal colonic and vaginal flora [Sobel & 
Kaye, 2004].Treatment of uncomplicated UTIs have in the past included aminopenicillins 
(amoxicillin, ampicillin), first generation cephalosporins (cephalothin, cefazolin), second 
generation cephalosporins (cefoxitin, cefuroxime), third generation cephalosporins 
(cephotaxime, ceftriaxone, ceftazidime), sulfamethaxazole-trimethoprim combinations 
(cotrimoxazole), amoxicillin/clavulanic acid (augmentin), and the flouroquinolones such 
as ciprofloxacin [Duse & Klugman, 1993; Hindler et al., 1994; Abdel-Rahman & Kearns, 
1998; Bannister et al., 2000]. With their excellent bioavailability when orally 
administrated, good tissue penetration, low incidence of side effects and broad 
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spectrum of activity, fluoroquinolones are prescribed to combat a variety of clinical 
infections and are especially favored in combating complicated UTIs [Mulholland, 1996; 
Mascaretti, 2003]. 
1.8 Bioinformatics, drug-discovery and MDR-research 
Bioinformatics is the application of tools of computation and analysis to the capture and 
interpretation of bioiogical data [Bayat, 2002]. Novel approaches to rational drug 
discovery have been exploding in the last years as high-throughput data (structure, 
binding affinity and functional effects) become available for both targets and ligands of 
pharmaceutical interest [Rognan, 2007]. An example of the application of bioinformatics 
in therapeutics was the development of designer targeted drugs such as imatinib 
mesylate (Gleevec), which interfered with the abnormal protein made in chronic 
myeloid leukaemia. The ability to identify and target specific genetic markers by using 
bioinformatic tools facilitated the discovery of this drug [Bayat, 2002]. 
Scientists are increasingly using bioinformatics in MDR-research these days 
[Gonzalez-Pons et al., 2009]. The rapid diversification of ESBLs capable of hydrolyzing 
our most potent 3-lactams is of serious concern. The efficient inhibition of these 
enzymes is therefore need of the hour in clinical research. There is a paucity of data 
concerning ESBLs prevalent in India. To the best of our knowledge there is no study that 
reports modelling of CTX-M-15, the most frequently encountered ESBL in India. Also, the 
present study describes docking of carbapenemases like KPC2, SMEl, IMI l and SFCl 
with target drugs (carbapenems) and various inhibitors. This information might help in 
designing versatile inhibitors against the rapidly emerging 3-lactamase-variants. 
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1.9 Objectives of the study 
In view of the present background we initiated our study with the following objectives. 
1(a) To find the prevalence of ESBL-producing E. coli and K. pneumoniae in the 
neonatal intensive care unit (NICU) of Aligarh, hospital, India and to identify the 
risk factors associated with the acquisition of these organisms. 
(b) To characterize the mode of transmission of btocn-M and WOTEM among the ESBL-
producing £ coli strains of the NICU and to identify risk factors for "sex-
associated ESBLisroducing £ coli acquisition status" of the neonates. 
2(a) To assess potential risk factors for diabetic foot ulcers infected with multidrug 
resistant organisms (MDROs) and to investigate antibiotic susceptibility patterns 
and ESBL-production in bacteria isolated from these ulcers. 
(b) To characterize the mode of transmission of b/oc™-M and blo^M among ESBL-
producing £ coli strains isolated from infected diabetic foot ulcers, and to 
identify the risk factors for "sex-associated MDRGNB infection status" of the 
ulcers. 
3 To screen A. baumannii strains isolated from patients having community-
acquired urinary tract infections for the presence of b/ocrx-M, blcht^M, anvA, rmtA, 
rmtB and integrons and to characterize the mode of transmission of bloax-M and 
b/oTEM in the ESBL-producers among them. 
4 To identify the amino acid residues crucial to the "enzyme-drug" and "enzyme-
inhibitor" interactions with reference to CTX-M variants as well as 
carbapenemase enzymes by using homology modelling and docking studies. 
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2.1 Materials 
Materials used during the study are listed below: 
2.1.1 Antibiotics 
All the antibiotic discs were purchased from Hi-Media, Pvt. Ltd, Mumbai, India. 
Amikacin 
Amoxyclav 
Ampicillin/Sulbactam 
Cefaclor 
Cefaiothin 
Cefazolin 
Cefepime 
Cefoperazone 
Cefotaxime 
Cefoxitin 
Ceftazidime 
Ceftriaxone 
Cefuroxime 
Chloramphenicol 
Ciprofloxacin 
Clindamycin 
Co-trimoxazole 
Erythromycin 
Gatifloxacin 
Gentamicin 
Imipenem 
Ak 
Ac 
As 
Cj 
Ch 
Q 
Cpm 
Cs 
Ce 
Cn 
Ca 
Ci 
Cu 
C 
Cf 
Cd 
Co 
E 
Gf 
G 
1 
30ng 
20/10 ng 
10/10 ng 
30 Mg 
30 Jig 
30 Jig 
30 ng 
75 ng 
30 ng 
30\ie 
30 ng 
30 [ig 
30 ng 
30 Mg 
5ng 
2Mg 
1.25/23.75 ng 
15 Mg 
5Mg 
10 Mg 
10 Mg 
39 
Chapter 2 
Levofloxacin 
Linezolid 
Methicillin 
Nitrofurantoin 
Norfloxacin 
Piperacillin 
Piperacillin/Tazobactam 
Tetracyclin 
Tobramycin 
Vancomycin 
Le 
Lz 
M 
Nf 
Nx 
PC 
Pc/Tz 
T 
Tb 
Va 
S\xg 
30 ng 
5^g 
30 ng 
30 tig 
100 Mg 
100/10 ng 
30 Jig 
30 Hg 
30 ng 
2.1.2 Culture media 
All types of culture media used for isolation and identification of the organisms were 
purchased from Hi-Media, Pvt. Ltd. Mumbai, India. 
Agar agar 
Brain-Heart Infusion Broth 
EMB-Broth 
Luria-Bertani broth 
Mac-Conkey agar 
Mueller-Hinton agar 
Nutrient broth 
Selective media of 'Hi-crome series' (Hi-media, Mumbai, India), which are highly specific 
for single target organism each (e.g. Hi-crome Klebsiella selective agar, Hi-crome E. coli 
selective agar, Hi-crome S. aureus selective agar etc.) 
2.1.3 Some of the important chemicals/reagents/kits used 
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Agarose 
Bromophenol blue 
CaCl2 
Chloroform 
Cotton swab 
DNA ladder (100 bp) 
DNA ladder (lOObp) 
DNA ladder (Ikb) 
DNA mass ruler 
EDTA 
Ethanol 
Ethedium bromide 
Glacial acetic acid 
Glycerol 
HiComb MIC Test strips 
Hydrochloric acid 
Isoamyl alcohol 
Lysozyme 
MgCb 
NaOH 
Tris-saturated Phenol 
Proteinase K 
PCR master-mix 
RNase 
SDS 
Sodium acetate 
Hinfl 
Tris-HCI 
SRL, India 
Hi-Media, India 
SRL, India 
SRL, India 
Hi-Media, India 
Genei-Bangalore, IruJia 
Fermentas, Canada 
Genei-Bangalore, India 
Fermentas, Canada 
SRL, India 
E. Merck, India 
Sigma, USA 
E. Merck, India 
SRL, India 
Hi-Media, India 
SRL, India 
SRL, India 
Sigma, USA 
SRL, India 
SRL, India 
Genei-Bangalore, India 
Sigma, USA 
Genei-Bangalore, India 
Sigma, USA 
Hi-Media, India 
SRL, India 
Fermentas, Canada 
E. Merck, India 
41 
Chapter 2 
Xylene cyanol Bio-Rad, USA 
Gel extraction Kit Qiagen, USA 
Plasmid DNA Isolation kit Qiagen, USA 
Genomic DNA isolation kit Qiagen, USA 
Qiagen cloningplus kit Qiagen, USA 
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2.2 Methods 
2.2.1 Bacterial identification, susceptibility testing, i\fllC determinations and ESBL detection 
Standard methods for isolation and identification of bacteria were used throughout the 
study [Cowan & Steel, 1970; Sutter et a!., 1985]. The identified bacteria were also 
confirmed by the selective media of the 'Hi-crome series' (Hi-media, Mumbai, India). 
Final confirmation of bacterial identities was done by 16S rDNA sequencing using the 
universal primers 27F and 1525R (Table 2.1). 
Antimicrobial susceptibility testing of the isolates was performed by the 
standard disc diffusion method as recommended by the Clinical and Laboratory 
Standards Institute [CLSI, 2009]. MICs of various antimicrobials were determined by the 
CLSI microbroth dilution method [CLSI, 2009] and further confirmed by HiComb MIC test 
strips (Figure 2.1) as per manufacturer's instructions (Hi-media, Mumbai, India). Gram-
negative Isolates for which the MIC of ceftazidime and/or cefotaxime was >2 ng/ml 
were classified as probable ESBL-producers. The ESBL phenotypic confirmatory test with 
ceftazidime, cefotaxime, ceftriaxone and cefixime was performed for all these probable 
isolates by disk diffusion method [Jarlier et al., 1988] on Mueller-Hinton agar plates with 
and without 10 pg of amoxyclav. A iSmm increase in the zone of diameter of third 
generation cephalosporins, tested in combination with amoxyclav versus its zone when 
tested alone was considered indicative of ESBL production. £ coli ATCC 25922 was used 
as ESBL negative and K. pneumoniae 700603 was used as ESBL-positive reference strain. 
Staphylococcus species were tested for methicillin resistance by using oxacillin l-fig disc, 
oxacillin HiComb minimum inhibitory concentration (MIC) test as per manufacturer's 
instructions (Himedia, Mumbai, India), oxacillin screen agar (6 ng/ml) and cefoxitin 30 
43 
Table 2.1 Details of the primers used 
Chapter 2 
S.NO. 
1. 
2. 
3. 
«. 
S. 
6. 
7. 
8. 
9. 
10. 
PriRMf IMMnS 
CTX-MUl 
CTX-MU2 
TEM-S 
TEM-AS 
s-cs 
3'CS 
hrtl-F 
intl-R 
sull-F 
sull-R 
arniA-F 
armA-R 
rmtA-F 
ntrtA-R 
rnrtB-F 
rnrtB-R 
ERiaR 
ERIC2 
27F 
1S25R 
Primtr iMiiienee (S'-3') 
ATGTGCAGVACCAGTAARGT 
T6GGTRAARTARGTSACCAGA 
ATAAAATTCTTGAAGACGAAA 
GACAGTTACCAATGCTTAATC 
GGCATCCAAGCAGCAAG 
AAGCAGACTTGACCT6A 
CTACCTCTCACTAGTGAGGGGCGG 
GG6CAGCA6CCAAGTCGA6GC 
ATGGTGACGGTGrrTOaGCAT 
CTAGGCATGATaAACCCTC 
CCGAAATGACAGTTCCTATC 
GAAAATGAGTGCCTTGGAGG 
CTA GC6 TCC ATC CTT TCC TC 
TTT GCT TCC ATG CCC TTG CC 
AT6AACATCAACGATGCCCT 
CXTrCTGATTGGCTTATCCA 
ATGTAAGCTCCTGGeeATTCAC 
AA6TAAGT6ACTGGG6TGAGCG 
GAGTTTGATCaGGCTCAG 
AGAAAG6AGGTGATCCAGCC 
Product t iM(bp) 
604 
1090 
variable 
845 
840 
846 
756 
769 
variable 
1500 
Raferanoa/AcoKtion No. 
Pagani et al., 2003. 
AB103S06 
MT^WS 
u u ^ 
Galimand et al., 2003. 
Calimand et al., 2003. 
Park etal., 2006. 
Doi et al., 2004. 
Vwsalovic St al., 1991. 
Allen etal., 2007. 
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HI comb MIC tests 
Fig 2.1 A typical HiComb MIC test (Himedia, India). The balloon shaped region is the inhibition 
zone. The base-point of the balloon shaped region (marked with an arrow) corresponds to MIC 
of the test antibiotic. 
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Hg disc [CLSI, 2009]. Only the isolates, which were simultaneously positive for all these 
tests, were designated as methiciiiin-resistant. Staphylococci were also tested for 
vancomycin resistance by HiComb MIC test as per manufacturer's instructions (Himedia, 
Mumbai, India) and confirmed by vancomycin screen agar (6 ng/ml). 
2.2.2 Plasmid DNA preparation 
The p\asmid DNAs were extracted by QlAprep Spin Miniprep Kit (Qiagen, USA). In brief, 
one colony from each strain was inoculated in 5 ml of LB (Luria-Bertani broth) containing 
a suitable concentration of antibiotic for selection, for 18 hours at 37 °C. The overnight 
cultures were centrifuged at 8,000 rpm for 15 minutes at 4 °C to pellet the cells. The 
pellets were resuspended in 250 pi of Buffer PI (50 mM TRIS-HCI, 10 mM EDTA, pH 8.0 
containing 100 ^ig/ml RNase A). 250 \i.\ of Buffer P2 [200 mM NaOH, 1% SDS (w/v)] was 
added to the samples, mixed thoroughly by vigorously inverting 4-6 times and incubated 
at room temperature for 5 minutes. Then 350 nl of chilled Buffer N3 (3.0 M potassium 
acetate, pH 5.5) was added to the cell lysates, mixed thoroughly by vigorously inverting 
4-6 times and incubated on ice for 15 minutes. The samples were centrifuged for 10 
minutes at 13,000 rpm at 4 "C. The supernatants containing the plasmids were applied 
to the QIAprep spin columns. The columns were washed twice with 0.75 ml of Buffer RE 
[70% ethanolj. The flow-through was discarded, and centrifugation was done for an 
additional 1 min to remove residual wash buffer. The plasmid DNAs were eluted with 50 
pi of Buffer EB [10 mM Tris-CI, pH 8.5]. 
2.2.3 Total genomic DNA preparation 
Total DNA from strains containing studied plasmids were extracted by QIAamp DNA 
Mini Kit (Qiagen, USA), by the following procedure: one colony from each strain was 
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inoculated in 5 ml of LB (Luria-Bertani broth) containing a suitable concentration of 
antibiotic for selection, for 18 hours at 37 "C. 1 ml of overnight cultures were transferred 
in a 1.5 ml micro-centrifuge tube and centrifuged at 7500 rpm for 10 minutes to pellet 
the cells. To lyse the cells, the pellets were resuspended in 180 ^1 of Buffer ATL, 20 pi of 
proteinase K was added, mixed by vortexing, and incubated at 56 °C until the cells were 
completely lysed (lysis is usually complete in 1-3 hours). Vortexing was done 
occasionally during incubation to disperse the sample, 4 \i\ of RNase Solution (100 
mg/ml) was added to cell lysates, mixed by pulse vortexing for 15s, and incubated at 37 
*C for 2 minutes. 200 nl Buffer AL was added to the RNase-treated cell lysates, vigorous 
vortexing done for 15s and incubation done at 70 *C for 10 minutes. Then, 200 ^1 
ethanol (96-100%) was added to the sample, and mixed by pulse vortexing. This mixture 
was then applied to the QIAamp Mini spin column with 2 ml collection tube and 
centrifugation done at 8000 rpm for 5 minutes. The QIAamp Mini spin column was 
placed in a clean 2 ml collection tube, and the tube containing the filtrate was 
discarded. 500 ^1 Buffer AWl was added and centrifugation performed at 8000 rpm for 
2 minutes. The columns were washed again with 500 ^1 Buffer AW2 and centrifuged at 
8000 rpm for 3 minutes. The flow-through was discarded, and centrifugation done for 
an additional 1 min to remove residual wash buffer. The genomic DNAs were eluted 
with 200 nl of Buffer AE [10 mM Tris-CI, pH 8.5]. 
2.2.4 Molecular typing and PCR 
Enterobacterial repetitive intergenic consensus (ERIC)-PCR was used for the analysis of 
genetic relatedness of the ESBL-producers as described by Versalovic et al [Versalovic et 
al., 1991]. A search for blOcn-M, WortM, armA, rmtA and rmtB genes in the isolates which 
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were positive for ESBL synergy test was performed by PCR amplification. Both genomic 
and plasmid DNA of the selected strains were screened for the presence of the said 
genes. Plasmids were obtained by the Qiagen miniprep kit (Qiagen USA). Screening of 
integrons was also performed for the same isolates as described previously [Guerra et 
al., 2000; Galimand et a!., 2003]. Briefly, standard PCRs were carried out in 50 uL 
volumes containing 5 \il of 10 x PCR buffer (100 mM Tris-HCI (pH 8.8), 500 mM KCI, 15 
mM MgCIa, 1% Triton X-100), 5 nLof 10 x deoxynucleotide triphosphate mix (2 mM each 
dATP, dCTP, dGTP and dTTP) (Sigma,USA.), 2 nL of each primer stock solution (25 
pmol/nL), 35 \il sterile distilled water and 1 piL Taq- polymerase (1.5 U/nL diluted 
solution) (Sigma,USA), and 2-5 \il (100ng-l(ig) of template DNA. Amplification was 
performed in a thermocycler (Applied Biosystem, Veriti, 96-well thermal cycler 9902, 
Connecticut, USA). The amplification conditions used have also been reported 
previously [Pagani et al., 2003; Doi et al., 2004, Lee et al., 2006] and the relevant sets of 
PCR primers are listed in table 2.1. Briefly, PCR conditions used for amplification of 
blOcTx-M, fc/OriM, armA, rmtA, rmtB, integrons, 16S rDNA as well as for ERIC-PCR consisted 
of the following steps: [1] Initial denaturation step of 10 min (95°C) [2] 35 cycles 
consisting of (i) Denaturation step of 1 min (95°C) (ii) Annealing step of 1 min (50°C for 
to/ocnc-M, blOftM and 16S rDNA; 55'C for armA, rmtA, rmtB, integrons and ERIC-typing) (iii) 
Extension step of 3 min (72"'C) [3] Final extension step of 10 min (72°C) [4] Storage at 
4'C. 
2.2.5 Agarose gel electrophoresis, staining and visualization of gel 
Plasmid DNA, Genomic DNA or PCR products (25 \i\) were mixed with 2-8 ^1 of 10 x TAE 
buffer and 1-4 \i.\ of bromophenol blue (0.25%). The mixtures were applied to 1-1.5% 
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agarose gels (Sigma, USA) and products separated by electrophoresis for 2-4 h at 90 V 
using 1 X TAE running buffer {4.84 g/L Tris, 0.37 g/L EDTA, pH 8). To stain the gel after a 
run, the gel was slid off the platform into a trough containing O.Sng/ml ethidium 
bromide solution in 1 x TAE buffer and was let to be stained for 20-30 minutes. The gel 
was destained in distilled water for 1-2 hours. The DNA samples were visualized by 
placing gel on a UV transilluminator (254-360 nm) and photographed using Gel 
Documentation (Bio-Rad Laboratories, USA). A 100 bp DNA ladder, Ikb DNA ladder and 
DNA mass ruler (Fermentas, Canada) were included in this study. 
2.2.6 DNA extraction from agarose gel 
PCR products (100 ^1) were separated by agarose gel electrophoresis on 1% gels and 
bands of predicted sizes were cut from the gels with minimum exposure to UV 
illumination. The DNA was extracted from the gel slices using a DNA extraction kit 
(Qiagen, USA) by incubation in sodium perchlorate (for extracting fragments <500 bp) or 
sodium iodide (for fragments >S00 bp) at SS'C for 5 min. Resin (15 pi) was then added 
and the samples incubated at room temperature for 1 min. After centrifugation at 
16000 X g for 30 sec, the pellet was resuspended in 1 ml washing solution, followed by a 
1:1 dilution with 99% ethanol. The sample was again centrifuged at top speed for 30 s 
and the supernatant was discarded. The pellet was incubated at 55°C (tube with open 
lid) until all the alcohol had evaporated. Sterile distilled H2O (10 nl) was added to the 
pellet after 1 min incubation at room temperature. After centrifugation for 30 s the 
supernatant containing the DNA was carefully removed to a clean tube. The final step 
was repeated to yield approximately 20 ^1 of DNA sample. 
2.2.7 Cloning and sequencing 
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PCR amplified b/oox-M genes, were ligated into 'pDrive-easy-PCR-cloning-vector' and 
transformed into competent E. coli C600 ceils using Qiagen Cloningplus Kit as per 
manufacturer's instructions (Qiagen,USA). Transformed colonies were selected on Luria-
Bertani agar plates, containing isopropyl-p-D-thiogalactopyranoside (1 mM), 5-bromo-4-
chloro-3-indolyl-P-D-thiogalactopyranoside (40 mg/L) and kanamycin (30 mg/L). A well-
isolated white colony was picked and inoculated in Luria-Bertani broth. After overnight 
incubation at 37°C, plasmids were isolated from each of these cultures. PCR 
amplifications of blocn^ genes were again performed using these plasmids as 
templates. The same plasmids were transformed [Lederberg & Cohen, 1974] into azide-
resistant f. coli J53 cells. The transformants were selected on LB-agar plates containing 
azide (250 mg/L), cefotaxime (2 mg/L) and kanamycin (30 mg/L). The transformed cells 
were checked for ESBL-production. Sequencing of the genes was performed using the 
same primers which were used for PCR amplifications (Table 2.1). DNA sequences were 
analyzed with an ABI3130 Genetic Analyzer (Applied Biosystems). 
2.2.8 Marker transfer experiments 
Marker transfer experiments were performed to check the transmissibility of resistance 
markers. Bacterial strains that were PCR-positive for any of the tested genes were used 
as donors in transconjugation experiments as described previously [Gray et at., 2006]. 
Transformation was performed for the strains in which conjugation failed repeatedly by 
the method of Lederberg [Lederberg & Cohen, 1974]. Azide-resistant f. coli J53 was 
used as the recipient in all marker transfer experiments. Transconjugants/transformants 
were selected on Luria-Bertani agar plates containing azide (250 mg/L) and either 
cefotaxime (2 mg/L) or gentamicin (50 mg/L). 
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2.2.9 Computational Methods 
For the bioinformatic analyses of the sequences obtained during the thesis work, the 
Basic Local Alignment Search Tool (BLAST) program of the National Center for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov) was used to search databases 
for similar nucleotide and amino acid sequences. BLAST-P was performed to retrieve 
suitable templates for homology modelling using the blocn-M sequences obtained in 
different studies that constitute the work presented in this thesis. Protein Data Bank 
(PDB) IDs of the templates retrieved for modelling for each of the studies are mentioned 
in tables of the subsequent chapters. Modelling was performed using Swiss Model 
Server [Arnold et al., 2006]. The models were duly verified by Procheck [Laskowski et al., 
2005] and verify3D programmes [Eisenberg et al., 1997]. PDB structure of drugs 
(cefotaxime, ceftazidime, doripenem, meropenem, imipenem and ertapenem) as well as 
inhibitors (clavulanate and tazobactam) were retrieved from Drug bank 
(http://www.druebank.ca/search/chemquerv: accessed on 17/10/09). In case any 
structure (e.g. sulbactam) was not available in pdb format with DrugBank, its 2-D 
structure was retrieved from Pubchem (http://vtfVtfw.pubchem.ncbi.nlm.nih.gov/search: 
accessed on 17/10/09). CORINA software was then employed to construct 3-D 
coordinates from 2-D structure by using 'SMILES' notation, thereby generating its 3-D 
structure in pdb format. The ligand (either inhibitor or target drug) was docked into 
each of the modelled enzyme-structures using the targeted docking mode of 'Molecular 
Docking Server* (http://www.dockingserver.com). This server uses the MMFF94 force 
field for energy minimization of ligand molecules and is based on the well-known 
AutoDock program. Accelrys Discovery Studio 2.0 
(http://www.accelrvs.com/products/discoverv-studiol was used to prepare 
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Ramachandran plots for the modelled structures. Ramachandran Z-scores for the 
modelled enzyme-structures were calculated using 'WHATIF' package. Ramachandran Z-
score expresses how well the backbone conformations of all the residues correspond to 
the known allowed areas in the Ramachandran plot. ClustalW program was used for 
alignment of CTX-M sequences to look for important mutations, if any. Expasy translate 
tool (httD://www.exDasv.ch/tools/dna.htmn was used in all the instances when 
translation of a nucleotide sequence to amino acid sequence was required throughout 
the work. 
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3.1 Introduction 
Emergence of multidrug resistant (MDR) bacteria in hospitals is a cause of concern [Chiu 
et al, 2000]. iVIDR bacteria are difficult to treat [Shakil et al., 2008; Chen et al., 2009]. 
There is a widespread occurrence of extended-spectrum 3-lactamases (ESBLs), 
particularly in the hospital environment [Paterson & Bonomo, 2005; Pfaller & Segreti, 
2006]. ESBLs demonstrate resistance to third-generation cephalosporins and are now a 
threat to hospitalized patients giobailY. The ESBL phenomenon was first detected in 
Germany [Knothe et al., 1983]. However, it was not long before ESBLs were detected in 
the United States and Asia. A study in Connecticut, USA found that only 5.4% (2/130) of 
clinical microbiology laboratories could detect an ESBL producing challenge strain 
[Tenover et al., 1999]. Thus, these resistant strains can be missed by routine 
susceptibility testing, leading to adverse therapeutic outcomes. ESBLs are dangerous 
because they are plasmid-associated and the plasmids can get horizontally transferred 
among a variety of bacterial species. Moreover, these plasmids can carry genes for co-
resistance to other antibiotics such as aminoglycosides, fluoroquinolones, tetracyclines, 
chloramphenicol and sulfamethoxazole-trimethoprim. The presence of such multidrug-
resistant strains limits the use of p-lactam and other antibiotics, and can lead to the 
prescription of more broad-spectrum and expensive drugs such as carbapenems. 
Antibiotic selection for such isolates thus becomes a therapeutic challenge. 
Outbreaks by ESBL-producing organisms have been described frequently in 
neonatal intensive care unit (NICU) settings [Miranda et al., 2004; Boo et al., 2005; 
Bagattini et al., 2006]. Clinical conditions and treatments predisposing to infection 
and/or colonization by such pathogens have been investigated but very few studies 
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were able to identify independent risit factors [Singh et al., 2002; Pessoa-Silva et al., 
2003; Linkin et al., 2004; Pfaller & Segreti, 2006]. Moreover variables associated with 
colonization and/or infection may vary considerably between different studies. Due to 
lack of clinical awareness and non-use of standard microbiological techniques, there is a 
paucity of ESBL data concerning neonates, particularly in India. Moreover, E. coli is the 
most common cause of neonatal sepsis by gram-negative bacteria [Kaufman & Fairchild, 
2004] and a high resistance to third-generation cephalosporins in E. coli and K. 
pneumoniae isolates has been recorded by many studies [Couto et al., 2007; Akram et 
al., 2007]. A high prevalence of ESBL-producing K. pneumoniae in Indian NICUs has been 
reported earlier [Krishna et al., 2007]. Accordingly, we selected these two organisms for 
this study. Aims of the present study were: (i) to study the prevalence of ESBL-producing 
f. coli and K. pneumoniae in an NICU in India and (ii) to identify the risk factors 
associated with the acquisition of these organisms. 
3.2 Experimental outline 
The study was conducted in the NICU of JNMC Hospital, Aligarh, which is a tertiary care 
hospital in north India. The total study period was of 14 months i.e. from January 2006 
to February 2007. The NICU admits about 300 neonates annually. Surveillance swabs 
from the nose, pharynx and rectum of each neonate admitted to the ward were 
analyzed weekly. Informed consent for the study was obtained from the parents of the 
neonates and clearance was obtained from the institute's ethics committee. Strains of f. 
coli and K. pneumoniae (both ESBL-producing and non-ESBL-producing) isolated from 
surveillance swabs and from clinical samples of the neonates were included in the study. 
Sterile cotton swabs (Hi-media, Mumbai, India) were used for sample collection. All the 
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specimens were quickly sent to the laboratory to be processed for microbial pathogens. 
Demographic and other relevant details were retrieved from the patients' records 
available with the NICU. Patients enrolled in the analysis were those enrolled in the 
active surveillance system (NICU stay >48 h and weekly surveillance swabs taken at least 
once). Neonates admitted to the ward before January 2006 and/or discharged after 
February 2007 were excluded. 
Bacterial identities were confirmed as mentioned in section 2.2.1. Antimicrobial 
susceptibility testing of the isolates was performed by the CLSI standard disc diffusion 
method as outlined in section 2.2.1. MICs of ceftazidime and cefotaxime were 
determined by the CLSI microbroth dilution method and further confirmed by HiComb 
MIC test strips [Hi-media, Mumbai, India]. The ESBL phenotypic confirmatory test was 
performed for all the probable ESBL-producers as mentioned in section 2.2.1. 
Risk factors associated with ESBL-producing E. coli and/or K. pneumoniae 
acquisition status of neonates were assessed. With the exception of length of stay in the 
NICU, length of exposure to the other time-dependent risk factors was evaluated until 
the first positive culture for ESBL-producing E. coli and/or K. pneumoniae was found. 
Qualitative variables were expressed as percentages and quantitative variables were 
expressed as means ± SD (Standard Deviation). The association of study variables with 
ESBL and non-ESBL-producing £ coli and/or K. pneumoniae acquisition status of 
neonates was tested by using Student's t-test or Fisher's exact test as appropriate. The 
odds ratios (ORs) with 95% confidence intervals (CIs) for having ESBL-associated 
acquisitions were calculated. Using isolation of ESBL-producing £ coli and/or K. 
pneumoniae as the main outcome, all risk factors which proved to be statistically 
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significant on univariate analysis were entered by bloclcwise entry in a logistic regression 
model after exclusion of multicollinearity and interaction between variables. A two-
tailed p value of <0.05 was taken as significant. Statistical analysis was performed using 
SPSS (version 11.5, Chicago). 
3.3 Results 
A total of 253 neonates were admitted to the ward during the 14-month period from 
January 2006 to February 2007, and 238 of these entered the active surveillance system. 
Thirty-two hospital-acquired infections were registered (12 sepsis, 12 conjunctivitis, 
three pneumonia, one meningitis and four urinary tract infections) in the medical 
records during the study period. ESBL-producing E. coli or K. pneumoniae were 
responsible for 16 of these infections (50%), in 16 different neonates. None suffered 
infection by both the organisms. Three neonates, infected by ESBL-producing E. coli 
suffered mortality. 
During the study period, ESBL-producing K. pneumoniae was responsible for 7 
infections (two sepsis, two pneumonia, one conjunctivitis and two urinary tract 
infections) and 51 colonizations while ESBL-producing E. coli was responsible for nine 
infections (Four sepsis, two urinary tract infections and three conjunctivitis) and 88 
colonizations. Concurrent isolation of both the organisms occurred in 30 neonates. 
Recognized colonization preceded infection in eleven of the 16 infected neonates, in all, 
110 ESBL-producing E. coli and/or K. pneumoniae colonized 104 neonates (43.7%) over 
the 14-month study period, 30 of whom (12.6%) were colonized with both the 
organisms. 
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A total of 469 isolates of K. pneumoniae and E. coli were obtained in the study. 
Out of 203 K. pneumoniae isolates, 58 (28.6%) were ESBL-producers while 97 (36.5%) 
ESBL-producers were identified among the 266 E. coli isolates. Antibiotic susceptibility 
tests were performed for all the isolates (both ESBL-producing and Non-ESBL-
producing). Imipenem was found to be the most effective antibiotic. Zero percent 
resistance was found against imipenem among K. pneumoniae isolates while it was 1.5% 
(n=4) among E. coli isolates. 29.6% (n=60) resistance was observed against cefepime in 
K. pneumoniae isolates while it was 37.9% (n=101) in E. coli isolates. 34.9% (n=71) K. 
pneumoniae and 38.7% (n=103) E. coli isolates were found to be resistant against 
amikacin. Among the third-generation cephalosporins, maximum resistance was 
observed against ceftazidime, which was 56% (n=149) and 55.2% (n=112) in E. coli and 
K. pneumoniae isolates, respectively (these data are inclusive of both ESBL +ve and ESBL 
-ve study isolates). The first-generation cephalosporins and tetracycline were met with 
the highest resistance by the study isolates. Table 3.1 shows percent resistance to 
selected antimicrobials exclusively among the ESBL-producing study isolates. 
All the isolates from term neonates were found to be susceptible to imipenem 
while four of the E. coli isolates from preterm infants were found to be imipenem 
resistant. Birthweights of the neonates were grouped into classes and plotted against 
the percentage of total ESBL-positive study organisms obtained from each of these 
classes (Fig. 3.1). The highest percentage (28.4%, n=44 isolates) of these isolates was 
obtained from neonates who weighed 1.5 kg to 2 kg. Figure 3.2 shows the distribution 
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Fig 3.1 Percentage of ESBL-positive organisms in different groups of neonates based on 
birthweight. 
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of neonates colonized by ESBL-producing study isolates during the study period. 
Univariate analysis of various study variables was performed for 211 neonates who 
were positive for £ coli and/or K. pneumoniae. Out of these, 104 neonates were positive 
for acquisition of ESBL-producing E. coli and/or K. pneumoniae while 107 neonates 
acquired the same organisms that were Non-ESBL-producing. The mode of delivery for 
more than half of these neonates (67.3%) was cesarean. Since only five neonates 
developed infection, before colonization was recognized so, analyzed risk factors were 
mainly referred to the colonization status. In the univariate analysis, many study 
variables namely birthweight, gestational age, prolonged rupture of membrane, total 
hemoglobin, length of stay in the NICU, endotracheal intubation and ampicillin/amikacin 
use (all p=0.00) were found to be very closely associated with ESBL- and non-ESBL-
producing E. coli and/or K. pneumoniae acquisition status of neonates (Table 3.2). 
Hence, multivariate analysis was performed. In the final logistic regression model, only 
the length of stay in the NICU was found to be independently associated (p=0.001) with 
acquisition of ESBL-producing E. coli and/or K. pneumoniae. Identical results were 
obtained when the five neonates who developed infection before colonization was 
recognized were excluded. 
3.4 Discussion 
Gram-negative bacilli are frequently associated with infections in the patients admitted 
to the intensive care units of hospitals [Torres et al., 2007] and the incidence of infection 
is higher in the neonatal period than at any time of life [Fanos et al., 2007]. Moreover, 
the problem of global antibiotic resistance continues to worsen [Shakil et al., 2008]. The 
61 
Chapter 3 
Table 3.2 Study characteristics in two groups of neonates according to acquisition of 
extended-spectrum p-lactamase {ESBL)-producing and Non-ESBL-producing E. coli 
and/or Klebsiella pneumoniae 
Serial 
No. 
1. 
2. 
3. 
4. 
5. 
Study variables 
Birth weight(g) 
Gestational age 
(weeks) 
Sex 
Male 
Female 
Mode of Delivery 
Cesarean 
Vaginal 
Neonate as a case 
Neonates with 
acquisition 
of ESBL-
producing 
E. coli and/or 
Klebsiella 
pneumoniae 
(n=104) 
1883 ±175 
29 ± 1 
80(76.9) 
24(23.1) 
74(71.2) 
30(28.8) 
20(19.2) 
Neonates with 
acquisition 
of Non-ESBL-
producing 
E. coli and/or 
Klebsiella 
pneumoniae 
(n=107) 
2930 ± 284 
35 ± 1 
67(62.6) 
40(37.4) 
68(63.6) 
39(36.4) 
35(32.7) 
P 
value 
0.00 
0.00 
0.03 
0.04 
0.03 
OR(95%CI) 
-
1.00 
1.99(1.09-
3.63) 
1.00 
1.84(1.03-
3.31) 
0.49(0.26-
62 
Chapter 3 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
of first delivery 
Tetanus Toxicoid 
vaccination of 
mother 
Maternal anemia 
Maternal 
intrapartum fever 
Maternal 
intrapartum 
symptomatic 
infection 
Leaking PV 
Bleeding PV 
Meconium-stained 
liquor 
Prolonged rupture 
of membrane 
Unclean vaginal 
examination of the 
mother 
89(85.6) 
48(46.2) 
6(5.8) 
1(0.9) 
10(9.6) 
6(5.8) 
24(23.1) 
38(36.5) 
13(12.5) 
93(86.9) 
52(48.6) 
8(7.5) 
0(0) 
13(12.1) 
8(7.5) 
29(27.1) 
8(7.5) 
17(15.9) 
0.84 
0.78 
0.78 
0.49 
0.66 
0.78 
0.53 
0.00 
0.56 
0.92) 
0.89(0.41-
1.96) 
0.91(0.53-
1.56) 
0.76(0.25-
2.26) 
0.77(0.32-
1.84) 
0.76(0.25-
2.26) 
0.81(0.43-
1.51) 
7.13(3.13-
16.24) 
0.76(0.35-
1.65) 
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15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
Retinopathy of 
prematurity 
Congenital heart 
diseases* 
Respiratory distress 
syndrome 
Patent ductus 
arteriosus 
Intraventricular 
hemorrhage 
Bacterial sepsis 
Urinary tract 
infections 
Conjunctivitis 
Thrombocytopenia: 
<100,000/mm^ 
39(37.5) 
12(11.5) 
83(79.8) 
30(28.8) 
36(34.6) 
6(5.8) 
4(3.8) 
4(3.8) 
12(11.5) 
41(38.3) 
9(8.4) 
77(71.9) 
27(25.2) 
34(31.8) 
1(0.9) 
0(0) 
5(4.7) 
10(9.3) 
1.00 
0.49 
0.20 
0.64 
0.77 
0.06 
0.06 
1.00 
0.66 
0.97(0.55-
1.68) 
1.42(0.57-
3.53) 
1.54(0.81-
2.91) 
1.20(0.65-
2.21) 
1.14 (0.64-
2.02) 
6.49(0.77-
54.87) 
0.82(0.21-
3.13) 
1.27(0.52-
3.07) 
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24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
Neutropenia 
Hyperglycemia 
Total Hemoglobin 
(g/di) 
Length of stay in 
the NICU (days). 
Apgar score at 1 
min 
Apgar score at 5 
min 
Resuscitation 
Ventilation 
Days on 
supplemental 
oxygen 
Endotracheal 
intubation 
Amptcillin/Amikacin 
use 
17(16.3) 
18(17.3) 
13 ±2 
35 ±23 
4 ± 3 
6 ± 2 
30(28.8) 
6(5.8) 
14 ±10 
31(29.8) 
67(64.4) 
15(14) 
10(9.3) 
14±2 
25 ±22 
3 ± 4 
6 + 2 
29(27.1) 
1(0.9) 
15 ±11 
13(12.1) 
42(39.3) 
0.70 
0.11 
0.00 
0.00 
0.04 
1.00 
0.88 
0.06 
0.49 
0.00 
0.00 
1.19(0.56-
2.55) 
2.03(0.89-
4.64) 
1.09(0.59-
1.99) 
6.49(0.77-
54.87) 
3.07(1.50-
6.28) 
2.8(1.60-
4.89) 
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35. 
36. 
37. 
Medications 
Dexamethasone 
Histamine type 2 
receptor blocicers 
Educational status 
of mother 
Literate 
illiterate 
Mortality 
33(31.7) 
29(27.9) 
23(22.1) 
81(77.9) 
3(2.9) 
31(28.9) 
31(28.9) 
31(28.9) 
76(71) 
0(0) 
0.76 
0.88 
0.27 
0.12 
1.14(0.63-
2.05) 
0.95(0.52-
1.72) 
0.69(0.37-
1.29) 
-
Data are means ± SD or n (%) unless otherwise indicated. 
*lnclude any anatomy other than normal 4-chamber heart with left ventricle, excluding 
patent formamen ovalae and patent ductus arteriosus. 
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widespread clinical use of broadspectrum 3-lactam antibiotics has led to a marked 
increase in the incidence of ESBL-producing gram-negative microbes. However, the 
prevalence of occurrence of these organisms varies significantly in different 
geographical regions. The SENTRY surveillance program reported the frequency of ESBL-
producing K. pneumoniae to be approximately 37% in Latin America vs. 7% in the United 
States [Sader et al., 1998]. Many authors have analyzed the epidemiology of non-
outbreak patients with culture-positive ESBL-producing organisms [Schiappa et al., 1996; 
Einhorn et al., 2002]. Considering the Asian Pacific region, the prevalence of ESBL-
producing Klebsiella spp. was reported to be 5%, 21.7%, 31% and 38% in Japan, Taiwan, 
Philippines and Malaysia/Singapore, respectively [Parasakthi & Ariffin, 2001]. The 
prevalence of ESBL-producers in K. pneumoniae and f. coli in neonates varies between 
countries, ranging from 11.8% to 100% [Parasakthi & Ariffin, 2001]. The prevalence of 
ESBL positivity in f. coli and K. pneumoniae isolates in the present study were 36.5% 
{97/266) and 28.6% (58/203), respectively. This is not much different from one of our 
earlier studies from the same hospital in which ESBL positivity for E. coli and K. 
pneumoniae isolates was found to be 34.42% and 27.3%, respectively [Akram et al., 
2007]. 
Our bacterial isolates showed resistance against aminoglycosides, advanced-
generations cephalosporins, fluoroquinolone, tetracycline and piperacillin. This is 
consistent with most of the recent findings [Couto et al., 2007; Fanos et al., 2007; 
Bizzarro & Gallagher, 2007]. In the present study, E. coli and K. pneumoniae isolates 
were found to be highly resistant to tetracycline (79.7% and 62%, respectively). This is 
probably due to the fact that this antibiotic has been widely used over the past decade 
in this region, its low cost also makes it affordable to the poor people residing in various 
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underdeveloped pockets of the otherwise developing nation. Similar studies have also 
been performed from other parts of India [Manchanda & Singh, 2003; Babypadmini & 
Appalaraju, 2004; Shobha et al., 2007]. 
Infections caused by ESBL-producing organisms in neonates are usually reported 
to be hospital-acquired and associated with invasive procedures [Roilides et al., 2000]. 
Similarly, many authors have found birthweight as a significant factor that makes the 
neonates prone to infection by different types of pathogens [Simchen et al., 2000; 
Bruinsma et al., 2000]. However, in our study, both endotracheal intubation and 
birthweight were found to be insignificant in the final multiple regression analysis. As 
opposed to our findings, several noble studies like that of Crivaro et al. [2007] and 
Cassettari et al. [2009] have observed empiric antibiotic treatment to be a significant 
risk factor associated with ESBL-producing K. pneumoniae acquisition status of 
neonates. In another study by Kristof et al. [2007], the authors observed that mortality 
rate was higher in ESBL-producing Klebsiella spp. group of patients but this was 
statistically not significant. They held their 'small sample size' as one of the possible 
explanations for this lack of significance. We also observed a higher mortality rate in the 
group of patients positive for ESBL-producing organisms which were statistically not 
significant. Length of NICU stay was found to be the single independent risk factor 
(p=0.001) associated with ESBL- producing E. coli and/or K. pneumoniae acquisition 
status of neonates, in the final regression model. This is partially in harmony with the 
results of a study by Boo et al. [2005], in which duration of hospital stay and early-onset 
pneumonia were found to be the only independent factors associated with colonization 
by ESBL-producing K. pneumoniae. Hence it is clear that NICU environment plays a key 
role in the transmission of these pathogens. 
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3.5 Conclusions 
Presence of ESBL-producing pathogens in NICU is a matter of concern. It is equally 
disturbing to note that most of our study isolates were found to be resistant against 
four or more antibiotics, imipenem, cefepime and amikacin can be suggested as the 
drugs of choice in our study. Length of NICU stay was found to be the single 
independent risk factor associated with ESBL-producing E. coli and/or K. pneumoniae 
acquisition status of neonates. This is the main finding of the present study. Formulation 
of strict antibiotic-prescription guidelines by the policy makers and their ground level 
implementation by the concerned authorities is the need of the hour for India. Frequent 
surveillance studies from different regions across the world that could help in updating 
the empirical antibiotic regimen for the neonates admitted to NICUs are highly 
recommended. 
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4.1 Introduction 
ESBL-producing bacteria in hospital environments have become increasingly common. 
Several studies have reported 16S rRNA methylase genes (e.g. armA and rmtB) that 
confer resistance to aminoglycosides [Lee et al., 2006; Bogaerts et a!., 2007]. 
Concomitant p-lactam and aminoglycoside resistance is increasingly being reported [Ma 
et al., 2009]. E. coli is the most common cause of neonatal sepsis by gram-negative 
bacteria [Kaufman & Fairchild, 2004]. A high resistance to third-generation 
cephalosporins in E. coli isolates has been recorded by many studies [Akram et al., 2007; 
Couto et al., 2007]. Moreover, fa/ocrx-M-is and b/orEM-i resistance markers are increasingly 
being reported from this part of the worid [Muzaheed et al., 2009]. Aims of the study 
were: (i) to characterize the mode of transmission of b/Ocrx-M and fa/ojEM resistance 
markers among ESBL-producing E. coli strains isolated from NICU, (ii) to identify the risk 
factors for "sex-associated ESBL-producing E. coli acquisition status" of the neonates. 
4.2 Experimental outline 
The ESBL-producing E. coli strains identified in the previous study (Chapter 3) were 
selected for molecular studies. In addition to ceftazidime and cefotaxime, MICs of 
gentamicin, tobramycin, kanamycin, amikacin, streptomycin, cefazolin, ceftriaxone, 
cefepime, ciprofloxacin, norfloxacin, piperacillin, amoxyclav and tetracycline were 
determined as described in section 2.2.1. A search for blocn-M, ^/OTEM, armA, rmtA, rmtB 
genes and integrons was made among these strains using both genomic and plasmid 
DNA and typing was performed by ERIC-PCR, as outlined in section 2.2.4. Cloning of 
blocn-M was performed using Qiagen cloningplus kit (Qiagen, USA) and sequencing was 
done as mentioned in section 2.2.7. Transmissibility of b/ocrxM markers was checked by 
either conjugation or transformation as described in section 2.2.8. Homology model of 
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CTX-M-15 corresponding to accession number [GenBank: FJ9978651 was prepared using 
Swiss Model Server and verification was done as described in section 2.2.9. Significance 
of the study variables for "sex-associated ESBL-producing E. colt acquisition status" of 
the neonates was tested by using Student's t test or Fisher's exact test as appropriate. 
All risk factors which proved to be statistically significant on univariate analysis were 
entered by blockwise entry in a logistic regression model after exclusion of 
multicollinearity and interaction between variables. A two-tailed p value of <0.05 was 
taken as significant. Statistical analysis was performed using SPSS (version 11.5, 
Chicago). 
4.3 Results 
Figure 4.1 shows the distribution of the 97 ESBL-producing E. coli obtained from 
neonates divided into 2-month periods from January 2006 to February 2007. Only 5 
strains were confirmed to harbor b/Ocrx-M genes by PCR. Strain D183 was positive for 
both bfac™-M and blom^ while strain D200 possessed only b/ortw. Only 2 strains were 
PCR-positive for rmtB. All the PCR products were of the expected size (Table 2.1). None 
of the strains were simultaneously positive for b/Ocrx-M and any of the 16S rRNA methyl 
transferase genes. Also, none of the strains harbored armA or rmtA. Thirteen integrons 
were detected whose sizes ranged from 600bp to 1.5Kb. All these integrons were found 
to be Classl type and were positive for intl and sull genes of the expected sizes 845bp 
and 840bp, respectively. None of the b/ocrx-w or rmtB genes were located in the 
integrons. The C600 cells harboring cloned bloax-M (C600 " ' '^ -^) were again found to be 
PCR-positive for the said gene in all instances. Hinfl digestion of these genes produced 
identical digestion profiles (Figure 4.2a). Figure 4.2b shows result of gene cloning (Blue-
White-Selection) with reference to the blocn^gene obtained from strain D8. Moreover, 
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Fig 4.1 Distribution of ESBL-producing E. coll obtained from neonates divided into 2-month 
periods from January 2006 to February 2007. 
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0 .6Kb 0 .604Kb 
Fig 4.2a Hinf 1 digestion of blOcrx-M 
4.2b Result of gene cloning (Blue-White-Selection) with reference to the blocrx^ gene 
obtained from strain D8 of E. coli. 
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cultures derived from C600 '''"^'^ cells gave a positive ESBL synergy test. Azide resistant 
E. coli J53 cells transformed with the plasmidic DNA extracted from C600 " " ^ " ^ cells 
became cefotaxime resistant. Also, cultures derived from these transformed E. coli J53 
cells were found to be positive for the ESBL test. Sequencing results confirmed all the 
blocTx-M genes obtained in this study as blacn.M-15 and all the b/OjEM genes as b/OjEM i-
The WocTx-M-15 positive strains had an MIC of 32-64 mg/L against ceftazidime 
(Table 4.1). The highest MIC against cefotaxime (512 mg/L) was observed for strain 
D295. The highest MIC against gentamicin (1024 mg/L) was observed for the rmtB 
positive strain D203. The ceftazidime and cefotaxime resistance markers were located 
on the plasmidic DNA of all the blacn-M-15 positive strains and were transmissible through 
conjugation. Aminoglycoside (Kanamycin) resistance was co-transferred with cefotaxime 
resistance, in only one of the blocn-M-is positive isolates. Transfer frequencies (Total no. 
of transconjugants or transformants per plate/Total no. of recepients per plate) 
observed were of the order 10'^ to 10"* (Table 4.2). 
As 15 of the 97 strains had identical susceptibility patterns for all the tested 
antibiotics, only a single representative strain was randomly selected for typing from 
this group. ERIC-PCR divided the 83 ESBL-producers into 29 major profiles (Figure 4.3). 
Four b/ocTx-M-15 positive strains namely D8, D183, D295 and D296, were found to be 
donally related and displayed ERIC-profile XI while D282 displayed an unrelated profile 
K (Table 4.3). Considering the remaining ESBL-producing strains, there was much 
diversity in ERIC-profiles. The most common profile B l was shared by 13 strains (Figure 
4.3). 
Over 90% of the amino acid residues in the protein structures modelled from 
b/ocTx-M-15genes obtained in this study (Figure 4.4) were found to be present in the most 
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Table 4.1 MICs of antibiotics used against E. coll strains which were PCR-positlve for any 
of the genes investigated in the study 
Antibiotics 
Gentamicin 
Tobramycin 
Kanamycin 
Amikacin 
Streptomycin 
Cefazolin 
Ceftazidime 
Cefotaxime 
Ceftriaxone 
Cefepime 
Ciprofloxacin 
Norfloxacin 
Piperacillin 
Amoxyclav 
Tetracycline 
IMiC (mg/L) for E. coU strains 
D8 
64 
64 
32 
4 
64 
>256 
64 
>128 
256 
64 
64 
64 
>256 
4 
512 
0183 
64 
32 
32 
2 
64 
>256 
64 
128 
256 
64 
64 
32 
512 
2 
256 
D200 
>256 
256 
128 
2 
256 
>256 
16 
2 
8 
2 
64 
64 
>256 
4 
256 
D203 
1024 
256 
512 
32 
256 
128 
64 
>8 
64 
2 
32 
64 
128 
4 
128 
D204 
>256 
128 
64 
32 
128 
>128 
64 
16 
32 
8 
64 
32 
>128 
2 
512 
D282 
2 
16 
16 
2 
32 
>128 
64 
>64 
128 
64 
32 
32 
1024 
2 
>512 
D295 
64 
64 
32 
2 
64 
>512 
64 
512 
>256 
32 
64 
32 
128 
4 
128 
0296 
8 
16 
16 
2 
8 
>256 
32 
256 
>256 
64 
32 
32 
>512 
4 
256 
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neonates. 'M' stands for marl<er (the first lane of each figure). 
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favorable regions as revealed by their respective Ramachandran plots. The 
Ramachandran Z-score for modelled enzyme from strain D183 fGenBank: FJ9978651 
w/as found to be 0.096, which further confirmed the accuracy of the modelled structure. 
The beginning and end of the active site omega loop are clearly marked in the figure 
(Figure 4.4). The corresponding Ramachandran plot is show/n in Figure 4.5. 
Univariate analysis of various study variables was performed for the 97 
neonates who were positive for ESBL-producing E. coli acquisition. In the univariate 
analysis, many study variables including mode of delivery, birthweights, length of stay in 
NICU etc, (all p<0.05) were found to be significant for "sex-associated ESBL-producing E. 
coli acquisition status" of neonates (Table 4.4). Hence, we performed multivariate 
analysis. The multiple logistic regression model confirmed 'length of stay in the NICU' to 
be the single independent risk factor for the same (p=0.001). 
4.3.1 Nucleotide sequence accession numbers 
The GenBank accession numbers of the E. coli genes sequenced in this study are 
[GenBank: FJ9978641. FGenBank: FJ9978651. [GenBank: GQ1452161. [GenBank: 
GQ1452171. fGenBank: GQ14522n. [GenBank: GQ1452221. [GenBank: GQ1745031. 
[GenBank: GQ1745041 and [GenBank: GQ1745051. 
4.4 Discussion 
This is the first study to report on risk factors for "sex-associated ESBL-producing E. coli 
acquisition status" of the neonates from North India (Uttar Pradesh). The widespread 
use of broadspectrum P-lactam antibiotics has led to a marked increase in the incidence 
of ESBL-producing bacteria. 
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Fig 4.5 Ramachandran plot corresponding to the enzyme model shown in fig 4.4. 
Ramachandran Z-score for the modelled structure (calculated by 'WHATIF' package) was 
equal to 0.096. The glycines and prolines are represented by triangles and squares, 
respectively. All other amino acids are represented by circles. The plot was constructed 
using Discovery StudioZ.O (Accelrys). 
Plot statistics 
Residues in most favored regions 
Residues in additional allowed regions 
Residues in generously allowed regions 
Residues in disallowed regions 
92.0% 
7.2% 
0.8% 
0.0% 
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Table 4.4 Characteristics of the neonates positive for acquisition of ESBL-producing E. coli 
with respect to sex. 
s. 
No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
Characteristics of the neonates positive 
for acquisition of ESBL-producing 
e.coll 
Mode of delivery: 
Cesarean 
Vaginal 
Birth weight(g) 
Gestational age (weeks) 
Neonate as a case of first delivery 
Tetanus Toxicoid vaccination of mother 
Maternal anemia 
Maternal intrapartum fever 
Maternal intrapartum symptomatic 
infection 
Leaking PV 
IMale 
(n=78) 
55(70.5) 
23(29.5) 
1729 ± 
123 
28 ± 1 
15 (19.2) 
66(84.6) 
35(44.9) 
4(5.1) 
3(3.8) 
7(8.9) 
Female 
(n=19) 
8(42.1) 
11(57.9) 
1856 ± 
145 
29 ± 1 
8(42.1) 
16(84.2) 
5(26.3) 
1(5.3) 
1(5.3) 
2(10.5) 
value 
0.03 
0.00 
0.00 
0.16 
1.00 
0.46 
0.99 
0.99 
0.99 
0R(9S%a) 
1.00 
3.29 (1.17-
9.23) 
-
0.46(0.17-
1.23) 
1.00(0.48-
2.11) 
1.71(0.59-
4.94) 
0.97(0.10-
9.23) 
0.73(0.07-
7.42) 
0.85(0.16-
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10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
Bleeding PV 
Meconium-stained liquor 
Prolonged rupture of membrane 
Undean vaginal examination of the 
mother 
Retinopathy of prematurity 
Congenital heart diseases 
Respiratory distress syndrome 
Patent ductus arteriosus 
Intraventricular hemorrhage 
Bacterial sepsis 
Urinary tract infections 
Conjunctivitis 
3(3.8) 
17(21.8) 
25(32.1) 
8(10.3) 
27(34.6) 
8(10.3) 
55(70.5) 
19(24.4) 
26(33.3) 
4(5.1) 
0(0) 
1(1.3) 
0(0) 
5(26.3) 
6(31.6) 
2(10.5) 
6(31.6) 
1(5.3) 
9(47.3) 
4(21.1) 
5(26.3) 
0(0) 
2(10.5) 
2(10.5) 
0.99 
0.77 
1.00 
0.99 
1.00 
0.99 
0.40 
1.00 
0.79 
1.00 
0.04 
0.11 
4.43) 
" 
0.82(0.27-
2.53) 
1.02(0.37-
2.82) 
0.97(0.19-
4.97) 
1.09(0.39-
3.03) 
1.95(0.23-
16.54) 
1.49(0.63-
3.54) 
1.16(0.35-
3.8) 
1.27(0.43-
3.73) 
-
-
0.12(0.01-
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22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
Thrombocytopenia: <100,0(X)/mm' 
Neutropenia 
Hyperglycemia 
Length of stay in the NICU {days). 
Resuscitation 
Ventilation 
Days on supplemental oxygen 
Endotracheal intubation 
Ampicillin/Amikacin use 
Educational status of mother: 
Literate 
illiterate 
Mortality 
r 
7(8.9) 
12(15.4) 
13(16.7) 
38 ±14 
19(24.4) 
4(5.1) 
15 ±9 
21(26.9) 
51(65.4) 
17(2L8) 
61(78.2) 
2(2.6) 
2(10.5) 
3(15.8) 
2(10.5) 
28 ±13 
5(26.3) 
1(5.3) 
14 ±11 
4(21.1) 
9(47.3) 
3(15.8) 
16(84.2) 
1(5.3) 
0.99 
0.99 
0.73 
0.00 
1.00 
0.99 
0.72 
0.78 
0.52 
0.76 
0.85 
0.49 
1.41) 
0.85(0.16-
4.43) 
0.97(0.25-
3.79) 
1.58(0.33-
7.61) 
~ 
0.93(0.31-
2.79) 
0.97(0.10-
9.23) 
-
1.28(0.39-
4.17) 
1.38(0.58-
3.29) 
1.38(0.37-
5.19) 
0.93(0.44-
1.96) 
0.49(0.04-
5.66) 
84 
Chapter 4 
Plasmid mediated b/Oox-M-is ^^^ '"'"^^ among clinical isolates have also been 
reported earlier [Yu et a!., 2004; Ma et a!., 2009]. Only 5 of our 97 strains were PCR-
positive for b/ocrx-Mis- This is in harmony with a study in which the authors detected 
only 3 strains out of 365 clinical isolates that were PCR-positive for b/oox M is ITouati et 
al., 2006]. However, this observation was contrary to many findings, which have 
reported a high prevalence of b/OcTK-M-is ^n^ong clinical isolates [Muzaheed et al., 2008; 
Mshana et al., 2009]. None of our £ coli strains were PCR-positive for rmtA. It was 
predictable because to date rmtA has been reported only from Pseudomonas spp [Chen 
etal., 2007]. 
Integrons are gene expression elements that play an important role in the 
recruitment of antimicrobial drug resistance determinants via site-specific 
recombination events catalyzed by the integron-encoded integrase [Chu et al., 2009]. 
Classl integrons are the most commonly found integron type in Gram-negative bacteria 
[Khemtong & Chuanchuen, 2008]. Accordingly, we detected 13 classl integrons all of 
which were invariably PCR-positive for intl and sull. None of the fa/OcrxMIS or rmtB 
markers were found to be located within the integrons. Hence, it is confirmed that the 
horizontal transfer of these markers was not integron-mediated but plasmid-mediated 
in our setting. Authors have earlier reported plasmid-mediated transfer of fa/oaxw is 
despite the presence of integron [Kim et al., 2007]. The presence of strains co-resistant 
to aminoglycosides, quinolones and third generation cephalosporins as observed in our 
setting is a matter of due concern. Such strains, if combined with the production of 
carbapenemase might result in therapeutic dead-ends [Walsh, 2008; Zarrilli et al., 2008]. 
This is the first study to report modelling of CTX-M-15 enzyme which is one of 
the most common ESBLs in India. Moreover, there is no entry for CTX-M-15 in the 
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Protein Data Bank to date. From molecular modelling studies of TEM/SHV ESBLs, the 
amino acid substitution at residue 240 had been associated with an expansion of activity 
towards ceftazidime, most probably due to its position in a key p-strand of the catalytic 
site of class A p-lactamases [Huletsky et a!., 1993; Knox, 1995]. Moreover, it is confirmed 
now that residues specifically in the active site omega loop (position 161-179) of CTX-M 
enzymes play an important role in the substrate profile for cephalosporins [Bonnet et 
al., 2001; Sturenburg et al., 2004]. The SDN (positions 130-132), and KTG (positions 234-
236) sequences, were found to be conserved in all the study sequences, typical of class 
A enzymes [Xiong et al., 2004]. All the CTX-M-15 sequences harbored the D240G 
mutation with respect to CTX-M-3. 
Several noble studies have investigated the association of different study 
variables with ESBL and non-ESBL-producing f. coli or K. pneumoniae acquisition status 
of neonates [Crivaro et al., 2007]. Risk factors for neonatal infection and mortality with 
respect to sex have also been investigated long back [Berman et al., 1987]. This is the 
first study from this part of the world (North India), which identifies significant risk 
factors for "sex-associated ESBL-producing E. coli acquisition status" of the neonates. 
Several authors have found birthweight as a significant factor for neonatal infection 
[Bruinsma et al., 2000; Simchen et al., 2000], which was found to be insignificant in the 
final multiple regression analysis in our setting. There was no significant sex difference in 
neonatal mortality (p = 0.49) as observed previously [Berman et al., 1987]. However, the 
male sex has been considered more prone to neonatal infections by many authors 
[Fanaroff et al., 1998; Pessoa-Silva et al., 2001]. Accordingly, in this study, the average 
length of stay in NICU was considerably higher for the male neonates (Table 4.4). In the 
final logistic regression model, 'length of stay in NICU' proved to be the single 
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independent risk factor for "sex-associated ESBL-producing E. coli acquisition status" of 
the neonates (p=0.001). 
4.5 Conclusions 
All the bfacn(-M-i5 positive isolates, except one were clonaliy related. Plasmid-mediated-
conjugal transfer albeit at a low frequency might be the possible mechanism of transfer 
of blacTK-M-is resistance marker in the described setting. Male neonates who are 
colonized or infected by ESBL-producing f. coli might have a longer stay in NICU 
compared to their female counterparts. Scope is still left to determine the 3D structures 
of the rapidly emerging variants of CTX-M by X-ray crystallography. 
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p/^ tteriA^s of p/^ thogeiA s^ ls>olated from 
liA f^ected diabetic foot ulcers. 
Chapter 5 
5.1 Introduction 
Foot ulcers are a very common complication of type 1 and type 2 diabetes [Rathiur & 
Boulton, 2007]. In developing countries like India, the matter is w/orse because of poor 
sanitation that creates an infection-prone environment [Mohan & Pradeepa, 2004]. The 
Indian diabetic population is expected to increase to 57 million by 2025 [Abdul et al., 
1999]. Infections with multidrug resistant strains of bacteria are becoming a major 
problem in the whole world and individuals with diabetes have at least a 10-fold greater 
risk of being hospitalized for soft tissue and bone infections of the foot [Boyko & Lipsky, 
1995] than the individuals without diabetes. Over 20-40% of diabetic wounds have been 
found to be MRSA infected by many studies [Shanker et al., 2005; Tentolouris et al., 
2006]. 
Studies related to infections by multidrug resistant organisms (MDROs) in 
diabetic foot ulcers may be helpful as they provide basis for empirical antimicrobial 
therapy. There was an urgent need for a study that could deal with the association of 
different factors with MDRO and non-MDRO infection status of ulcers in due detail, 
from this region. The main aim of this study was to assess potential risk factors for 
diabetic foot ulcers infected with MDROs. The association of study variables with MDRO 
and non-MDRO infection status of ulcers has been analyzed. 
5.2 Experimental outline 
Seventy-seven diabetic patients having clinically infected foot ulcers admitted to the 
endocrinology ward at the J. N. Medical College, Aligarh, over a period of 2 years (April 
2007 to November 2008) were studied in a consecutive series. Wagner classification was 
employed to grade the ulcers [Wagner, 1981]. Forty-four study factors were recorded 
for each patient which are listed in Table 5.1. BMI i.e. Body Mass Index (<18.5 kg/m^ = 
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Table 5.1 Association of study characteristics in two groups of diabetic patients according 
to infection of foot ulcers with multidrug resistant organisms (MDROs) and Non-
MDROs 
S.No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
Oiaracteristic 
n 
Age (years) 
Sex 
Male 
Female 
Type of diabetes 
Typel 
Type2 
Duration of diabetes (years) 
Duration of ulcer(months) 
^3 
>3 
Duration of hospital stay(months) 
^1 month 
>1 month 
Size of ulcer(cm^) 
54 
>4 
Nature of ulcer 
Non-
MDRO 
21 
59 ± 10.00 
15(71.4) 
6(28.6) 
1(4.8) 
20(95.2) 
8.76 ± 5.13 
1.64 ± 1.02 
21(100) 
0(0.0) 
0.66 + 0.18 
19(90.48) 
2(9.52) 
12(57.14) 
9(42.86) 
MDRO 
56 
53.91 ± 
3.86 
47(83.9) 
9(16.1) 
6(10.71) 
50(89.29) 
11.38 ± 
2.88 
4.54 ± 0.87 
0(0.0) 
56(100) 
0.70 ± 0.22 
40(71.43) 
16(28.57) 
7(12.5) 
49(87.5) 
P 
value 
0.03 
0.33 
0.67 
0.04 
<0.01 
<0.01 
0.46 
0.13 
<0.01 
OR(95%CI) 
1.00 
0.48(0.15-
1.57) 
1.00 
0.42(0.05-
3.68) 
-
-
-
1.00 
3.8(0.79-
18.23) 
1.00 
9.33(2.89-
30.14) 
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9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
Non-necrotic 
necrotic 
Wagner Grade 
2 
3 
4 
5 
BMI (kg/m^) 
Underweight 
Normal weight 
Overweight 
Systolic Blood Pressure (mmHg) 
Diastolic Blood Pressure (mmHg) 
Random plasma glucose (mg/dl) 
Fasting plasma glucose (mg/dl) 
2-h plasma glucose (mg/dl) 
Total Hemoglobin (g/di) 
Glycated Hb (%) 
White Blood Cell count (per mm )^ 
Neutrophil count (per mm^) 
18(85.7) 
3(14.3) 
9(42.86) 
5(23.8) 
7(33.33) 
0(0.0) 
23.50 
±2.78 
2(9.52) 
15(71.43) 
4(19.05) 
134 ± 
15.74 
82 ± 5.89 
240 ± 
65.28 
153 ± 
43.13 
210 ± 
57.88 
8.80 ± 2.98 
8.2 + 2.12 
6987 ± 
1394 
4104 ± 982 
43(76.8) 
13(23.2) 
40(71.43) 
10(17.9) 
5(8.93) 
1(1.8) 
23.40 
±3.26 
5(8.93) 
38(67.86) 
13(23.21) 
144 ± 
23.75 
84 ± 7.55 
243 ± 
59.77 
250 ± 
70.45 
276 ± 
64.75 
7.0 ± 2.80 
9.0 ± 1.86 
7000 ± 
1449 
4302 ± 997 
0.53 
0.03 
0.90 
1.00 
1.00 
0.76 
0.04 
0.23 
0.85 
<0.01 
<0.01 
0.02 
0.14 
0.97 
0.44 
1.00 
1.81(0.46-
7.14) 
1.00 
0.45(0.12-
1.64) 
0.16(0.04-
0.62) 
-
0.99(0.17-
5.65) 
1.00 
1.28(0.36-
4.57) 
-
-
-
-
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20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38 
39. 
Monocyte count (per mm )^ 
Lymphocyte count (per mm )^ 
Eosinophil count (per mm )^ 
Basophil count (per mm )^ 
Erythrocyte sedimentation rate 
(mm/h) 
Triglycerides (mg/dl) 
HDL(mg/dl) 
LDL (mg/dl) 
VLOL (mg/dl) 
Phospholipids (mg/dl) 
Urinary creatinine excretion rate 
(g/24h) 
Urinary glucose (mmol/day) 
Co-morbid conditions and other 
complaints 
Hypertension 
Non proliferative diabetic 
retinopathy 
Proliferative diabetic retinopathy 
Nephropathy 
Neuropathy 
Peripheral Vascular Disease 
Osteomyelitis 
Fever 
4841143 
2204 ±442 
173 ±123 
33 + 17 
52 ± 19.66 
120.5 ± 20 
34.018 
115 ± 37 
24.015 
215.5 ±48 
0.98 ±0.2 
164.4 ± 
140 
14(66.67) 
0(0.0) 
1 (4.76) 
9 (42.86) 
7 (33.33) 
10 (47.62) 
2(9.52) 
0 (0.0) 
555 ±130 
1935 ±411 
191±110 
39115 
49 ± 19.44 
99.50 ± 17 
30.0 ±5 
83.0 ± 21 
19.014 
185.5 133 
0.9910.3 
165.0 ± 
141 
52(92.86) 
9 (16.07) 
15 (26.78) 
38 (67.86) 
35 (62.50) 
34 (60.71) 
10(17.85) 
11 (19.64) 
0.06 
0.02 
0.56 
0.17 
0.55 
<0.01 
0.04 
<0.01 
<0.01 
0.01 
0.87 
0.99 
<0.01 
0.10 
0.06 
0.07 
0.04 
0.32 
0.49 
0.03 
. 
-
-
-
-
-
-
-
-
0.15(0.04-
0.60) 
0.14(0.02-
1.11) 
0.36(0.13-
0.99) 
0.30(0.10-
0.86) 
0.59(0.21-
1.62) 
0.48(0.09-2.42 
-
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40. 
41. 
42. 
43. 
44. 
Surgical Treatment History 
Diet 
Vegetarian 
Non-vegetarian 
Diabetic diet 
Smoking 
No 
Yes 
Discharge status 
Alive 
Dead 
Glycemic control at discharge 
9 (42.86) 
12 (57.14) 
5 (23.81) 
4 (19.05) 
16(76.19) 
5(23.81) 
21(100) 
0 (0.0) 
14 (66.67) 
46 (82.14) 
25 (44.64) 
28 (50) 
3 (5.36) 
23(41.07) 
33(58.93) 
53 (94.64) 
3 (5.36) 
18 (32.14) 
<0.01 
0.04 
<0.01 
0.56 
<0.01 
0.16(0.05-
0.49) 
2.78(0.54-
14.43) 
13.33(2.3-
77.25) 
1.00 
1.00 
0.22(0.07-
0.68) 
-
4.22(1.45-
12.27) 
Data are means ± SD or n (%) unless otherwise indicated. 
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underweight; 18.5-22.9 kg/m^ = normal weight; 23.0-24.9 l<g/m^ = overweight), 
presence of nephropathy (creatinine ^150 nmol/l or presence of micro- or 
macroalbuminuria), neuropathy (absence of perception of the Semmes-Weinstein 
monofilament at 2 of 10 standardized plantar sites on either foot) and peripheral 
vascular disease (ischemic symptoms and intermittent claudication or rest pain, with or 
without absence of pedal pulses), were some of them. Osteomyelitis was diagnosed on 
suggestive changes in the radiographs and bone scans. If a patient had multiple ulcers, 
specimens from all the ulcers were taken; and the patient was grouped in the MDRO 
infected category if any of the ulcers was found to be MDRO positive. Fasting HDL and 
VLDL were measured and LDL was calculated by subtracting their sum from total 
cholesterol. 
Clinical assessment for signs of infection (swelling, exudate, surrounding 
cellulitis, odor, tissue necrosis, crepitation, and pyrexia) was made. Ulcer size was 
determined by multiplying the longest and widest diameters and expressed in 
centimeters squared. Demographic and other relevant details were retrieved from 
medical records available with the hospital. Each patient was minutely tracked until 
discharge or death during the stay. Informed consent was obtained from all subjects, 
and clearance was obtained from the institute's ethics committee. As an empiric 
treatment at admission, amoxyclav (1.2 g i.v. every 8 h) was given to all patients, 
intravenously which was switched to oral administration (625 mg p.o. every 8 h). If 
cellulitis or gangrene was detected, metronidazole (500 mg i.v. every 8 h) was added to 
the regimen. To target specific pathogens, drug regimen had to be modified in 
accordance with the culture susceptibility reports, as appropriate. 
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Culture specimens were obtained at the time of admission, after tlie surface of 
the wound had been washed vigorously by saline, and followed by debridement of 
superficial exudates. Specimens were obtained by scraping the ulcer base or the deep 
portion of the wound edge with a sterile curette. The soft tissue specimens were quickly 
sent to the laboratory and processed for microbial pathogens, which were identified as 
outlined in section 2.2.1. Final confirmation of bacterial identities was done by 16S rDNA 
sequencing as mentioned in section 2.2.1. Antimicrobial susceptibility testing of the 
isolates was performed by the standard disc diffusion method [CL5I, 2009]. All anaerobic 
isolates were tested for susceptibility to metronidazole and amoxyclav by microbroth 
dilution test [Finegold, 1997]. Gram-negative bacilli were tested for ESBL production by 
the double disc diffusion method and MRSA/VRSA were confirmed as descrit)ed in 
section 2.2.1. 
MRSA, VRSA, ESBL-positive Gram-negative bacteria, and all the Gram-negative 
bacteria that were resistant to at least four of the test antibiotics were considered as 
MDROs in our study. For this study, bacteria resistant to at least 4 of the test antibiotics 
were designated as MDROs because a large number of isolates were resistant to 2 or 3 
test antibiotics. 
Qualitative variables were expressed as percentages and quantitative variables 
were expressed as means ± SD (Standard Deviation). The association of study variables 
with MDRO and non-MDRO infection status of ulcers was tested by using Student's t 
test or Fisher's exact test as appropriate. The odds ratios (ORs) with 95% CIs (Confidence 
Intervals) for having MDRO-associated ulcers were calculated. Multiple logistic 
regressions were employed to identify independent predictors of MDRO infections and 
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predictors of glycemic control. A two-tailed P value of <0.05 was taken as significant. 
Statistical analysis was performed using SPSS (version 11.5, Chicago). 
5.3 Results 
Patients had ulcers with Wagner's grade 2-5. Forty-nine (63.6%) patients had grade-2 
ulcer. Grade-5 was found only in 1 patient belonging to the MDRO group. Males were 
predominant (80.5%) in the study. Fifty-six (72.7%) subjects, out of 77 had MDRO 
infected ulcers. Nine (60%) out of 15 females had MDRO- infected ulcers. All the MDRO 
infected patients had ulcer duration >3 months. It might be merely a coincidence. The 
majority of subjects (90.9%) had type 2 diabetes. Ulcer was necrotic in 16 (20.8%) 
subjects. 
Fifty-nine (76.6%) patients had diabetes for >10 years. Sixty-six (85.7%) were 
hypertensive, 25 (32.5%) had retinopathy, 47 (61%) had nephropathy, 42 (54.5%) had 
neuropathy and 44 (57.1%) had peripheral vascular disease. Twelve (15.6%) patients 
had osteomyelitis. Fifty-five patients (71.4%) had undergone surgical treatment for foot. 
Only 7 (9.1%) subjects were taking diabetic diet. Three patients died during the hospital 
stay. 
A total of 217 isolates were detected from the 95 samples obtained from 77 
patients. Percent occurrence of different bacterial isolates is detailed in Table 5.2. ESBL-
positive strains constituted 19.8% of total isolates. The highest ESBL production was 
noted in Pseudomonas aeruginosa (32.8%), followed by E. coli (27.5%) and K. 
pneumoniae (23.7%). Staphylococcal isolates identified as methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA), 
were 3.7% (n=8) and 0.5% (n=l) of the total 217 isolates, respectively. The numbers of 
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Table 5.2 Percent occurrence of bacterial strains isolated from infected foot ulcers in 
diabetic patients' specimens (N = 77 patients; Total 217 bacterial isolates) 
Bacterial isolates 
Gram Negative aerobes 
E.a^i 
Pseudomonas aeruginosa 
Klebsiella pneumoniae 
Acinet(ri>acter species 
Proteus species 
Enterobacter species 
Morganella morganii 
Gram Positive aerobes 
Methicillin Susceptible Staphylococcus aureus 
Methicillin Resistant Staphylococcus aureus 
Vancomycin Resistant Staphylococcus aureus 
(also methicillin-resistant) 
Anaerobes 
Occurrence 
Number (%) 
51(23.5) 
61(28.1) 
38(17.5) 
5(2.3) 
20(9.2) 
1(0.5) 
1(0.5) 
19(8.8) 
8(3.7) 
1(0.5) 
13(5.9) 
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anaerobic isolates obtained was only 13(6%). The anaerobes belonged to Veillonella 
species, Bacteroides species, Peptostreptococcus species and Clostridium species. 
Antimicrobial susceptibility patterns of the isolates are shown in table 5.3. 
Linezolid was found to be the most potent drug against S. aureus isolates. Staphylococci 
exhibited a high level of resistance against erythromycin (88.9%); tetracycline, 
ciprofloxacin, levofloxacin and cotrimoxazole (81.5% each). All the Gram-negative 
isolates showed 100% susceptibility to imipenem. Quinolones were effective against 
Proteus species (80% susceptibility to ciprofloxacin). Amikacin was the most effective 
aminoglycoside against the Gram-negative organisms. Tetracycline and piperacillin were 
uniformly met with a high level of resistance by these isolates. After imipenem, 
piperacillin/tazobactam was the most potent option against E. coll and K. pneumoniae 
strains. P. aeruginosa exhibited a high level of resistance (72.1%) against gentamicin. 
Cefepime and quinolones were equally potent against Acinetobacter species (80% 
susceptibility to each). Imipenem and linezolid were the most potent antimicrobials in 
our study. All the anaerobes were susceptible to metronidazole and amoxyclav. 
Study factors such as duration of ulcer, ulcer size, fasting and postprandial 
plasma glucose, triglycerides, LDL, VLDL, phospholipids, hypertension, surgical 
treatment history for foot, smoking and glycemic control at discharge were found to be 
very closely associated with MDRO and non-MDRO infection status of ulcers (all P<0.01; 
for phospholipids P = 0.01). A moderate association was observed for factors such as 
mean age, Wagner grade and fever (ail P = 0.03); duration of diabetes, systolic blood 
pressure, HDL, neuropathy, diet (all P = 0.04); and lymphocyte count (P = 0.02). ORs and 
95% CIS can be seen from table 5.1. 
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Chapter 5 
Patients with MDRO-infected ulcers had significantly higher blood glucose 
levels, both fasting and postprandial, on the day of admission. Regarding a fasting blood 
glucose level of <110 mg/dl and/or postprandial level of <160 mg/dl as glycemic control, 
the number of patients achieving glycemic control over the hospital stay was compared 
between those with and without MDRO infections. 
As in the univariate analysis many study factors were found to be significantly 
associated with MDRO infection status of ulcers, we performed multivariate analysis. 
Multiple logistic regressions showed a high degree of interaction between presence of 
neuropathy and ulcer size. Taking the absence of neuropathy as a baseline (OR 1.00), 
presence of neuropathy with an ulcer size <4 cm^ showed an OR of 0.45 (95% Wald CI 
0.08-2.41) while the same with an ulcer size >4 cm^ showed an OR of 17.4 (95% Wald CI 
2.55-118.88). Thus, an ulcer size of > 4 cm^ with the presence of neuropathy could be a 
strong indicator of MDRO infections. Hence we found that in the multivariate analysis, 
the presence of neuropathy and the ulcer size >4 cm^ were still significantly associated 
with MDRO infections. Taking the achievement of glycemic control at discharge (yes/no) 
as the outcome, the association of various study variables with this outcome was 
examined by multiple logistic regression. We found that MDRO status was the only 
significant, independent predictor of glycemic control (OR 4.22, P <0.01). Hence our 
main finding is that, patients with MDRO ulcers have poor glycemic control during the 
hospital stay. 
5.4 Discussion 
This study presents analysis of infected diabetic foot ulcers in hospitalized patients. We 
regret that we could not use bone biopsy sample in case of osteomyelitis. Bone biopsy is 
not routinely performed in our hospital. Moreover, Pellizzer et al. [2001] have reported 
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that samples taken from the base of the wound after debridgement are adequate to 
identify the infecting organism. Gram-negative bacteria were dominant in diabetic foot 
ulcers in our study contrary to the previous studies [Dang et al., 2003; Lipsky & 
Stoutenburgh, 2005]. These variations might be due to the differences in the study 
settings. Nonetheless, our results from the northern region of the country are in 
harmony with reports from the southern parts of India [Shanker et al., 2005], which also 
concluded gram-negative bacteria to be the dominant pathogens in diabetic foot ulcers. 
A high prevalence of multidrug resistant P. aeruginosa reported from south India, is in 
accord with our findings. P. aeruginosa was the most frequently isolated pathogen in 
our study (28.1%). This raises a serious concern, as P.aeruginosa may sometimes be 
quite an aggressive pathogen [Jones, 2007]. 
Ours is a tertiary care hospital with widespread usage of broad-spectrum 
antibiotics. High selection pressure might be the reason for high rates of antibiotic 
resistance observed in the present study. Compared with earlier reports, we recovered 
fewer anaerobic species [Viswanathan et a!., 2002]. Our patients did not have chronic 
draining wounds, and very few had gangrene associated with their infections. This may 
be an indication of fewer anaerobic species among nonthreatening lower-extremity 
infections, which has been reported earlier [Lipsky & Berendt, 2000]. We found similar 
duration of hospital stay in both MDROs and non-MDROs. This is contrary to previous 
reports that state that MDRO infections might increase hospital stay and cost 
[Bentkover & Champion, 1999]. 
It is well established until now, that those patients with diabetic foot ulcers 
whose blood glucose levels are poorly controlled exhibit higher mortality rates [Ikem et 
al., 2002]. Our results indicate that patients with MDRO-infected ulcers have poor 
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glycemic control. Hence, MDROs might lead to higher mortality among patients having 
diabetic foot infections. 
5.5 Conclusions 
In conclusion, this study reveals that there is a high frequency of occurrence of MDRO 
infections in diabetic foot ulcers. MDRO infected patients have poor glycemic control. 
Imipenem and linezolid can be suggested as the drugs of choice in the described setting. 
We recommend frequent surveillance studies that could help in updating the empirical 
antibiotic regimen in diabetic foot ulcers. 
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6.1 Introduction 
Multidrug resistant Gram-negative bacteria (MDRGNB) are a major therapeutic 
challenge both in community and hospital settings [Chiu et al., 2000]. Concomitant P-
lactam and aminoglycoside resistance involving armA and rmtB genes is increasingly 
being reported [Ma et a!., 2009]. Foot ulcers are a very common complication of type 1 
and type 2 diabetes, as mentioned in the previous study (Chapter 5). Infections of foot 
ulcers by ESBL-producing MDRGNB in diabetic patients have been described frequently 
[Sotto et al., 2007]. Due to non-use of standard microbiological techniques, there is a 
paucity of ESBL data concerning diabetic foot ulcers particularly in India. 
CTX-Ms have become the most prevalent ESBLs worldwide. Also, CTX-M-15 
enzyme is increasingly being reported from the Indian subcontinent [Muzaheed et a!., 
2009; Huang et al., 2009]. Moreover, Escherichea coli is one of the most common 
infecting organisms isolated from soft tissue infections [Cunha, 2000]. Accordingly we 
looked for the mode of transmission of WOCTX-M and b/or™ resistance markers among the 
E. coli strains isolated from infected foot ulcers of diabetic patients admitted to the 
endocrinology ward of the Aligarh hospital. The study aimed at (i) characterizing the 
mode of transmission of fa/ocrx-w and d/oxEM among ESBL-producing E. coli strains isolated 
from infected diabetic foot ulcers, and (ii) identifying the risk factors for "sex-associated 
MDRGNB infection status" of the ulcers. 
6.2 Experimental outline 
For this study, bacteria resistant to at least 4 of the test antibiotics were designated as 
MDRGNB. Also, all ESBL-producers were considered as MDRGNB. The MDRGNB 
identified among the Gram-negative bacteria isolated in the previous study (Chapter 5) 
were further studied. MICs of gentamycin, tobramycin, amikacin, kanamycin, 
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streptomycin, cefalothin, cefazolin, cefuroxime, cefoxitin, ceftazidime, cefotaxime, 
ceftriaxone, cefepime, ciprofloxacin, norfloxacin, tetracycline, piperacillin, imipenem, 
amoxyclav and piperacillin/tazobactam were determined for the ESBL-producing E. coli 
strains as described in section 2.2.1. A screening for blocn^, WOTIM, armA, rmtA, rmtB 
genes and integrons was performed among the ESBL-producing E. coli strains using both 
genomic and plasmidic DNA. The ESBL-producing f. coli (14/51; 27.5%), K. pneumoniae 
(9/38; 23.7%) and P. aeruginosa (20/61; 32.8%) strains identified in the previous study 
(Chapter 5) were subjected to molecular typing by ERIC-PCR, as outlined in section 2.2.4. 
Cloning of WOCTX-M was performed using Qiagen cloningplus kit (Qiagen, USA) and 
sequencing was done as mentioned in section 2.2.7. Transmissibility of b/oox-M markers 
was checked by conjugation as described in section 2.2.8. Homology model of CTX-M-15 
corresponding to accession number [GenBank: FJ9978661 was prepared using Swiss 
Model Server and model verification was done as described in section 2.2.9. 
Significance of the study variables for "sex-associated MDRGNB infection status" 
of the foot ulcers was tested by using Student's t test or Fisher's exact test as 
appropriate. Both univariate and multivariate analyses were performed. A two-tailed p 
value of <0.05 was taken as significant. Statistical analysis was performed using SPSS 
(version 11.5, Chicago). 
6.3 Results 
6.3.1 General results 
Out of the 185 Gram-negative bacteria (including Gram-negative anaerobes) isolated in 
the previous study (Chapter 5), 149 (80.5%) were found to be MDRGNB. Sixty-six 
samples which belonged to 55 patients were found to harbor these MDRGNB. Figure 6.1 
shows the distribution of MDRGNB 
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Fig 6.1 Distribution of multidrug resistant Gram-negative bacteria obtained from infected 
diabetic foot ulcers divided into 2-month periods from April 2007 to November 2008. 
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obtained from infected diabetic foot ulcers divided into 2-month periods from April 
2007 to November 2008. Characteristics of male and female patients having MDRGNB-
infected foot ulcers were recorded (Table 6.1). Among the 55 MDRGNB-infected 
patients, 46 (83.6%) were males while 9 (16.4%) were females (Table 6.1). Grade-5 ulcer 
was found in one male patient only. Three male patients died during the hospital stay 
(Table 6.1). Imipenem alone and the piperacillin/tazobactam combination were found to 
be the therapies of choice against ESBL-producing E. coll. 
6.3.2 PCR amplifications, cloning and sequence analysis of PCR amplified products 
Only 2 strains were confirmed to harbor b/Oox-M by PCR. Strain D253 was positive for 
both b/ocTx-M and bithtM while strain D281 possessed only blocrn-u- None of the strains 
were positive for any of the 16S rRNA methyl transferase genes (i.e. armA, rmtA or 
rmtB). Seven strains were detected to harljor integrons of varying sizes (600bp to 
ISOObp). All these integrons were found to be Classl type and were further 
characterized for the presence of intl and sull genes of expected sizes 845bp and 
840bp, respectively. None of the genes was found to be located on the integrons. E. coli 
C600 cells harboring cloned bloax^ (C600 '''°^-**) were again found positive for the said 
gene after PCR-amplification, in all instances. Moreover, cultures derived from C600 
" ° ^ " " cells gave a positive ESBL synergy test. Azide resistant E. coll J53 cells transformed 
with the plasmidic DNA extracted from C600 ' ' ' °*^-" cells became cefotaxime resistant. 
Also, cultures derived from these transformed £ coli J53 cells were found to be positive 
for the ESBL test. Sequencing results confirmed all the blocrx-M genes obtained in this 
study as fa/oox-M-isand all the WOJEM genes as WoreM.i. 
6.3.3 Plasmid mediated transfer of blaax-u-is and genetic relatedness of strains 
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Table 6.1 Characteristics of male and female diabetic patients having foot ulcers infected 
by multidrug resistant Gram-negative bacteria (MDRGNB) 
S.No. 
1. 
2. 
3. 
4. 
5. 
6. 
Characteristics 
N (Number of 
patients) 
Type of diabetes 
Typel 
TypeZ 
Duration of diabetes 
(years) 
<5 
5-15 
2:15 
Duration of ulcer 
(months) 
53 
>3 
Duration of hospital 
stay (months) 
51 month 
>1 month 
Size of ulcer (cm )^ 
<A 
>4 
Nature of ulcer 
MDRGNB-
infected 
males 
46 
4(8.7) 
42(91.3) 
11.91 ± 
2.56 
0(0.0) 
39(84.8) 
7(15.2) 
4.25 ± 0.74 
0(0.0) 
46(100) 
0.71 ± 0.26 
38(82.6) 
8(17.4) 
4(8.7) 
42(91.3) 
MDRGNB-
infected 
females 
9 
2(22.2) 
7(77.8) 
10.50 ±1.68 
0(0.0) 
6(66.7) 
3(33.3) 
4.8710.52 
0(0.0) 
9(100) 
0.68 ±0.21 
2(22.2) 
7(77.8) 
2(22.2) 
7(77.8) 
p-value 
0.25 
0.12 
0.34 
0.00 
1.00 
0.82 
0.00 
0.25 
OR (95% CI) 
1.00 
0.33(0.05-2.18) 
-
-
-
-
-
" 
1.00 
16.63(2.89-
95.35) 
1.00 
0.33(0.05-2.18) 
108 
Chapter 6 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
Non-necrotic 
necrotic 
Wagner Grade 
2 
3 
4 
5 
BMI (kg/m^) 
Systolic Blood 
Pressure (mmHg) 
Diastolic Blood 
Pressure (mmHg) 
Random plasma 
glucose (mg/dl) 
Fasting plasma 
glucose (mg/dl) 
2-h plasma glucose 
(mg/dl) 
Glycated Hb (%) 
White Blood Cell 
count (per mm') 
Triglycerides (mg/dl) 
HDL (mg/dl) 
LDL (mg/dl) 
VLDL (mg/dl) 
Phospholipids (mg/dl) 
Urinary creatinine 
excretion rate (g/24h) 
39(84.8) 
7(15.2) 
39(84.8) 
4(8.7) 
2(4.3) 
1(2.2) 
24.34 ± 
3.78 
145 ± 24.0 
85 ± 5.45 
244 ±60 
253 ± 71 
277 ± 65 
9.1 ±1.77 
7255 ± 
1500 
100 ± 15 
32 ±7 
84 ±16 
18.5 ±3 
188 ± 35 
0.99 ± 0.2 
4(44.4) 
5(55.6) 
1(11.1) 
5(55.6) 
3(33.3) 
0(0.0) 
22.75 ± 2.25 
142 ± 21.86 
83 ± 6.32 
241 ± 58 
247 ± 68.8 
274 ± 63 
9.0 ±2 
6482 ±1388 
98 ±11 
30±3 
82114 
19±2 
182 ± 31 
0.99 ± 0.4 
0.02 
0.00 
0.23 
0.73 
0.33 
0.89 
0.82 
0.89 
0.88 
0.16 
0.71 
0.41 
0.73 
0.54 
0.62 
1.00 
1.00 
6.96(1.49-
32.53) 
-
-
-
-
-
-
-
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22. 
23. 
24. 
25. 
26. 
11. 
28. 
29. 
30. 
31. 
32. 
Urinary glucose 
(mmol/day) 
Co-morbid conditions 
and other complaints 
Hypertension 
Non proliferative 
diabetic retinopathy 
Proliferative diabetic 
retinopathy 
Nephropathy 
Neuropathy 
Peripheral Vascular 
Disease 
Osteomyelitis 
Surgical Treatment 
History 
Discharge status 
Alive 
Dead 
Glycemic control at 
discharge 
167 ±141 
45(97.8) 
6(13) 
12(26.1) 
33(71.7) 
31(67.4) 
29(63) 
7(15.2) 
40(86.9) 
43(93.5) 
3(6.5) 
9(19.6) 
164 ±138 
6(66.7) 
2(22.2) 
2(22.2) 
4(44.4) 
3(33.3) 
4(44.4) 
2(22.2) 
5(55.6) 
9(100) 
0(0) 
8(88.9) 
0.95 
0.01 
0.60 
0.99 
0.13 
0.07 
0.46 
0.63 
0.05 
0.99 
0.00 
22.5(2.00-
252.58) 
0.53(0.09-3.15) 
1.24(0.22-6.79) 
3.17(0.73-
13.70) 
4.13(0.91-
18.84) 
2.13(0.50-9.04) 
0.63(0.11-3.67) 
5.33(1.11-
25.64) 
-
0.03(0.00-0.28) 
Data are means ± SD or n (%) unless otherwise indicated. 
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Table 6.2 shows MICs of some of the antibiotics against the fa/oox-Mis positive strains of 
£ coli. The ceftazidime and cefotaxime resistance markers were located on the 
plasmidic DNA of both the blaax-M-is positive strains and were transmissible through 
conjugation. Quinolone (ciprofloxacin) resistance was co-transferred with cefotaxime 
resistance, in only one of the b/Ocrx-M-is positive isolates. Transfer frequencies (Total no. 
of transconjugants per plate/Total no. of recepients per plate) observed were of the 
order 10"^  (Table 6.3). Randomly taking a single representative strain in case of identical 
susceptibility patterns, figure 6.2 shows ERIC-profiles of 40 ESBL-producers. P. 
aeruginosa, K. pneumoniae and E. coli displayed 5, 5 and 8 major ERIC-profiles 
respectively (Fig 6.2). Both the b/ocrx-M-is positive strains were found to be clonally 
related and displayed ERIC-profile M l (Table 6.4). 
6.3.4 Results of homology modelling 
Over 90% of the amino acid residues in the protein structure modelled from fa/OoxMIS 
gene obtained in this study [GenBank: FJ9978661 were found to be present in the most 
favorable regions as revealed by the Ramachandran plot (Fig 6.3). The Ramachandran Z-
score for modelled enzyme (Fig 6.4) from strain D253 was found to be 0.027, which 
further confirms the accuracy of the modelled structure. 
6.3.5 Results of risk factor analysis 
In the univariate analysis, many study variables including mean age, mean ulcer 
duration, smoking, Wagner grade and 'glycemic control at discharge' (all p = 0.00) were 
found to be significant for "sex-associated MDRGNB infection status" of the foot ulcers 
(Table 6.1). Hence, we went for multivariate analysis. The multiple logistic regression 
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Table 6.2 MICs of some of the antibiotics used against 6/OCTX-M-IS positive strains of E. coli 
Antibiotics 
Gentamicin (G) 
Tobramycin (Tb) 
Kanamycin (Ka) 
Amikacin (Ak) 
Streptomycin (St) 
Cefazolin (Cz) 
Ceftazidime (Ca) 
cefotaxime (Ce) 
Ceftriaxone (Ci) 
Cefepime (Cpm) 
Ciprofloxacin (Cf) 
Norfloxacin (Nx) 
Piperacillin (Pc) 
Amoxydav (Ac) 
Tetracycline (T) 
MiC(mg/L)for WocnM«-u 
D253 
128 
64 
64 
32 
64 
>256 
32 
256 
256 
64 
64 
64 
>256 
4 
256 
positive £. coli strains 
D281 
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(a) P. aeruginosa (19 strains) 
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(b) K. pneumoniae (7 strains) 
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Fig 6.2 ERIC-profiles of extended-spectrum p-lactamase producing bacteria isolated from 
infected foot ulcers of diabetic patients. 'M' stands for marker (the first lane of each 
figure). 
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Table 6.4 Analysis of b/ocnt-M-is markers using bioinformatic approach and clinical profile 
CTX-M-15 posithre f. coli strain 
ERIC profile 
Qassl integron 
intl 
sull 
Sex of the patient 
"PDB ID of the template retrieved for modelling 
Cefotaxime MIC of the strain (mg/L) 
Ceftazidime MIC of the strain (mg/L) 
Genbank accession numbers (This study) 
D253 
M l 
+ 
+ 
+ 
Female 
liysA 
256 
32 
FJ997866 
D281 
M l 
+ 
+ 
+ 
Male 
liysA 
64 
32 
GQ145220 
TDB = Protein Data Bank 
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Fig 6.3 Ramachandran plot corresponding to the CTX-M-15 enzyme modelled from the 
GenBank sequence [GenBank: FJ9978661. Ramachandran Z-score for the modelled 
structure (calculated by 'WHATIF' package) was equal to 0.027. The glycines and 
prolines are represented by triangles and squares, respectively. All other amino acids 
are represented by circles. The plot was constructed using Discovery Studio2.0 
(Accelrys). 
Plot statistics 
Residues In most favored regions 
Residues in additional allowed regions 
Residues in generously allowed regions 
Residues in disallowed regions 
91.5% 
7.8% 
0.7% 
0.0% 
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Fig 6.4 CTX-M-15 enzyme modelled from the blOcn-M-is gene sequence [Genbank: FJ9978661 of 
E. coH strain D253. The active site 0-loop, the SDN loop and the KTG motif are labeled. 
Amino acid residues Asnl04, Asnl32 and Ser237 (supposed to fix cefotaxime into the 
active site of CTX-M-15) are also marked. 
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model confirmed 'glycemic control at discharge' to be the single independent risk factor 
for the same. (p=0.001). ORs and 95% CIs can be seen from Table 6. 1. Hence our main 
finding is that, male diabetic patients having MDRGNB-infected foot ulcers have poor 
glycemic control during the hospital stay. 
6.3.6 Nucleotide sequence accession numbers 
The accession numbers of the £ co//genes sequenced in this study are [GenBank: 
FJ9978661. [GenBank: FJ9978671 and [GenBank: GQ1452201. 
6.4 Discussion 
This is the first study to report on risk factors for "sex-associated MDRGNB-infection 
status" of diabetic foot ulcers from this region of India (Uttar Pradesh). We do not claim 
that these 77 patients represent the entire region. Hence, similar studies from this 
region and across the globe that could help in updating the empirical antibiotic regimen 
in diabetic foot ulcers are highly recommended. Infections due to multidrug resistant 
organisms in hospitalized patients with diabetic foot ulcers have been reported 
previously [Hartemann-Heurtier et al., 2004]. Patients with diabetic foot ulcers whose 
blood glucose levels are poorly controlled exhibit higher mortality rates [Ikem et al., 
2002]. Our results indicate that male diabetic patients with MDRGNB-infected foot 
ulcers have poor glycemic control. Hence, male diabetic patients having MDRGNB-
infected foot ulcers might have higher mortality than their female counterparts. Studies 
have reported 'male sex* as a significant risk factor for non-healing foot ulcers 
[Prompers et al., 2008]. 
Plasmid mediated WOOK-M-IS among clinical isolates have also been reported 
earlier [Yu & Cheng, 2004]. Only 2 of our 43 ESBL-producing strains were PCR-positive 
for blocn-M-is- This is in harmony with a study in which the authors detected only 3 
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strains out of 365 clinical isolates that were PCR-positive for fa/Oox-M-is [Touati et al., 
2006]. However, this observation was contrary to many findings, which have reported a 
high prevalence of /J/OOX-M-IS among clinical isolates [Muzaheed et al., 2009]. ESBL-
production in the remaining ESBL-positive strains might be due to ESBL-types other than 
CTX-Ms such as SHV/OXA/TEM/GES/BES/PERALA/ IBC etc. as each of these have many 
variants. A high prevalence of ESBL-producers was observed in strains of P. aeruginosa 
(32.8%), which is generally considered to be a rare ESBL-producer. This result was in 
harmony with the reports from Peshawar, Pakistan (close to North India) and even Delhi 
(India) which is adjacent to Aligarh. The authors of these studies have reported 35.85% 
and 33.6% ESBL-producers among P. aeruginosa isolates, respectively [Rajini et al., 
2008; Ullah et al., 2009]. However, since the sample sizes were not large, we prefer to 
conclude that the observations regarding high prevalence of ESBL-producers among P. 
aeruginosa strains made in these studies as well as ours might have been simply matters 
of coincidence. 
Classl integrons are the most commonly found integron type in Gram-negative 
bacteria [Khemtong & Chuanchuen, 2008]. Accordingly, we detected 7 classl integrons 
all of which were invariably PCR-positive for intl and sull. None of the fa/ooxMis 
markers were found to be located within the integrons. Hence, it is confirmed that the 
horizontal transfer of these markers was not integron-mediated rather plasmid-
mediated in our setting. Such studies have also been reported earlier where plasmid-
mediated transfer of b/Ocrx-M-is was observed despite the presence of integron [Kim et 
al., 2007]. Transconjugation experiments were successful in case of both the blaax-M-is 
positive £ coli strains in the present study. It is important to mention here that in 
medical literature, not all transfer experiments were successful with ESBL-producing £ 
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coli. In a study, 19 of 24 strains did not transfer tlie ESBI^  [Schmitt et al., 2007]. Similarly 
only 38% success was attained in transfer of markers by conjugation in another study 
[Lim et al., 2009]. The presence of strains co-resistant to aminoglycosides, quinolones 
and third generation cephalosporins as observed in our setting is a matter of due 
concern. Such strains if combined with the production of carbapenemase might result in 
therapeutic dead-ends [Walsh, 2008; Zarrilli et al., 2008]. 
As stated earlier, we are the first to report modelling of CTX-M-IS enzyme, one 
of the most prevalent ESBLs in India. Residues specifically in the active site omega loop 
(position 161-179) of CTX-M enzymes play an important role in the substrate profile for 
cephalosporins [Bonnet et al., 2001; Sturenburg et al., 2004]. But residues outside the 
omega loop might also help in fixing cefotaxime into the active site of the enzyme. The 
omega loop (positions 161-179), SDN loop (positions 130-132), KTG motif (positions 
234-236), and the amino acid residues Asnl04, Asnl32 and Ser237 which are supposed 
to fix cefotaxime into the active site of CTX-M enzymes [Bonnet, 2004] are clearly 
marked in the figure (Fig 6.4). 
6.5 Conclusions 
The following conclusions can be drawn from this study: (/) Male diabetic patients with 
MDRGNB-infected foot ulcers have poor glycemic control and hence they might have 
higher mortality rates compared to their female counterparts {//) Plasmid-mediated 
conjugal transfer, albeit at a low frequency might be the possible mechanism of transfer 
of blocTx-u-is resistance marker in the present setting. 
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7.1 Introduction 
Acinetobacter baumannii is an important opportunistic pathogen implicated in urinarv 
tract infections (UTIs) [Bergogne-Berezin & Towner, 19961. Extended spectrum p-
lactamases (ESBLs) are the bacterial enzymes that impart resistance against advanced-
generation-cephalosporins. Simultaneous ESBL and carbapenemase production in 
pathogens might lead to therapeutic dead-ends. CTX-M enzymes have become the most 
prevalent ESBLs [Canton & Coque, 2006]. This study reports amplification of d/OcncM is 
genes from two carbapenem-resistant A. baumannii strains isolated from community-
acquired urinary tract infection samples and their mode of transmission. 
7.2 Experimental outline 
The samples for this study were originally collected from patients attending outpatient 
clinics at Aligarh Hospital, India between August 2004 and July 2005. Freshly voided 
midstream specimens of urine (n= 920) were submitted to the clinical microbiology 
laboratory of the hospital for processing. Semi quantitative urine culture using a 
calibrated loop was used to inoculate blood agar and Mac-Conkey agar plates [Claridge 
et al., 1987]. Following the recommendations of Kass [Kass, 1957] in distinguishing 
genuine infection from contamination, significant monomicrobic bacteriuria was defined 
as culture of a single bacterial species from the urine sample at a concentration of >10^ 
cfu/ml. Only a single positive culture per patient was included in the analysis. The 
cultures were quickly sent to the laboratory and processed for microbial pathogens. Six 
carbapenems-resistant A. baumannii isolates from amongst these were selected for 
further studies. 
Antimicrobial susceptibility testing was performed by the standard disc-diffusion 
method and minimum inhibitory concentrations (MICs) were determined by the 
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microbroth dilution method. The test antibiotics included imipenenn, meropenenn, 
ciprofloxacin, norfloxacin, ampicillin/sulbactam, gentannicin, tobramycin, amikacin, 
streptomycin, kanamycin, cefazolin, cefuroxime, cefoxitin, ceftazidime, cefotaxime, 
ceftriaxone and cefepime. The ESBL double-disk-synergy-test was performed as 
described in section 2.2.1. The ESBL-producers were subjected to molecular typing by 
ERIC-PCR, as outlined in section 2.2.4. Also, a search for blOcn-M, blojo*, anvA, rmtA, 
rmtB genes and integrons was made among the ESBL-producing A. baumannii strains 
using both genomic and plasmidic DNA, as mentioned in section 2.2.4. Cloning of blocn-
M was performed using Qiagen cloningplus kit (Qiagen, USA) and sequencing was done 
as mentioned in section 2.2.7. Transmissibility of blocn-M markers was checked by 
conjugation as described in section 2.2.8. Homology model of CTX-M-15 corresponding 
to accession number [GenBank: GQ1452191 was prepared using Swiss Model Server and 
verification was done as described in section 2.2.9. 
7.3 Results 
Four out of 6 strains were identified as ESBL-producers. Plasmid DNA from two strains 
(206 and 207) was found to be PCR-positive for WOCTX-M along with WOTEM- GenBank 
accession numbers of the genes sequenced in this study are GQ145218. GQ145219. 
GQ174506 and GQ174507. Figure 7.1, 7.2 and 7.3 represent modelled CTX-M from 
GQ145219. corresponding Ramachandran plot and ERIC-profiles of ESBL-producers, 
respectively. Bioinformative details of the modelled CTX-M enzyme are shown in table 
7.1. All strains were found to be resistant to imipenem, meropenem, ciprofloxacin and 
norfloxacin while the same showed susceptibility to ampicillin/sulbactam. Imipenem 
MICs for strains 206 and 207 were found to be 64 mg/L each (Table 7.2). Table 7.3 
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Fig 7.1 CTX-M-15 enzyme modelled from the b/Ocrx-M-is gene sequence [GenBank: GQ145Z191 
of Acinetobacter baumannii strain. The SDN loop and residues Asnl04 and Asnl32 
(important to fix cefotaxime into the active site of crX-M-15) are also marked. 
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Fig 7.2 Ramachandran plot corresponding to the CTX-M-15 enzynne modelled from the 
GenBank sequence [GenBank: GQ1452191. Ramachandran Z-score for the modelled 
structure (calculated by 'WHATIF' package) was equal to 0.044. The glycines and 
prolines are represented by triangles and squares, respectively. All other amino acids 
are represented by circles. The plot was constructed using Discovery Studio2.0 
(Accelrys). 
Plot statistics 
Residues in most favored regions 
Residues in additional allowed regions 
Residues in generously allowed regions 
Residues in disallowed regions 
91.0% 
5.59% 
3.41% 
0.0% 
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M A1 A2A3A2 
10 Kb 
1Kb 
Fig 7.3 ERIC-profiles of ESBL-producing Acinetobacter baumannii strains isolated from urinary 
tract infection patients. 'M' stands for marlcer. 
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Table 7.1 Bioinformative details of the CTX-M-15 model shown in fig 7.1 
Accession number of the 
modelled gene sequence 
PDB ID of the template retrieved 
for modelling 
Modelled residue range 
Sequence identity 
E-value 
Final total energy in Kj/mol 
(Modelling log) 
Ramachandran Z-score 
[GenBank:gQlflS21S] 
liYsA(1.65A) 
26 to 77 
75.926% 
6.20e-13 
-2074.462 
0.044 
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Table 7.2 MICs of antibiotics used against WOOX-M-IS positive and carbapenems resistant 
strains of Acinetobacter baumannii. 
Antibiotics 
Gentamicin (G) 
Tobramycin (Tb) 
Kanamycin (Ka) 
Amiicacin (Ale) 
Streptomycin (St) 
Cefazolin (Cz) 
Ceftazidime (Ca) 
Cefotaxime (Ce) 
Ceftriaxone (Ci) 
Cefepime (Cpm) 
Ciprofloxacin (Cf) 
Norfloxacin (Nx) 
Piperacillin (Pc) 
Tetracycline (T) 
Imipenem (1) 
Meropenem (M) 
Ampicillin/Sulbactam 
MIC (mg/L) for A. boummann//strains 
Strain 206 
32 
64 
32 
2 
64 
>128 
32 
64 
256 
64 
64 
32 
256 
512 
64 
64 
2 
Strain 207 
64 
64 
64 
32 
64 
>128 
32 
256 
256 
64 
64 
64 
>256 
512 
64 
64 
2 
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shows outcomes of the marker transfer experiments. The bloax-M positive strains were 
clonally related (identical ERIC-profile 'A2') and displayed resistance against 
aminoglycosides (gentamycin, tobramycin, streptomycin and kanamycin) and all the 
cephalosporins tested (Table 7.2). Strain 206 was found to be amikacin-sensitive. 
None of the strains was PCR-positive for armA, rmtA, or rmtB. Three integrons 
were amplified from genomic DNA of another two strains. Integron of SOObp was 
amplified from strain 611, while strain 815 harbored 2 integrons of 500 bp and 1Kb. All 
integrons were found to be Classl type and were positive for intl and sull of 845bp and 
840bp, respectively. The C600 cells harboring cloned bloax-M (C600 '^''^•**) were again 
found to be PCR-positive for the said gene. Moreover, cultures derived from C600 " " ' ^ ^ 
cells gave a positive 'ESBL-synergy-tesf. Azide resistant E. coll J53 cells transformed with 
the plasmid DNA extracted from C600 " ° * ^ - " cells became cefotaxime resistant. Also, 
cultures derived from these transformed E. colt J53 cells were found to be positive for 
the ESBL test. The ceftazidime and cefotaxime resistance markers were located on the 
plasmid DNA of the blocn-M positive strains and were transmissible through conjugation. 
Gprofloxacin resistance was co-transferred with cefotaxime resistance, in strain 206. 
Conjugation frequencies (Total no. of transconjugants per plate/Total no. of recepients 
per plate) observed were of the order 10'^ (Table 7.3). 
Sequencing results confirmed the WOOX-M and Wortw genes obtained in the study 
as WocTx^ i-15 and WOTEM-IM variants, respectively. Accession numbers [GenBank: 
6Q1745061 and [GenBank: GQ1452181 showed 89% and 86% identity to entries 
[GenBank: GQ3431691 (WOCTX-M-IS) and [GenBank: FJ3492551 (b/orcM-iso) in the database, 
respectively. Over 90% of the amino acid residues in the modelled-enzyme were found 
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to be present in the most favorable regions of the Ramachandran plot. Ramachandran 
Z-score for the modeHed-enzyme from strain 206 was found to be 0.044. 
7.4 Discussion 
The emergence of strains co-resistant to aminoglycosides, quinolones, advanced 
generation cephalosporins and carbapenems as observed in our setting is a matter of 
due concern. Only 2 of the 4 ESBL-producing A. baumannii strains were found positive 
for b/oax-M-15- ESBL-productions in the remaining ESBL-positive strains might be due to 
ESBL-types other than CTX-IVIs such as SHV/OXA/TEM/GES/BES/PER/TLA/IBC etc. as 
each of these have many variants. The fa/ocnc-w positive isolates displayed cefotaxime 
MICs up to 8 fold higher than ceftazidime MICs, characteristic to CTX-M-15 producers. 
Classl integrons are the most commonly found integron type in Gram-negative bacteria 
[Khemtong & Chuanchuen, 2008]. Accordingly, we detected 3 classl integrons all of 
which were invariably PCR-positive for intl and sull. None of the A. baumannii strains 
was PCR-positive for ormA, rmtA, or rmtB. Hence the aminoglycoside resistance 
observed in these isolates might be due to other mechanisms [Shakil et al., 2008]. None 
of the d/ocra-M-15-positive strains was found to harbor integrons. Hence, it is confirmed 
that the horizontal transfer of these markers was not integron-mediated rather plasmid-
mediated in our setting. 
The study also reports modelling of CTX-M-15 enzyme from -4. baumannii. 
Ramachandran Z-score expresses how well the backbone conformations of all the 
residues correspond to the known allowed areas in the Ramachandran plot. Accordingly, 
the Ramachandran Z-score for the CTX-M-15 model was found to be 0.044, which 
further confirms the accuracy of the model. Asnl04 and Asnl32, the residues supposed 
to 'fix* cefotaxime into the active site of CTX-M enzyme [Bonnet, 2004] are labeled in 
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Figure 7.1. The SON loop (positions 130-132), was found to be conserved in both the 
CTX-M-15 sequences, which is typical structure of class A enzymes [Xiong et a!., 2004]. 
Both the b/ocTx-M-15-positive strains were clonally related. This is not surprising as a 
recent study also observed correlation between high drug resistance and genetic 
relatedness for bacterial strains [Wu et al., 2009]. 
7.5 Conclusions 
In conclusion, this study reports transmissible CTX-M and TEM variants among 
carbapenems resistant strains of A. baumannii. Amikacin and ampicillin/sulbactam 
might be the drugs of choice against the study isolates. Emergence of such resistant 
strains highlights the need to increase the pace of research in the field of drug 
designing. Bioinformatics tools might help in understanding structures of the rapidly 
emerging variants of CTX-M. 
131 
Chapter 8 
hAolec^ular m.odeLLliA.g of CTX-M-
\/arl^iA.ts Pi\A(i their l\Aterc\ctloiA.s> with 
dru(?jS> a\A.d lviWibitDrs> 
Chapter 8 
8.1 Introduction 
Multidrug resistance in bacteria is a plienomenon of concern both in the community 
and nosocomial settings [Chiu et al., 2000]. The emergence of ESBL-producing organisms 
increases the difficulties of choosing appropriate antibiotic treatment [Cheng et al., 
2008]. ESBI-S hydrolyze the P-lactam ring present in the target antibiotics (such as 
cefotaxime and ceftazidime). CTX-M enzymes have become the most prevalent ESBLs 
[Canton & Coque, 2006]. The change in activities of CTX-Ms leading to the evolution of 
more variants may be due to point mutations present either inside or outside of the 
active site omega loop (amino acid positions 161 to 179) [Sturenburg et al., 2004]. CTX-
M-variants up to CTX-M-89 have already been reported (http://www.lahev.orR/studies: 
last accessed on 17/10/2009). Identification of the amino acid residues crucial to the 
interaction between CTX-M-variants (the bacterial enzymes) and target drugs (the drugs 
hydrolyzed by these enzymes) is a topic of priority research. This information might be 
useful for the scientists involved in designing CTX-M-resistant antibiotics. Variants of this 
bacterial enzyme are emerging at a fast pace. Hence, there is an urgent need to design a 
versatile CTX-M-inhibitor that might inhibit most of the emerging variants of this 
enzyme, if not all. Studying the mode of interaction of recently reported CTX-M-variants 
with the existing inhibitors might help in the search for a versatile CTX-M inhibitor. 
in view of the present background, we found it pertinent to study the mode of 
interaction of 2009 CTX-M variants with target drugs and known inhibitors. This study is 
based on interaction energies. The objectives of the study were: (i) Homology modelling 
of all the sequences of CTX-M-variants submitted in 2009 (ii) Docking of drugs 
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(cefotaxime and ceftazidime) as well as inhibitors (clavulanate, sulbactam and 
tazobactam) with these modelled enzyme-structures (iii) To identify amino acid residues 
crucial to the enzyme-drug and enzyme-inhibitor interactions (iv) To suggest potent 
inhibitors against these enzymes on the basis of interaction energies. 
8.2 Experimental outline 
The database maintained exclusively for p-lactamase enzymes 
(http://www.lahev.org/studies: last accessed on 17/10/2009) was searched for CTX-M 
enzyme sequences submitted in 2009 from across the globe. The five ESBL-types 
explored in the study included CTX-M-15, CTX-M-53, CTX-M-71, CTX-M-82 and CTX-M-
89. The sequences used in the present study appear in GenBank as [GenBank: 
6Q3391021. [GenBank: DQ2687641. [GenBank: FJ8154361. [GenBank: DQ2560911 and 
[GenBank: FJ9718991. GenBank sequence with accession number [GenBank: 
GQ3391021 was used as a reference sequence for detecting mutations. Protein Data 
Bank (PDB) IDs of the templates retrieved for homology modelling of the study 
sequences are shown in Table 8.1. Modelling was performed using the automated mode 
of Swiss Model Server. PDB structures of drugs (cefotaxime, ceftazidime) as well as 
inhibitors (clavulanate , tazobactam, sulbactam) were retrieved from either Drug bank 
or constructed by CORINA from 2-D structure obtained from Pubchem as mentioned in 
section 2.2.9. The ligand (either inhibitor or target drug) was docked into each of the 
modelled enzyme-structures using the targeted docking mode of 'Molecular Docking 
Server*. Alignments were performed by ClustalW program as outlined in section 2.2.9. 
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8.3 Results 
ClustalW alignments revealed that the SDN loop (positions 130-132) and KTG motif 
(positions 234-236) were conserved in all the study CTX-M sequences. Over 90% of the 
amino acid residues in the protein structures modelled from the study b/ocrxM 
sequences were found to be present in the most favored regions as revealed by their 
respective Ramachandran plots. For example, percent amino acid residues in most 
favored, additional allowed, generously allowed and disallowed regions of the 
Ramachandran plot for the modelled CTX-M enzyme corresponding to accession 
number [GenBank: DQ2687641 were 91.6%, 7.7%, 0.7% and 0.0%, respectively. 
The drugs (cefotaxime and ceftazidime) as well as inhibitors (clavulanic acid, 
sulbactam and tazobactam) were docked into each of the modelled enzyme-structures. 
Figures (8.1 to 8.5) show amino acid residues crucial to the interaction of each of the 
modelled enzyme structures with cefotaxime, ceftazidime, clavulanic acid, sulbactam 
and tazobactam, separately. Discovery Studio analysis of the docked structures involving 
ceftazidime revealed that irrespective of the CTX-M-type, ceftazidime interacted 
invariably with the residues A226, G227, L228, P229, A/T230, S231, W232, R285, T288, 
D289, G290 and LyY291. 
Regarding the inhibitors, all the CTX-M-types excluding CTX-M-71 interacted 
with clavulanic acid through the residues A226, G227, L228, P229, T288 and D289. For 
sulbactam, it was observed that the residue at position 285 (either K285 or R285) was 
common to all the interactions, excluding the one which involved CTX-M-53. The amino 
acid residue at position 291 (either L291 or Y 291) was found common to the 
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interactions of CTX-M-53, CfX-iVl-?! and CTX-IVI-89 with tazobactam. Among the studied 
enzyme-inhibitor-complexes, CTX-M complexes with sulbactam displayed the highest 
(negative) interaction energies (Table 8.2). 
8.4 Discussion 
Ramachandran Z-score expresses how well the backbone conformations of all the 
residues correspond to the known allowed areas in the Ramachandran plot. Accordingly, 
the Ramachandran Z-scores for modelled CTX-M enzymes from accession numbers 
[GenBank: GQ3391021. [GenBank: DQ2687641. [GenBank: FJ81S4361. [GenBank: 
DQ2S609n and [GenBank: FJ9718991 were found to be -0.083, 0.006, -0.103, -0.007 
and 0.092, respectively. This further confirms the accuracy of the modelled structures. 
SDN loop (positions 130-132) and KTG motif (positions 234-236) were conserved in all 
the study CTX-M sequences. These are typical structure of class A enzymes [Xiong et al., 
2004]. 
Higher (negative) free energy of interaction (simply called as 'interaction 
energ/) is regarded as an indicator of effective and tight binding for an enzyme-
inhibitor-complex. Sulbactam is a suicide inhibitor, which forms a dead-end complex 
with CTX-M enzyme. Among the studied enzyme-inhibitor-complexes, CTX-M complexes 
with sulbactam displayed the highest (negative) interaction energies (Table 8.2). Hence, 
sulbactam was found to be the most efficient inhibitor for all CTX-M-types in our study. 
Higgins et al., have reported sulbactam to be superior to clavulanic acid and tazobactam 
against multidrug resistant Acinetobacter baumannii strains [Higgins et al., 2004]. In a 
study by Banfi et al, authors observed that the calculated binding free energy values 
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were in agreement with the corresponding MIC values for enzyme inhibitor-complexes 
[Banfl et al., 2006]. In a similar 2009 study authors have used interaction energies of 
docking to compare the efficacy of different neuraminidase inhibitors against newly 
evolved strains of H l N l viruses [Khan et al., 2009]. Also, higher (negative) interaction 
energy has been correlated with stronger binding in yet another 2009 study 
[Danishuddin et al., 2009]. 
8.5 Conclusions 
This is the first study to report modelling of CrX-M-15/53/71/82/89 enzymes and their 
docking with target drugs and inhibitors to the best of our knowledge. In conclusion, the 
present study identifies amino acid residues crucial to 'CTX-M-drug' and 'CTX-M-
inhibitoK interactions. Researchers are expected to duly utilize these informations for 
designing new drugs resistant to hydrolysis by CTX-M enzymes as well as more potent 
and versatile CTX-M-inhibitors. Sulbactam was found to bind most efficiently into the 
active sites of the studied CTX-M-variants on the basis of interaction energies. More 
experimental studies are awaited to validate these findings. 
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9.1 Introduction 
Carbapenemases are a kind of p-lactamases that target carbapenems such as imipenem, 
meropenem, ertapenem and doripenem. SMEl, KPC2, IMl l and SFCl discussed in the 
present study are carbapenem hydroiyzing enzymes. Clavulanic acid, sulbactam and 
tazobactam are traditional p-lactamase inhibitors while LNl-255 (Pattanaik et al., 2009) 
and NXL-104 (Stachyra et al., 2009) are relatively new inhibitors. 
Identification of the amino acid residues crucial to the interaction between 
carbapenemases (the bacterial enzymes) and target drugs {the carbapenems) is of due 
importance. This information might be useful for the scientists involved in designing 
carbapenemase-resistant antibiotics. Also, there is an urgent need to design a versatile 
P-lactamase-inhibitor that might inhibit most of the emerging variants of these 
enzymes, including carbapenemases. Studying the mode of interaction of different 
carbapenemases with the traditional as well as novel inhibitors might help in the search 
for a versatile P-lactamase-inhibitor. 
Hence, we found it pertinent to study the mode of interaction of the said 
carbapenemases with target drugs and inhibitors. This study is based on interaction 
energies. The objectives of the study were: (i) Homology modelling of the sequences of 
SFCl and IMl l (ii) Docking of target drugs (imipenem, meropenem, ertapenem, 
doripenem) as well as inhibitors (davulanate, sulbactam, tazobactam, LNl-255 and NXL-
104) with these modelled enzyme-structures as well as structures of SMEl and KPC2 
retrieved from Protein Data Bank (iii) To identify amino acid residues crucial to the 
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enzyme-drug and enzyme-inhibitor interactions (iv) To suggest potent iniiibitors against 
these enzymes on the basis of interaction energies. 
9.2 Experimental outline 
The four carbapenemases explored in the study included SMEl, KPC2, IMIl and SFCl. 
The sequences corresponding to SFCl and IMI l appear in GenBank as 
fGenBank;AY354402l and rGenBank:U502781. Protein Data Bank (PDB) IDs of the 
templates retrieved for homology modelling of SFCl and IMIl sequences are shown in 
table 9.1. Modelling was performed using the automated mode of Swiss Model Server. 
PDB structures for SMEl and KPC2 were already available and hence retrieved from the 
Protein Data Bank (Table 9.1). PDB structures of drugs (imipenem, meropenem, 
ertapenem and doripenem) as well as inhibitors (clavulanate, sulbactam, tazobactam, 
LNl-255 and NXL-104) were obtained as mentioned in section 2.2.9. The ligand (either 
inhibitor or target drug) was docked into each of the enzyme-structures using the 
targeted docking mode of 'Molecular Docking Server' as mentioned in section 2.2.9. 
9.3 Results 
ClustalW alignments revealed that the SDN loop (positions 130-132) and KTG motif 
(positions 234-236) were conserved in all the study carbapenemase sequences. Over 
90% of the amino acid residues in the modelled protein structures (SFCl and IMIl) were 
found to be present in the most favored regions as revealed by their respective 
Ramachandran plots. For instance, percent amino acid residues in most favored, 
additional allowed, generously allowed and disallowed regions of the Ramachandran 
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Table 9.1 Bioinformative details of the studied enzyme models 
Enzyme 
GenBank Accession 
Number/PDB ID 
PDB ID of the template 
retrieved 
for modelling 
Modelled residue range 
Sequence identity 
E-value 
Final total energy in Kj/md 
(Modelling log) 
RamacharKiran Z-score 
SFCl 
[GenBank: 
AY354402] 
[PDB: ldy6A]; 
2.13A 
37 to 295 
64.479% 
1.25e-100 
-12811.345 
-0.837 
IMI l 
[GenBank: 
U50278] 
[PDB: IbueA]; 
1.64A 
28 to 292 
97.736 
2.196-145 
-14981.013 
0.741 
KPa 
[PDB: 
3dwO] 
-
-
-
0.647 
SMEl 
[PDB: 
ldy6) 
-
-
-
-0.656 
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plot for the modelled SFCl enzyme corresponding to accession number 
rGenBank:AY354402l were 91.8%, 7.6%, 0.6% and 0.0%, respectively. 
The target drugs and inhibitors were docked into each of the enzyme-structures. 
Figures (9.1 to 9.8) show amino acid residues crucial to the receptor-ligand-interaction 
for each of the docked complexes, separately. The binding of NXL-104 (a novel inhibitor) 
to KPC2 carbapenemase was found to be very similar to the binding of clavulanate (a 
traditional inhibitor) to the same. Eight out of the 11 interacting residues were found to 
be common between KPC2-NXL-104 and KPC2-clavulanate complexes (Table 9.2; Figure 
9.1). 
Among the studied enzyme-inhibitor-complexes, the complexes involving 
sulbactam displayed the highest (negative) interaction energies (Table 9.3). NXL-104 
displayed highest (negative) interaction energy in its binding to SFCl enzyme (-190.57 
Kj/mol). NXL-104 was found to interact with the residues N67, G161, D162, N163, V164, 
F165, T187, K189, A190, E193, S194 and K197 of SFCl (Figure 9.3). On the basis of 
interaction energies, NXL-104 emerged as the second best inhibitor next only to 
sulbactam against all the study enzymes, excluding IMI l . Overall, LNl-255 was found to 
be the poorest inhibitor against the study enzymes in terms of interaction energies. 
Docking of LNl-255 with SFCl failed. Ironically for IMIl , LNl-255 displayed the highest 
(negative) interaction energy (-199.04 Kj/mol) next only to sulbactam (-215.84 Kj/mol). 
9.4 Discussion 
The SDN loop (positions 130-132) and KTG motif (positions 234-236) were conserved in 
all the study carbapenemase sequences, which are the typical structures found in class 
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Table 9.3 Interaction energies in the docked complexes (Enzyme-inhibitor-complex). All 
energies are in Kj/mol. 
ENZYME 
SFCl 
KPC2 
IMI l 
SMEl 
INHIBITOR 
Clavulanate 
Tazobactam 
Sulbactam 
NXL-104 
Clavulanate 
Tazobactam 
Sulbactam 
LN1-255 
NXL-104 
Clavulanate 
Tazobactam 
Sulbactam 
LNl-255 
NXL-104 
Clavulanate 
Tazobactam 
Sulbactam 
LNl-255 
NXL-104 
E(totat) 
-172.83 
-164.89 
-228.21 
-190.57 
-183.04 
-172.17 
-216.69 
-22.23 
-187.32 
-151.26 
-162.09 
-215.84 
-199.04 
-146.65 
-88.63 
-135.28 
-175.78 
-29.64 
-153.18 
E(shape) 
-141.98 
-157.08 
-151.74 
-154.65 
-130.9 
-169.4 
-165.73 
-22.39 
-134.18 
-121.14 
-154.61 
-156.45 
-174.89 
-144.66 
-61.62 
-109.62 
-133.53 
-27.47 
-129.28 
E(force) 
-30.85 
-7.81 
-76.47 
-35.92 
-52.14 
-2.78 
-50.96 
0.16 
-53.14 
-30.12 
-7.47 
-59.39 
-24.15 
-2 
-27.02 
-25.66 
-42.24 
-2.17 
-23.9 
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A enzymes (Xiong et al., 2004). Ramachandran Z-score expresses how well the backbone 
conformations of all the residues correspond to the known allowed areas in the 
Ramachandran plot. Accordingly, the Ramachandran Z-scores for modelled IMIl and 
SFCl enzymes were found to be 0.741 and -0.837, respectively. This further confirms 
the accuracy of the modelled structures. 
Among the studied enzyme-inhibitor-complexes, the complexes involving 
sulbactam displayed the highest (negative) interaction energies (Table 9.3). Hence, 
sulbactam was found to be the most efficient inhibrtor for all the study 
carbapenemases. Higher (negative) interaction energy has been correlated with 
stronger binding previously [Danishuddin et al., 2009; Khan et al., 2009]. Since docking 
of LNl-255 with SFCl failed, we speculate that it might not be effective against SFCl-
producing bacteria. 
9.5 Conclusions 
In conclusion, this study reports modelling of carbapenemase enzymes and their 
interaction with target drugs as well as inhibitors. These informations might be useful 
for the future development of a versatile p-lactamase-inhibitor and improved drugs as 
well. On the basis of interaction energies, we conclude that sulbactam is overall superior 
inhibitor compared to davulanate, tazobactam, LNl-255 and NXL-104 against the 
studied carbapenemases. NXL-104 is next to sulbactam in efficacy. LNl-255 might only 
be effective against IMIl-producing bacteria. More experimental studies are awaited to 
validate the findings stated in this study. 
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Overview of conclusions 
To sum up, the studies presented in the thesis have explored the problem of multidrug 
resistance in bacteria using different approaches. The thesis has elements of various disciplines 
e.g. (a) Clinical Microbiology: finding the prevalence of ESBL-producers among bacteria isolated 
from various sources like neonates, diabetic patients with infected foot ulcers and UTI-patients 
(b) BiostatJstics: assessing the risl< factors for acquisition of these organisms using univariate 
analysis and multiple logistic regression (c) Molecular Biology: PCR amplification of antibiotic 
resistance genes, cloning and molecular typing to asl< for genetic relatedness of the bacterial 
strains (d) Bioinfomnatics: molecular modelling of CTX-M-variants and selected carbapenemases 
and their docking with target drugs and inhibitors. The main findings of the thesis work can be 
summarized as follows: 
(1) The first study (Chapter 3) dealt with bacterial strains isolated from neonates. The 
prevalence of ESBL-producers among E. coli and K. pneumoniae isolates was found to be 
36.5% and 28.6%, respectively. Imipenem, cefepime and amikacin were suggested as 
the drugs of choice. 'Length of NICU s ta / was found to be the single independent risk 
factor associated with ESBL-producing E. coli and/or K. pneumoniae acquisition status of 
neonates. 
(2) The second study (Chapter 4) explored the ESBL-producing £ coli strains (n=97) which 
were identified in the first study, at the gene level. Five bhax^is. 2 rmtB, 2 b/oTtw i and 
13 Classl integrons were amplified (all from plasmidic DNA). All the b/ocwwis positive 
isolates, except one were donally related. The WOOX-MIS markers were transmissible 
through conjugation. The study concluded that male neonates colonized or infected by 
ESBL-producing E. coli, might have a longer stay in NICU compared to their female 
counterparts. 
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(3) The third study (Chapter 5) dealt with multidrug resistant organisms (MDROs) isolated 
from infected foot ulcers of diabetic patients. Fifty-six (72.7%) subjects, out of 77 had 
MDRO-infected ulcers. Imipenem and linezolid were suggested as the drugs of choice. 
Statistical analysis revealed that MDRO-infected patients had poor glycemic control. 
(4) The fourth study (Chapter 6) mainly explored the ESBL-producing £ coli strains which 
were identified in the third study, at the gene level. Seven Classl integrons, 2 b/ocrx-M is, 
and 1 WOTEM-I were amplified from the plasmidic DNA of the said strains. Plasmid-
mediated-conjugal transfer albeit at a low frequency might be the possible mechanism 
of transfer of fa/Ocrx-w-is resistance marker in the described setting. Statistical analysis 
revealed that male diabetic patients with MDRGNB-infected foot ulcers had poor 
glycemic control and hence they might have higher mortality rates compared to their 
female counterparts. 
(5) The fifth study (Chapter 7) reported detection of transmissible b/ocrx M « and b/OjEMiso 
genes from plasmidic DNA of carbapenems-resistant A. baumannii strains, which were 
isolated from urinary tract infection patients. Amikacin and ampicillin/sulbactam were 
suggested as the drugs of choice. 
(6) The sixth study (Chapter 8) reported modelling of cn(-M-15/53/71/82/89 enzymes and 
their docking with target drugs and inhibitors. Amino acid residues crucial to 'CTX-M-
drug* and 'CTX-M-inhibitor' interactions were identified. Sulbactam was found to bind 
most efficiently into the active sites of the studied CTX-M-variants on the basis of 
interaction energies. 
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(7) The seventh study (Chapter 9) reported modelling of carbapenemase enzymes and their 
interaction with target drugs (carbapenems) as well as traditional and novel inhibitors. 
On the basis of interaction energies, we concluded that sulbactam was overall superior 
inhibitor compared to clavulanate, tazobactam, LNl-255 and NXL-104 against the 
studied carbapenemases. NXL-104 was next to sulbactam in efficacy. 
The first five studies (i.e. Chapter 3 to Chapter 7) presented in the thesis might 
be helpful in updating the empirical antibiotic regimen and minimizing risl< factors for 
infection among patients, particularly in this region (Uttar Pradesh, India). It is important 
to mention here that the last two studies (i.e. Chapter 8 and Chapter 9) were purely 
computational in nature. Hence, more experimental studies are awaited to validate the 
findings stated in the last two studies. Scope is still left to determine the 3D structures 
of the rapidly emerging variants of CTX-M and other ESBLs by X-ray crystallography, 
thereby helping in the design of more potent and versatile inhibitors against these 
bacterial enzymes. 
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